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Characterisation of Drug-Specific T-Cell Responses in Hypersensitive 
Patients and Healthy Donors 
Zaid Al-Attar 
Drug hypersensitivity reactions represent a significant clinical problem and an 
impediment to drug development. It is currently impossible develop drugs with no 
immunological liability; furthermore, it is very difficult to predict which individuals will 
develop hypersensitivity when exposed to a therapeutic treatment regimen. This is 
because susceptibility is a function of the chemistry of the drug, the genetic background 
of the patient and environmental factors such as patient demographics, disease and 
concomitant medications. In this study, we focused on two drugs: piperacillin and 
telaprevir as examples of idiosyncratic hypersensitivity reactions.  
Regarding piperacillin, we characterized the piperacillin reactive T-cells response of 
piperacillin hypersensitive patients with cystic fibrosis in terms of proliferation, cytokine 
secretion in addition to TCR-Vβ and chemokine receptor expression. Piperacillin-
responsive CD4+ clones expressing a diverse TCR-Vβs proliferated and secreted 
Th1/Th2 cytokines in a dose-dependent manner. Clones expressed chemokine receptors 
consistent with a mixed Th1/Th2 response. Piperacillin responsive T-cells displaying a 
similar phenotype were also generated from naïve healthy volunteers using a dendritic 
cell-T-cell priming technique.  However, TCR-Vβ expression was more restricted; high 
expression of TCR-Vβ 9, 13.2, 18 and 4 was detected.  Piperacillin is β-lactam antibiotic 
that is known to covalently modify lysine residues on proteins such as human serum 
albumin. Therefore, we characterized the absolute levels of piperacillin protein binding in 
patients and in vitro culture and whether piperacillin albumin adducts activate patient T-
cells. With the aid of mass spectrometry, we identified the main lysine residues that 
piperacillin modifies and synthesized a piperacillin modified peptide incorporating amino 
acid residues of albumin to establish a standard curve for quantification of binding. The 
level of modified Lys541 ranged from 2.7-4.7% in patients. Analysis of incubation medium 
from piperacillin-responsive clones revealed that a similar level of piperacillin-modified 
Lys541 in albumin was required for the stimulation of T-cells. Antigen presenting cells 
cultured with piperacillin for 24h also activated the clones with 2.8% Lys541 modification 
at this time-point. Piperacillin-albumin conjugates that had levels and epitopes identical 
to those detected in patients were synthesized and purified, and were shown to stimulate 
T cells in an antigen processing dependent manner. Piperacillin-albumin conjugate 
clones expressed a restricted pattern of TCR-Vβ with high expression of TCR-Vβ 9 in 
many clones.  
Telaprevir is antiviral drug used for the management of hepatitis C. We succeeded in 
generating clones responsive to a telaprevir metabolite (VRT-127394) using PBMCs 
priming technique and these clones were found to be 100% cross reactive with telaprevir. 
These clones were found to be activated via the direct binding of the drug (metabolite) to 
MHC molecules on antigen presenting cells. Most clones were CD4 T-cells and they 
displayed a restricted pattern of TCR-Vβ expression.  
Together, our results define in immunological, chemical and quantitative terms the drug 
immune receptor interactions that can drive a T-cell response. For β-lactam antibiotics, 
the levels of modification that activated T-cells in vitro are equivalent to the ones formed 
in patients. 
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1 General Introduction: 
In the last few decades, there was an increased burden from the problem of drug 
allergy especially in the developing countries. This issue has received a great deal 
of focus in the form of research effort and funding in order to discover and 
establish a comprehensive understanding of the mechanisms involved in 
immunological reactions. Collectively, the research was conducted with a deep 
recognition of the final target, which was the development of new therapeutic 
agents to combat the rising problem of drug allergy. Moreover, it is crucial to 
explore in depth to modify the current modalities of management and treatment 
to lessen the adverse drug reactions in general, and specifically drug 
hypersensitivity reactions.    
The aim of this chapter is to present a review about the main topics in 
immunology, pharmacology and drug-induced reactions. 
1.1  Adverse reaction and adverse event 
Adverse event is unpleasant or harmful effect or symptoms that may be 
associated with the administration of a drug or at some time later but may not be 
necessarily a result of the mechanism of drug action (Pirmohamed et al., 1998). 
In fact, it occurs just as a coincidence with no degree of probability or attribution 
e.g. accident, unintended pregnancy.  
On the other hand, the mechanism of drug action is the pivotal factor for adverse 
drug reactions (ADR). In general, adverse reaction can always be regarded as 
an adverse event but the reverse is not true always. This division between those 
two terms which was first recognized by Finney (2006) is crucial especially in 
clinical trials where researchers may use the term “events” to denote 
consequences that are not attributed to the drug (Finney, 2006). 
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1.2 Adverse drug reaction 
“An appreciably harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, usually predicting hazard from future 
administration and warranting prevention, or specific treatment, or alteration of 
the dosage regimen, or withdrawal of the product” (Aronson, 2011). One 
metanalytic study showed that the frequency of ADRs in hospitalized patients is 
16.88% (CI95%: 13.56,20.21%) (Miguel et al., 2012). Another study has shown 
that ADRs are responsible for 6.5% of admissions to hospitals with a median bed 
stay of 8 days (Pirmohamed et al., 1998;Williams et al., 2004). 
There is a high burden on the health services in terms of financial expenses which 
were estimated to be 466 million pounds annually in the UK (Pirmohamed et al., 
2004).   ADRs are a major cause for the withdrawal of drugs and it takes an 
average of 10 yrs to develop a new drug with a cost reaching approximately 866 
million pounds (Adams and Brantner, 2006).  
Therefore, there is a need to understand mechanisms of ADRs so that they can 
be predicted during early stages of research and development. 
1.3 Classification of ADRs 
The most widely used classification is the A/B classification, which is centred 
mainly on the recognized relationship between drug dose and the development of 
an adverse effect. 
1.3.1 Type A reactions: 
(Sometimes called: On target) They constitute (80% of ADRs) (Shah et al., 2012). 
They are defined as adverse effects that result as an exaggerated response of 
the pharmacological effect of the drug. They are dose related, reversible by 
lowering the dose or stopping the drug, predictable and rarely lethal (Page, 
2006;Park et al., 2010;McDowell et al., 2011).  
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Type A reactions are subdivided according to the classification of Rawlins and 
Thompson which is the most widely used classification system (Shah et al., 
2012;Rawlins and Thompson, 1991): 
  Toxicity or overdose 
Occurs as a result of an exaggeration of the drugs primary pharmacological 
action, which leads to cell damage at high doses. However, toxicity may occur at 
normal or low doses due to an underlying abnormality in the patient (e.g. hepatic 
failure with therapeutic doses of paracetamol) (Bennett et al., 2012). 
  Side effects 
 ”Any effect caused by a drug other than the intended therapeutic effect, whether 
beneficial, neutral or harmful” (e.g. sedation with antihistamines) (Ferner and Butt, 
2008).  
  Secondary effects 
Are indirect net results of the primary action of the drug (e.g. development of 
diarrhea with antibiotic therapy due to altered gastrointestinal bacterial flora) 
(Shah et al., 2012). 
  Drug Interaction 
Pharmacological reaction caused by the administration of a drug combination that 
is different from the predicted effect of each drug (e.g. theophylline toxicity in the 
presence of erythromycin therapy) (Shah et al., 2012;Helms and Quan, 2006). 
1.3.2 Type B reactions:  
(Sometimes called: idiosyncratic, off-target) They constitute (20% of ADRs) 
(Shah et al., 2012).  Unusually are unpredictable, and cannot be explained by the  
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pharmacology of the drug. Instead, they are explained by pathogenesis which 
often relates to an inadvertent activation of the hosts immunological system by 
the drug. Moreover, their occurrence has no clear relationship with the dose 
(Figure 1.1). Idiosyncratic drug reactions (IDRs) are often described as dose 
independent. This is not a precise description. Actually, the probability that a drug 
may cause IDRs is related to the therapeutic dose of the drug. Drugs given at a 
dose less than 10mg/day rarely cause IDRs (Uetrecht, 2007) and 77% of 598 
cases of liver IDRs were found to be caused by drugs given at doses higher than 
50mg/day (Lammert et al., 2008). What is true is that most patients would not 
develop any IDRs at any dose, and there may not be a significant difference of 
the incidence of IDRs in the narrow range of doses used therapeutically. 
Moreover, the required dose to trigger an IDRs may be lower in a patient who has 
been previously exposed to the drug. Nevertheless there will be always a dose 
that below which no one would develop an IDRs (Zhang et al., 2011). 
 
Figure 1.1: Relationship between drug dose and development of ADRs.  The therapeutic 
effect is dose dependent and usually the percentage of responding patients increase with 
increasing dose. Type B (IDRs) usually starts at low doses (lower than therapeutic doses) and 
the percentage of affected patients does not rise with increasing dose. If we increase the dose 
higher than therapeutic dose, we would have toxic dose with its consequent Type A reactions 
(On target) which are dose-dependent.     
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These reactions are usually delayed in onset and this is variable with the type of 
the IDR and even with the type of drug. However, IDRs tend to occur almost 
immediately on re-challenge. Surprisingly, the same drug can produce different 
types of IDRs. 
Type B reactions constitute a great burden on the pharmaceutical industry since 
they add a significant uncertainty to drug development, which is translated in the 
form of extra time and additional cost. Furthermore, there is a great risk of 
candidate failure (B.K. Park et al., 2010).   
Type B reactions are subdivided according to classification proposed by Rawlins 
and Thompson (1991) into:  
 Non-Immunological:  
Which are divided into: 
A. Intolerance: Lower threshold for the pharmacodynamic effect of the drug in 
comparison to the normal population (e.g. tinnitus with use of Aspirin) (Bennett et 
al., 2012).  
B. Pseudoallergic (Nonallergic Hypersensitivity):  
These reactions are characterized by a direct drug interaction with inflammatory 
cells; in particular, mast cells, eosinophils and basophils. There is no evidence of 
a role for the adaptive immune response (Pichler et al., 2015).  
In most of the cases such reactions are genetically determined and mediated by 
mechanisms that entail the endogenous release of biologically active substances 
like histamine and leukotrienes (Bennett et al., 2012). Other mechanisms may be 
implicated like complement activation, which may trigger mast cell activation 
(Pichler, 2007). In some of these reactions the drug interacts with MRGPRX2 
receptor on mast cells leading to IgE-independent mast cell degranulation (McNeil 
et al., 2014).   
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Remarkably, some patients may develop increased tryptase levels (proteinase 
enzyme contained in mast cells and plays an important role in allergic reactions); 
however, subsequent diagnostic tests do not show mastocytosis (Pichler et al., 
2010). Moreover, traditional provocation tests often yield negative results 
(Aronson, 2011). 
A prominent feature of pseudoallergic reactions that are caused by non-steroidal 
anti-inflammatory drugs (NSAIDS) is that they require higher doses and they arise 
slower in comparison to true IgE mediated reactions (more than 15 minutes) 
(Pichler, 2007). Pseudoallergic reactions that simulate type I reactions are called 
“anaphylactoid” e.g. morphine , tubocurarine  (Bennett et al., 2012). 
(Note: Types of hypersensitivity reactions (I-IV) are discussed under the heading 
1.3.2.2).  Regarding therapeutic approach, some mild pseudoallergic reactions 
have shown good response to antihistamines, but it is questionable whether 
reactions that are more serious will respond to antihistamines or corticosteroids 
(Bennett and Gracey, 2000;Pichler et al., 2010). 
In addition to anaphylactoid reactions, there are additional pseudoallergic 
reactions, which mimic other forms of immunological reactions: 
Type II reactions may be mimicked in patients with drug-induced hemolysis e.g. 
sulfonamides.  
Type III reactions may be mimicked in patients with penicillamine-induced 
nephropathy (Bennett et al., 2012). 
C. Metabolic idiosyncratic reactions: These reactions are an inherent abnormal 
reaction to a drug that does not occur in most patients at usually used clinical 
doses. Furthermore, these reactions do not involve the known pharmacology of 
the drug. They are usually mediated by reactive drug metabolites that are mostly 
generated by the liver (Uetrecht, 2008). In some cases there is evidence that 
susceptible patients are predisposed by a genetic abnormality (Bennett et al., 
2012). In liver, the enzymatic system of cytochrome P450 plays an important role 
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in metabolizing drugs and generating reactive metabolites. An important example 
is isoniazid, in which polymorphisms in metabolic enzymes (in this case N-
acetyltransferase and cytochrome P450 2E1) constitutes to be a risk factor for 
idiosyncratic liver toxicity (Huang et al., 2002). As a term, metabolic idiosyncrasy 
often used to describe specific forms of drug-induced hepatitis and cytopenias 
such as agranulocytosis (Guest et al., 1998). Several criteria are used to 
differentiate these reactions from the immune-mediated reactions. For example, 
if hepatotoxicity is associated with fever, rash, eosinophilia, antidrug antibodies 
with rapid occurrence after re-challenge, it is generally presumed that the reaction 
is immunological. In contrast, if these criteria are not present then most likely, the 
reaction is metabolic idiosyncrasy. This method of delineation is widely accepted 
by hepatologists (Uetrecht, 2008).   
  Immunological (Drug Allergy) 
Two researchers, Coombs and Gell, working in the UK in the 1963 assembled the 
key facts about allergic reactions into four clearly defined pathological processes 
and essentially established the first classification system for drug allergy (Gell and 
Coombs, 1963): 
Type I: IgE antibody mediated hypersensitivity, due to binding of the allergen to 
IgE on the surface of mast cells and basophils which causes the release of 
chemical mediators such as, histamine, kinins, prostaglandins and slow reacting 
substance of anaphylaxis with the net result of increased vascular permeability, 
vasodilation, smooth muscle contraction and oedema (Grant et al., 2007). These 
changes translate to the clinical presentation of urticaria, anaphylactic shock and 
asthma. This type of hypersensitivity develops within minutes and may last for 1-
2 hr and sometimes reactions are fatal (Bennett et al., 2012).  
Type II: antibody-antigen reaction involving IgG or IgM, which causes cell 
destruction by complement activation or by the cytotoxic effect of natural killer 
cells bearing Fc-IgG receptors. Other cells may mediate a similar effect. These 
include: macrophages, eosinophils and neutrophils. Cell lysis is mediated via 
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lysosomal enzymes and perforin e.g. Good-Pasteur syndrome (Pichler et al., 
2010).  
Type III: IgG mediated reaction. The end result is antibody-antigen immune 
complex deposition with subsequent tissue damage mediated by chemotaxis of 
polymorphonuclear leukocytes and natural killer cells with lysosomal enzyme 
release e.g. Serum sickness, Arthus reaction, heparin induced thrombocytopenia 
(Cruse et al., 2004). 
Type IV: Cell mediated immunity, which is mediated by T-helper and T-cytotoxic 
cells (Aronson, 2011). Type IV reactions have been subdivided according to the 
cytokines and type of cells involved into four subdivisions (Table 1.1):  
The peculiar feature of the A/B classification is the opportunity to use the 
alphabetical abbreviations to denote more expressive terms i.e. augmented and 
bizarre (Page, 2006). This classification was expanded later by the addition of 
another four divisions to become a six-category classification (A-F). 
These new divisions are denoted: 
Table 1.1: Subdivision of type IV hypersensitivity reactions.  
Adapted from (Posadas and Pichler, 2007). 
 
T-cell 
phenotype 
Immune reactant Effector cells 
Clinical symptoms 
(example) 
Type 
IVa 
Th1 IFN-γ, TNF-a 
Monocyte / 
macrophage 
activation 
  contact dermatitis, 
bullous exanthema  
Type 
IVb 
Th2 
IL-5, IL-4, IL-13, 
eotaxin 
T-cells driving 
eosinophilic 
inﬂammation 
Maculopapular and 
bullous exanthema, 
Type 
IVc 
Cytotoxic 
T-cells 
perforin, 
granzyme B, Fas 
ligand 
CD4 + /CD8 + 
mediated T-cell 
killing 
Contact dermatitis 
maculopapular, bullous 
exanthema, 
Type 
IVd 
T-cells  GM-CSF, CXCL-8 
T-cell leading to 
recruitment and 
activation of 
neutrophils 
Pustular exanthema 
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C: Chronic, for ADR that manifests after prolonged exposure and not with single 
dose. D: Delayed, for ADRs that are remote from the onset of therapy e.g. in the 
treated patients many years after treatment or in their offspring.  
E: End of use, for ADR that occurs after stopping the drug (especially if stopped 
suddenly, so-called withdrawal reaction).  
F: Failure, failure of treatment, which is usually caused by drug interactions (Scott 
and Thompson, 2011). 
In addition to the previously mentioned classification system which relies mainly 
upon immunological mechanisms there is also a clinical classification by Levine 
(1966); by which the ADRs are classified according to time factor (the time 
between drug administration and the start of the immunological reaction) into 
three groups: immediate (<1hr), accelerated (1-24hr) and delayed (>24hr).  
More recently, to make it more convenient and practical, the accelerated and the 
delayed types were combined together into a single form, which is called: non-
immediate reactions (NIRs). 
Immediate reactions (<1hr) are mediated by IgE antibodies and occur usually 
within minutes of drug administration. They present in the form of angioedema, 
urticaria and/or anaphylaxis (Romano et al., 2004). In contrast, non-immediate 
reactions (>1hr) are T-cell mediated. They may be manifested within hours, days 
or even weeks and are versatile in in their clinical presentation (Park et al., 2010).  
1.4 Drug Allergy 
The first use of the term “allergy” was made by the Austrian scientist Clemens von 
Pirquet who had noted in 1906 that patients who were receiving the 2nd dose of 
horse serum were developing quicker and more severe reactions compared to 
the 1st dose (Silverstein, 2000). 
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Allergy as a term and its related clinical manifestations e.g. anaphylaxis and 
hypersensitivity have greatly evolved over the decades since the initial 
observations of Clemens von Pirquet. 
The last updated definition of allergy was presented by EAACI: (European 
Academy of Allergology and Clinical Immunology) in 2001 and was advocated by 
World Allergy Organization (WAO) in 2003. The update in the terminology and 
definition is founded upon the mechanism of the reaction. According to this 
classification allergy is defined as “a hypersensitivity reaction initiated by speciﬁc 
immunologic mechanisms” (Johansson et al., 2003). Allergy could be IgE 
mediated or non-IgE mediated. In some conditions where other mechanisms have 
been proven e.g. hypersensitivity to aspirin, the term “pseudoallergic (nonallergic) 
hypersensitivity” is applied (Stevenson and Szczeklik, 2006;Li et al., 1991). 
The most recent definition for a hypersensitivity reaction is “objectively 
reproducible symptoms or signs initiated by exposure to a deﬁned stimulus at a 
dose tolerated by normal persons” (S.G.O Johansson et al., 2003). In comparison 
with the previous terms, the term “anaphylaxis” is more clinical and commonly 
used by physicians. It states, “Anaphylaxis is a severe, life-threatening 
generalized or systemic hypersensitivity reaction”. When immunological 
mechanism such as IgE immune complexes are the culprit in anaphylactic 
reaction, the term “allergic anaphylaxis “is used. Accordingly, peanut induced food 
anaphylaxis may be denoted as “IgE-mediated allergic anaphylaxis”, whereas 
anaphylaxis provoked by non-immunological mechanisms is usually classified 
under the term “pseudoallergic (nonallergic) anaphylaxis” (Johansson et al., 
2003;Aronson, 2011). 
1.4.1 Mechanisms of T-cell-mediated Drug Allergy 
Over the last 20 years, several hypotheses have been postulated to explain the 
development of drug allergy. However, the main ones that have wide acceptance 
are hapten/prohapten and pharmacological interaction (p-i) mechanisms. In 
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addition to these major mechanisms, there is a growing recognition that other 
mechanisms may be involved. For example, an immune-mediated reaction can 
be initiated by direct activation of antigen presenting cells, by alteration in the 
immune tolerance, and by epigenetic effects.  
However, it should be noted that these mechanistic classifications are designed 
to simplify the complex processes that occur in vivo. In other words, the immune 
system combines several mechanisms to deal with a real or putative antigen. 
Nevertheless, the clinical picture usually reflects the dominance of a particular 
mechanism over the others (Pichler, 2007). 
 The Hapten/pro-hapten hypothesis 
The traditionalist view of drug hypersensitivity dictates that drug-modified proteins 
are taken up by antigen presenting cells and processed into peptide fragments 
prior to presentation in the context of major histocompatibility complex (MHC) to 
T-cells. The first notion for this hypothesis came from Landsteiner who in 1935 
reported that it was not possible to trigger an immune response to small molecules 
unless such molecules are chemically reactive and bound to a protein 
(Landsteiner and Jacobs, 1935). The hapten hypothesis assumes that small 
molecules (less than 1000 Da) are unable to elicit immune response due to poor 
binding between such drug molecules and MHC proteins. Furthermore, if the 
binding between the drug molecule and the protein is reversible, such conjugates 
would be not successful in inducing an immune reaction (Uetrecht, 2008). 
According to hapten hypothesis, a chemically reactive drug (or active 
metabolite) binds covalently to a protein (which could be extracellular like 
albumin or cell membrane protein like integrin or intracellular protein like 
enzymes), and then this new product triggers an immune response against the 
altered self-protein (Pichler, 2007). 
T-cells sensitization occurs when drug-protein adducts are taken by APCs. In the 
presence of an appropriate cytokine micro-environment, the APCs travel to the 
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draining lymph nodes where these adducts are processed and presented by MHC 
molecules to the T-cells receptors (TCRs) on naïve T-cells. Then, naïve T-cells 
with appropriate specificity will be stimulated undergo clonal expansion (Naisbitt 
et al., 2000). Primed T-cells can evolve into functionally distinct subclasses: 
Effector T-cells (Teff), effector memory T-cells (Tem) which migrate to the peripheral 
tissues where the drug-protein adduct originated (Schnyder and Pichler, 2009). In 
contrast, central memory T-cells (Tcm) migrate to the draining lymph nodes (Ebert 
et al., 2005). 
Drug adducts that are processed and presented as hapten-peptides to Teff and 
Tem would result in local T-cell mediated inflammation, while drug-peptide 
presentation to Tcm in the draining lymph nodes would manifest in enlargement of 
the regional lymph nodes (Schnyder and Pichler, 2009).  
Following the work of Landsteiner proteins were shown to be processed and 
presented as small as 8-20 amino acids (aa) long peptides by the MHC molecules. 
Twelve human leucocyte antigen (HLA) alleles are encoded per individual. The 
respective MHC proteins present different peptides (mostly 8-10 aa for HLA class 
I, 14-20 aa for HLA class II) which fit into the peptide binding groove of the HLA 
molecule (Weltzien et al., 1996). Later work by Weltzien et al have shown that the 
location of the hapten modification has a influences the development of an 
antigen-specific T-cell response (Weltzien et al., 1996).    
The hapten hypothesis coincides with the classical “self” and “nonself” theory in 
that the immune system identifies drug-modified proteins as foreign antigens 
(Koen et al., 2006). 
It is important to mention that the first drug reaction studied and proven to support 
this hypothesis was penicillin allergy. The presence of an inherent reactive β-
lactam ring means that penicillin reacts irreversibly with free lysine amino acids 
on proteins. Consequently, this results in the generation of penicillin modified 
proteins that stimulate IgE antibody production and the activation of T-cells. 
Penicillin-specific IgE antibodies have been shown to provoke allergic reactions 
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through stimulating the degranulation of mast cells and basophils to release 
chemical mediators such as histamine, leukotrienes etc.  
The other possibility is that lysine modified peptides would be recognized as neo-
epitopes for activating reactive T-cells (Brander et al., 1995).    
Although, the hapten hypothesis has established a framework for studying allergic 
drug reactions, it should be kept in mind that the presence of antidrug antibodies 
does not per se indicates that an ADR is mediated by these antibodies or that this 
ADR is immune mediated (Uetrecht, 2008). 
Not every hapten modification leads to an efficient immune response that 
manifests as tissue injury. If the available MHC molecules do not present the 
hapten-modified peptide the modification will remain unnoticed. Also, if the innate 
immune response isn’t activated, the modification may be ignored which means 
there will be no effector immune response (Pichler, 2013). Moreover, many 
reactive compounds bind to proteins and modify cell-signalling pathways without 
causing an immune response. In fact, if the level of modification exceeds a 
threshold, cells are directed to die by apoptosis, preventing the release of its 
cellular content and the pro-inflammatory mediators (Behrens et al., 2007).  
Some drugs are not reactive by themselves but they undergo metabolism 
(bioactivation) to produce reactive metabolites, which then can bind to the 
proteins to induce an immune response. These drugs are called pro-haptens e.g. 
sulfonamides do not bind directly to protein but they are metabolized to aa 
hydroxylamine-metabolite by cytochrome P450 enzymes and peroxidases (Cribb 
and Spielberg, 1992). The hydroxylamine undergoes spontaneous oxidation to 
yield nitroso-sulfamethoxazole (SMX-NO) (Naisbitt et al., 1999) a hapten that 
binds irreversibly to cellular and serum protein (Naisbitt et al., 2002)(Callan et al., 
2009). Moreover, the adducts are immunogenic and antibodies that react with 
sulfonamide-modiﬁed protein have been detected (Harle et al., 1988). T-cells that 
are isolated from hypersensitive patients have been shown to secrete cytokines 
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and kill target cells in response to sulfonamide metabolite challenge (Nassif et al., 
2002).  
Although the main site of bioactivation is the liver by the action of cytochrome 
P450 in hepatocytes, the result of such bioactivation frequently is tolerance due 
to the tolerogenic behaviour of liver immune cells (Crispe, 2003). Otherwise, if the 
drug escapes liver environment and is metabolized in other tissues e.g. 
keratinocytes of the skin, it may lead to cutaneous hypersensitivity reactions with 
or without systemic symptoms (e.g. drug rash with eosinophilia and systemic 
symptoms [DRESS]) (Bowen et al., 2004). 
In contrast, it has been proposed that (1) hydroxylamine formation occurs in the 
liver and (2) the hydroxylamine circulates in the body and undergoes oxidation in 
organs such as the kidney giving rise to isolated interstitial nephritis (Spanou et 
al., 2006). 
Inactivation of drug metabolites usually follows bioactivation and the balance 
between the two processes is affected by many genetic and environmental factors 
which increase or decrease the level of reactive metabolites individuals are 
exposed to (Posadas and Pichler, 2007). It is important to note that not all 
metabolites are protein reactive. If they are not transformed into haptens, they 
may trigger the immune system in a way similar to that of the parent drug e.g. p-i 
concept discussed in detail below with allopurinol/oxypurinol (Pichler, 2013). 
Metabolic activation constitutes the base upon which the prohapten hypothesis 
stands; however, to date, no one can draw a detailed picture which shows a direct 
correlation between drug bioactivation in vitro and immunological ADRs in clinical 
practice. This is due to the fact that not all the drugs that are bioactivated will 
cause hypersensitivity reactions; Moreover, not all drug hypersensitivity reactions 
necessitates drug bioactivation as an essential step (Park et al., 2010).  
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 The danger signal and its relation with the hapten and pro-hapten 
hypothesis 
Ongoing research has shown a weak point in the hapten and the prohapten 
hypothesis regarding its consistency. The following question has been raised, “If 
a specific drug forms reactive metabolites, why it does not always produce a 
hypersensitivity reaction?”  
This issue was the basis for the Danger Hypothesis proposed by Matzinger 
(Matzinger, 1994) and discussed in the context of drug hypersensitivity by 
Pirmohamed (2002) and Uetrecht (1999). According to this hypothesis, the 
immune response that is produced by the hapten/prohapten-protein adduct 
should be strengthened by a signal (danger signal), otherwise the immune 
response will wean off giving rise to tolerance instead of an immune reaction.  
This hypothesis suggests that immune reaction is the product of three elementary 
signals outlined by (Curtsinger et al., 1999). 
Signal 1: is the net result of the interaction between antigen presenting cell (APC) 
MHC class I molecules and the TCR on T-cells. Being devoid of any other signals 
anergy will ensue.  
Signal 2: is the net result of co-stimulatory and co-inhibitory molecule interaction 
between APCs and the T-cells. Costimulatory molecules are ignited when APCs 
are activated by danger signals that are generated from stressed cells (Pichler et 
al., 2010). Such an interaction would shape the outcome of the T-cell mediated 
response that would propagate into tissue injury and a hypersensitivity reaction 
(Sckisel et al., 2015;Schwartz, 2003) (Figure 1.2. & Table 1.2).  
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Signal 3: is polarizing cytokines, which polarize T-cells to either a Th1 or Th2 
phenotype. Th1 secreting cells are known for their pivotal role in stimulating 
macrophages and triggering cell mediated immunity by the release of IL-12 and 
IFN-γ.  On the other hand, Th2 cells have a fundamental role in humeral immunity 
through the release of IL-4 and IL-13 which mediate immunoglobulin class 
switching from IgG to IgE (Naisbitt et al., 2000). 
 
Table 1.2: The main co-stimulatory and co-inhibitory molecules. The interaction of these 
molecules between APCs and T-cells shape the outcome of the T-cell immune response. 
Co-stimulation Co-inhibition 
APC T-cell APC T-cell 
CD40 CD40L PD1-L PD-1 
ICOS-L ICOS CD80/86 CTLA4 
CD80/86 CD28 HVEM BTLA 
 
Figure 1.2 : Hapten and prohapten hypothesis and the role of danger signal. For a drug to 
initiate an immune response, it must bind to a protein. If the drug is reactive, it can bind to a 
protein directly; otherwise, it needs to be metabolized to produce reactive metabolite that can 
bind protein. Peptides derived from the modified (processed) protein are presented by the APC 
to helper T-cells. If this is accompanied by signal 2 triggered by danger signals from stressed 
cells, the result is an immune response otherwise it would lead to tolerance.   
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The actual nature of the danger signals is presently ill-defined; however, there are 
now many possible candidates which include interleukins IL-2, IL-1a, tumor 
necrosis factor TNF-α, and interferon IFN-γ, high mobility group box 1 protein 
(HMGB1), heat shock protein (HSP70), S100 proteins and uric acid (Li and 
Uetrecht, 2010). These molecules share the feature of acting through toll-like 
receptors. Any kind of cell stress and/or necrotic cell death would trigger the 
release of these danger signals. Such cell stress could be caused by physical or 
chemical factors or infection, which may explain the higher incidence of drug 
hypersensitivity in patients with conditions such as HIV or cystic fibrosis. Another  
good example for this is the high prevalence of rash 95% in patients who receive 
amoxicillin in the presence of EBV infection (Sullivan and Shear, 2001).  This can 
be explained by the high level of inflammatory cytokines which mediates the 
status of tissue stress and augments the potential for drugs to cause 
hypersensitivity reactions (Pirmohamed and Park, 2001). Thus, in addition to its 
importance in explaining the drug hypersensitivity, the danger hypothesis 
provides the answer for the question, “Why drug hypersensitivity is more common 
in patients with certain infectious diseases?” 
Recent studies have shown that polymorphism of the genes controlling the 
synthesis of  these  “danger  signals” has an important influential role on the 
occurrence and severity of drug hypersensitivity (Ghosh et al., 2011). 
  The p-i hypothesis (pharmacological interaction) 
According to p-i hypothesis chemically inert drugs are not capable of interacting 
with proteins to form adducts but they interact with TCR and/or MHC molecules (I 
or II) (signal 1) to induce immune cells. This interaction is not of the kind of 
irreversible covalent binding (as in hapten or prohapten hypothesis), instead it is 
a series of reversible Van der Waals interactions, electrostatic forces and/or 
hydrogen bonds. Therefore, these drugs are less toxic in comparison to drug 
hapten (Pichler, 2013). The players in p-i interaction are the drug, TCR molecule 
(αβ) and peptide-MHC complex. MHC molecules include those expressed on 
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tissue cells and professional antigen presenting cells. In contrast to haptenic 
reactions involving drugs such as the β-lactam antibiotics, B-cells or NK cells are 
not activated via a p-i mechanism (Pichler et al., 2015).           
For this hypothesis to be effective, several criteria must be met; first; T-cells with 
specific TCR for the drug must be present. Secondly, such cells should have a 
low threshold so that they are stimulated by a low binding threshold. Finally, the 
TCR should interact with MHC on APCs to strengthen the immune response 
(Ghosh et al., 2011). Recent research suggests that these conditions exist in the 
skin of susceptible patients. Skin contains huge populations of effector memory 
T-cells which may act as a sentinel cells (Rogers et al., 2000). Such memory T-
cells have a low threshold for activation in comparison to the naive T-cells since 
they were primed by prior peptide contact. In addition, skin contains a dense 
network of dendritic cells that can act as APCs.  
Clinical features patients with hypersensitivity that support the p-i hypothesis 
include: 
 Positive skin test response to inert drugs in the absence of any known 
cutaneous metabolism of these drugs  
 The immune response is sometimes observed at the first encounter without 
a latent period for sensitization which indicates that the drug interacts with 
pre-existing specific memory T-cells. 
 Generalized immune responses to drugs occur in the absence of local 
danger signs. 
 The immune response reflects an abnormal vigorous T-cell stimulation with 
massive destructive (or even fatal) outcome as seen in SJS/TEN and 
DRESS (Pichler et al., 2010).  
A brief comparison of hapten and p-i mechanisms is shown in Table 1.3. 
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P-i reactions are divided into two types according to the preferential binding to 
either TCR or HLA: 
1.4.1.2.1 P-i TCR 
The drug binds primarily to the specific TCR molecule (by non-covalent labile 
bonds) rendering the interaction of MHC molecule (of APC) a necessary but only 
an additional stimulatory effect for the development of an efficient immune 
response (Depta et al., 2004;Schmid et al., 2006) (Figure 1.3). This pathway 
evolved through computer modelling of drug TCR interactions and it had been 
proposed that CD4+ T-cells clones (TCCs) might be activated via this pathway in 
an MHC class II restricted fashion (Pichler et al., 2015).   
Research conducted with lidocaine and the SMX models have sown that the MHC 
bound peptide could be removed or exchanged without affecting CD4+ T-cell 
activation (von Greyerz et al., 2001;Hari et al., 2001). Moreover, some clones 
reacted to the drug in the presence of allogenic MHC alleles indicating the 
absence of HLA restriction for lidocaine and SMX. (Zanni et al., 1999;von Greyerz 
et al., 2001). 
Table 1.3. Comparison of the hapten and p-i concepts adapted from (Pichler et al., 2015) 
Hapten concept P-i concept 
Chemical binding to proteins or peptides 
which may act as antigens for T and/or B-
cells 
Structural binding to HLA or TCR leading 
to direct and exclusive T-cell stimulation. 
No role of innate immune response. 
Covalent interactions Non covalent interactions (labile)   
Often dependent on processing by APC 
and drug metabolism  
Processing and metabolism not required 
Onset depends the time required for drug 
metabolism and processing within APCs 
(> 4hrs) 
Mostly immediate (<10 min) to activate T-
cells 
Important role for danger signals  
Danger signals have no role in p-i HLA but 
some p-i TCR reactions may require 
danger signals 
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A recent study has shown that the response of certain SMX specific TCCs can be 
blocked by structurally related sulfanilamides (Watkins, 2013). Docking studies 
with these blocking sulfanilamides show that they bind to the same site as SMX 
(CDR3), but without stimulating T-cell signalling (Pichler, 2013). Why might this 
be the case? It was found that only SMX binds to CDR3 with its NH2 group pointing 
to the peptide-binding groove (Pichler et al., 2015).  
In contrast, the NH2 group of non-stimulatory sulfonamides points toward the TCR 
(J. Pichler and Watkins, 2014). Thus, it seems that the orientation of bound drug 
serves a role in the activation of T-cells.       
Another example of the vital role of certain TCR clonotypes (clonotype is defined 
as T-cells that express identical TCR phenotype) is TCR triggering in 
carbamazepine (CBZ) hypersensitivity. Patients with CBZ-induced SJS/TEN and 
HLA-B*15:02 background react to normal peptides and not against hapten-
modified peptides (Yang et al., 2007). The T-cells use the TCR-Vβ-11-ISGSY 
clonotype (Ko et al., 2011). This clonotype was present in 16 of 19 patients and 
absent in all the 17 CBZ-tolerant patients. Moreover, CBZ-specific T-cells could 
be primed in vitro using PBMCs of healthy individuals who were carriers of the 
 
Figure 1.3. P-I TCR: The drug binds to a TCR. Then, the MHC peptide complex binds and 
stimulates the T-cells. MHC binding would provide the 2nd signal that is necessary for generating 
an efficient immune response. 
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HLA risk allele and TCR-Vβ-11-ISGSY. These data show that in some disease 
manifestations the TCR phenotype may play a crucial role.  
1.4.1.2.2 p-i HLA 
One of the important steps toward understanding the mechanisms underlying 
hypersensitivity reactions was the description of a strikingly high HLA allele 
association for certain severe hypersensitivity reactions. The HLA allele 
associations were extremely high with a negative predictive value near 100% for 
certain severe reactions linked to specific drugs (Hung et al., 2005;Chung et al., 
2004;Mallal et al., 2002). This high association raised the question: Is the T-cell 
response dependent on the drug binding to the allele itself or the presented 
peptide?  
The majority of reported associations were for HLA class I alleles, but some were 
for HLA class II alleles (Singer et al., 2010) mostly resulting in less severe 
reactions. There is no role for danger signals in T-cells activation (Pichler et al., 
2015).      
Mass spectrometry has been used to show that peptides eluted from MHC 
molecules are not modified covalently with either CBZ or abacavir (Yang et al., 
2007;Norcross et al., 2012;Ostrov et al., 2012). The binding interaction of these 
two drugs with the respective HLA risk alleles (HLA-B*15:02 [in Han Chinese] and 
HLA-B*57:01) was characterized by crystallography (Chung et al., 2004;Illing et 
al., 2012). Both drugs bind to the HLA molecule directly underneath the antigenic 
peptide. 
Mechanisms of abacavir-specific T-cell activation has been studied extensively 
and the results obtained has resulted in new models of drug-specific T-cell 
activation. Specifically, the drug has been shown to modify HLA-B*57:01 
molecules via intracellular and extracellular pathways discussed in detail below: 
(Figure 1.4). 
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 The Altered Peptide Model of p-i HLA (intracellular pathway)   
After being transported into the cell, abacavir enters the endoplasmic reticulum; 
within the endoplasmic reticulum, it competes with peptides for binding with F9 
pocket of HLA-B*57:01. 
Abacavir alters the structure of HLA-B*57:01 and hence the peptide binding 
properties of the MHC molecule. Altered peptides then bind to the modified MHC 
in place of the usual peptides (Illing et al., 2012). Thus, abacavir binding would 
make the abacavir-HLA-B*57:01 appear like a foreign HLA-protein. Illing et al 
(2012) proposed that these new abacavir-modified HLA-B*57:01 binding peptides 
activate T-cells that cause hypersensitivity in the exposed patients; however, the 
nature of these peptides is yet to be defined.   
 The Allo-Immune Model of p-i HLA (extracellular pathway)   
By the extracellular pathway, abacavir binds directly to F9 pocket of the peptHLA-
B*57:01 complexes (Pichler et al., 2015).    
Experiments using abacavir and allopurinol suggest that drug binding immediately 
changes the peptHLA complex configuration without a peptide change. Such a 
binding interaction  is thought to trigger direct allorecognition by T-cells (Pichler et 
al., 2015). Drug binding occurs due to the flexibility of the peptHLA binding which 
allows abacavir to enter the binding site below the peptide without the need for 
peptide exchange (Yun et al., 2014).  
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1.4.2 Role of costimulation (danger signals) in p-i reactions 
Costimulation is not required in p-i HLA abacavir model, since abacavir-B*57:01 
peptide complexes are thought to act as an allo-allele and incite a strong direct T-
cell response.  
On the other hand, p-i TCR reactions are different and some may require 
costimulation. There are two possibilities:  
(1) The presence of a high-risk allele could be relevant when a peculiar T-cell 
clonotype is present (as the activation of CBZ specific T-cells in the presence of 
HLA-B*15:02 and TCR-Vβ-11-ISGSY).  
(2) Activation of T-cells by concomitant infection yielding upregulation of adhesion 
molecules and cytokine secretion. This may lower the threshold for T-cell 
reactivity (Pichler et al., 2015).     
  
Figure 1.4: P-i HLA concept showing its two possibilities (A):  Altered Peptide Model of 
p-i HLA (intracellular pathway) After being transported into the cell, abacavir binds to the 
peptide leading to altered peptide bound to HLA molecule. (B): The Allo-Immune Model of p-
i HLA (extracellular pathway) abacavir binding would trigger altered peptide-HLA complex 
configuration without a peptide change. In both possibilities, the change would be sensed by 
TCR as a new antigen that would incite an immune response. 
A B 
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1.4.3 Which hypothesis is the predominant? Hapten or 
Pharmacological Interaction? 
Advocates of the hapten hypothesis have used the sulfamethoxazole (SMX)-
nitroso (which is a metabolic derivative of SMX) as an example to support their 
hypothesis. SMX-nitroso acts as a hapten to instigate antigen-specific T-cell 
responses. SMX-nitroso is deactivated in vivo by antioxidants such as the non-
protein thiol glutathione (or ascorbate) and the addition of glutathione to T-cell 
assays blocks responses to SMX-nitroso. Individuals with low levels of cellular 
thiols (like people suffering from HIV) have higher levels of SMX-nitroso in their 
body. Patients with HIV develop hypersensitivity to SMX more often than the 
normal population and this has been attributed to decreased detoxification of the 
nitroso metabolite (Naisbitt et al., 2000). 
On the other hand, it has been shown that the addition of glutathione does not 
inhibit T-cell responses to the parent drug (SMX). In fact, clones responsive to the 
parent drug respond vigorously in the presence of SMX-nitroso and glutathione. 
This finding is explained by the reduction of the nitroso metabolite back to the 
parent drug and the activation of T-cells via the pharmacological interaction 
hypothesis (Naisbitt et al., 1999;Burkhart et al., 2001).  
  Other mechanistic hypotheses 
In addition to the above mentioned mechanisms, the immune system can also be 
triggered by alteration in the immune balance , epigenetic effects and direct 
activation of antigen presenting cells (Zhang et al., 2011). 
1.4.3.1.1 The immune imbalance 
The immune system is highly regulated, and various mechanisms control the 
balance between activation and tolerance. Over recent years, many new 
biological drugs have been developed to control autoimmune diseases such as 
multiple sclerosis (Uetrecht, 2009). 
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However, unexpectedly, although these drugs were developed to regulate 
immunosuppression, the response in some patients was autoimmunity. For 
example, anti-TNF antibodies have a promoter effect for a variety of 
immunological disorders like vasculitis and lupus (Ramos-Casals et al., 
2010;Mielke et al., 2008;Gonzalez-Lopez et al., 2008). Similarly, an interleukin-1 
receptor antagonist (Anakinra) induce psoriasis (Mielke et al., 2008;Gonzalez-
Lopez et al., 2008). Although the mechanisms underlying these findings are not 
clear, they may be linked to an unexpected alteration in the balance between 
activation and tolerance (Uetrecht, 2009). For example, anti TNF antibodies 
cause a shift of the T helper profile through blocking Th1 cytokine. Consequently, 
there would be a shift of the immune system toward Th2 profile. This would lead 
to the production of autoantibodies that would mediate the lupus like syndrome 
(Dedeoglu, 2009). 
1.4.3.1.2 Epigenetic effects 
Epigenetic effects are related to changes in gene expression that are caused by 
modifications of chromatin proteins (e.g. histone acetylation) , DNA (cytosine 5-
demethylation) (Szyf, 2009) and distinctive RNA types (e.g. non-coding RNA, 
miRNA and mRNA) (Trerotola et al., 2015). It has been shown that the 
pathogenesis of cancer, asthma, and some autoimmune diseases is linked to 
epigenetic changes. For example, hypomethylation of DNA in T-cells is related to 
the development of lupus disease. Epigenetic effects may be a potential 
mechanism involved in the generation of IDRs (Tesfa et al., 2009). For example, 
azacytidine, which is an anticancer drug used in treatment of myelodysplastic 
syndromes is also a causative factor for neutropenia via DNA hypomethylation-
induced apoptosis (Khan et al., 2008). 
1.4.3.1.3 Direct activation of antigen presenting cells  
Many drugs undergo oxidation to reactive metabolites by the action of 
myeloperoxidase in neutrophils and the antigen presenting cells (Uetrecht, 1990). 
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Such reactive metabolites stress APC or bystander cells and cause activation of 
APCs (i.e., upregulation of costimulatory receptors and/or cytokine release 
(Sanderson et al., 2007).  
The interaction between the APCs and the T-cell involves forming a reversible 
imine bond between the aldehyde group on the APC and an amino group on the 
T-cell (Rhodes, 1996). Drugs that have a hydrazine group in their structure like 
penicillamine and isoniazid bind to the aldehyde group on APCs irreversibly 
triggering their activation. This mechanism might contribute to the IDRs seen in 
patients exposed to isoniazid and penicillamine (Li et al., 2009;Rhodes, 1996). 
1.4.3.1.4 Bystander activation 
Bystander activation is the term given to the activation of unrelated (heterologous) 
T-cells with a different antigen specificity during an antigen specific T-cell 
response. This results in the production of phenotypic or functional changes 
through mechanisms that are independent of specific TCR stimulation. Bystander 
activation is thought to involve membrane bound receptors or soluble factors that 
bind to receptors other than TCRs (Bangs et al., 2006;Boyman, 2010). 
Bystander activation has been described in detail for CD8+ T-cells. Less is known 
about the bystander activation of CD4+ T-cells.  
Danger signalling molecules like LPS causes upregulation of activation markers 
in naïve and memory T-cells (Kamath et al., 2005). Furthermore, IFN-α/β induces 
memory CD8+/CD4+ T-cells proliferation that is mediated through IL-15 
production (Tough et al., 1996). Naïve CD8+ T-cells need an additional 
requirement that is the presence of MHC molecules in which there is “tickling” of 
TCR by interaction with low affinity self-peptide-MHC complexes without specific 
TCR stimulation. Following this activation naïve T-cells acquire memory 
phenotype (Kieper and Jameson, 1999).      
An alternative pathway has been suggested by Di Genova et al. for activation of 
heterologous memory CD4+ T-cells which express high levels of IL-2Rα CD25 
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(CD25high) and CD122int. These cells are proposed to undergo bystander 
activation by responding to IL-2 secreted from Ag-speciﬁc CD4+ T-cells 
stimulated by the TCR interacting with the MHC II-specific antigen complex (Di 
Genova et al., 2010). 
Bystander activation may play a role in drug hypersensitivity via two mechanisms: 
1. The activated DCs or the activated specific CD4+ T-cells by the drug 
antigenic determinants (which could be drug-modified peptides) would 
activate other (heterologous CD4/CD8) T-cells which are specific to 
alternative antigenic determinants that are present at sub-threshold levels. 
This would lead to an augmented drug-specific T-cell response and a more 
severe clinical syndrome. 
2. The activated DCs or the activated specific CD4+ T-cells by the drug 
antigenic determinants would activate the other (heterologous CD4/CD8) 
T-cells which are specific to autoantigens leading to a plethora of drug 
hypersensitivity reactions. 
1.4.3.1.5 Extended antigen priming (EAP) 
Extended antigen priming is defined as T-cell activation in response to suboptimal 
doses of cognate antigen x in the presence of fully activated T-cells in response 
to optimal dose of different antigen y. So far, this phenomenon has only been 
proven for CD4+ T-cells.   
This theory was proposed after the study of a three cell model incorporating DCs, 
responder T-cells specific to antigen y and an associator T-cell specific to antigen 
x. All these cells were in an environment in which there is optimal doses of antigen 
y and suboptimal doses of antigen x. The associator cells were shown to have a 
significantly higher proliferative response to suboptimal doses of antigen x, than 
when incubated with antigen x alone (Shibuya et al., 2015).   
The response was independent of IL-2.  This represents a distinctive feature that 
differentiates EAP from bystander activation of CD4+ T-cells, which is highly 
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dependent on IL-2 (Di Genova et al., 2010). EAP is however, dependent on CD40-
CD40L interaction which mediates costimulatory signals for CD4+ T-cell 
proliferation and IFN-γ secretion (Whitmire et al., 1999). It is postulated that 
responder cells stimulate the associator T-cells by providing critical signals like 
IL-12, IL-18, and IL-15 (Sattler et al., 2009). Moreover, the danger signals such 
as TLRs stimuli for APCs may trigger EAP by enhancing the secretion of 
costimulatory molecules and cytokines (Shibuya et al., 2015).                  
1.4.4 Risk factors for drug allergy:  
  Drug factors: 
 Nature of the drug:  
In general when the drug is highly protein reactive in nature, a high incidence of 
sensitization is expected (Thong and Vervloet, 2014). Moreover, the molecular 
weight of the drug may determine the mechanism of T-cell activation and the 
subsequent hypersensitivity reaction (see the mechanisms of drug allergy).  
 Degree of exposure (dose, duration, frequency):  
Sensitization is more frequent with higher doses and prolonged administration. Of 
great importance is intermittent administration in comparison to prolonged use. 
An example of this is penicillin, which has a high incidence of allergic reactions in 
the first two weeks of repeated administration compared to prolonged use (Thong 
and Vervloet, 2014).   
 Route of Administration:  
Topical administration is associated with the highest rates of cutaneous 
sensitization and should be avoided with certain agents. The intravenous route 
may be the least sensitizing route although it may be associated with severe 
anaphylactic reactions (Thong and Vervloet, 2014). 
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  Host Factors 
 Age and Sex:  
Some allergic reactions are less frequent in children and elderly people possibly 
owing to the immaturity or involution of the immune system respectively. 
Moreover, children are not generally exposed to multiple courses of the same 
drug. Allergic drug reactions are more common in females than males (Thong and 
Vervloet, 2014). 
 Pharmacogenetics (e.g. HLA type, acetylator status): 
Acetylation is an important metabolic detoxifying mechanism for drugs such as 
sulfonamides, isoniazid and hydralazine. The slow acetylator phenotype 
(common in African and Caucasian individuals (50-65%)), leads to drug 
accumulation in the body with its subsequent side effects (Scott and Thompson, 
2011).      
The discovery of a surprisingly strong association between expression of HLA 
alleles and specific forms of drug-induced liver and skin injury has changed the 
way in which researchers view this form of iatrogenic disease. In fact, certain 
reactions are no longer completely unpredictable. An example for this is the HLA-
B*1502 associated with carbamazepine induced SJS/TEN in Han Chinese in 
Taiwan, Thailand and India. However, some of these HLA allele associations are 
only seen in certain ethnicities. For example, HLA-B*1502 is not associated with 
carbamazepine induced SJS/TEN in patients with either Japanese or Europeans 
of non-Asian ancestry (Chung et al., 2004). 
Atopy by itself is not a risk factor for the development of allergic drug reactions 
although asthmatic patients are more prone to have severe reactions (as in food 
allergy) (Kewalramani and Bollinger, 2010).  
 Concurrent medical illness: (e.g. Epstein Barr virus (EBV), human 
immunodeficiency virus (HIV)). 
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The disease may promote the development of allergic drug reactions by altering 
the metabolic pathways and the immune status of the patient. Certain infections 
are associated with increased likelihood of developing an allergic drug reaction 
e.g. ampicillin maculopapular rashes in the patients with EBV (Epstein Barr virus) 
infections (Sullivan and Shear, 2001) and co-trimoxazole hypersensitivity in 
patients with HIV or AIDS (Harb and Jacobson, 1993). 
 Multiple Drug Hypersensitivity Syndrome: 
Certain patients will develop allergic reactions to multiple drugs. This 
phenomenon is referred to as multiple drug hypersensitivity syndrome (Thong and 
Vervloet, 2014). In recent years, Daubner et al (2010) reported that drug-reactive 
T-cells in patients with multiple drug hypersensitivity are contained in an in vivo 
pre-activated T-cell fraction and show a lower threshold for activation by drugs. 
Moreover, the patients have been shown to develop a primary immune response 
against each drug as studies with cloned T-cells revealed an absence of 
crossreactivity (Pichler et al., 2011).  
1.4.5 Genetic background of patients with drug hypersensitivity 
reactions 
There has been renewed interest in Pharmacogenetics after the completion of the 
first draft of the human genome. It is now recognized that most drug 
hypersensitivity reactions are polygenic. The outcome of drug exposure is 
dependent on the interaction of multiple genes in addition to the presence of 
specific, as yet ill-defined environmental factors. Each gene increases the risk of 
developing hypersensitivity reactions nevertheless it cannot per se induce the 
reaction. 
Over recent years, many genes have been shown to be risk factors for 
hypersensitivity reactions. Overall, these genes can be divided into four major 
categories: 
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  Bio-activation genes 
The genes control drug metabolism leading to the production of stable or reactive 
metabolites. This process is achieved by phase I drug metabolizing enzymes, 
which mediate oxidation, reduction and hydrolysis reactions (Bugelski, 2005). The 
most important of these are the cytochrome P450 superfamily of enzymes. Many 
of which are expressed polymorphically.  
  Bio-inactivation genes 
These are genes that influence the bioinactivation of the drug metabolites. Bio-
inactivation genes encode phase II enzymes that catalyse acetylation, sulfation, 
glutathione and glucoronidation reactions. The phase II metabolizing enzymes 
enhance the rate of detoxification of drugs. Altered detoxification can result in the 
development of immunogenicity. An example for that is the thiomersal toxicity 
(Bugelski, 2005). 
  Genes controlling immune-responsiveness 
Genes coding for MHC, T-cell receptors, and co-stimulatory/co-inhibitory 
molecules control the generation of the principal mediators of the cellular immune 
response. These are discussed in much greater detail below. 
  Genes controlling tissue injury and repair 
The balance between these genes is of critical importance for limiting tissue 
damage. Typically, the candidates would be cytokines, chemokines and 
prostaglandins. 
Although all the previously mentioned classes of genes are necessary to trigger 
an immune response to a drug, the latter two types are by far the most influential 
(Naisbitt et al., 2003a).  
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1.4.6 HLA typing, the old suspect, the new method 
HLA (human leukocyte antigen) system is a gene complex on chromosome 6 that 
is responsible for the expression of two types of MHC molecule: MHC-I (includes 
MHC-A, B and C) which are expressed by all nucleated cells, MHC-II (includes 
MHC-DP, DQ and DR) which are expressed by APCs, some endothelial cells, 
thymic epithelial cells and B-cells.  
Each individual has two sets of six HLA allele genes. Figure 1.5 summarizes the 
system for naming HLA alleles. 
MHC molecules have a vital role in adaptive immunity by presenting antigens to 
TCRs of T-cells. Since the discovery of HLA is a growing evidence of a 
relationship between expression of specific HLA alleles and susceptibility to 
different forms of drug hypersensitivity reaction. 
 
 
Figure 1.5: Nomenclature system for HLA 
   
Earlier studies utilized serology for HLA typing. In contrast, nowadays high-
resolution genotyping has been introduced. The knowledge of linkage 
disequilibrium patterns has made a significant contribution by helping researchers 
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to reach a definitive conclusion particularly in relation to the anti-retroviral drug, 
abacavir induced SJS with HLA-B*57:01 (Mallal et al., 2002); antiepileptic drugs 
(AEDs): carbamazepine (CBZ) and phenytoin (PHT) (Locharernkul et al., 2008) 
and lamotrigine (LTG) induced SJS with HLA-B*15:02 in Han Chinese  (Man et 
al., 2007)  and allopurinol induced SJS in  Han Chinese with HLA-B*58:01 (Hung 
et al., 2005). 
Carbamazepine (CBZ) contains an aromatic ring, which is shared between 
several drugs. These include phenytoin (PHT), lamotrigine (LTG) and 
oxcarbazepine (OXC). Clinically, it is known that certain patients exposed to each 
of these drugs develop a multiple hypersensitivity syndrome. A study conducted 
in Thailand has shown that the presence of HLA-B*15:02 allele is a risk factor for 
developing hypersensitivity to PHT in addition to CBZ. Consequently, HLA-
B*15:02 has gained extra focus by finding that it confers a class effect in addition 
to conferring a drug effect. Such a discovery has paved the way for the 
recommendation to avoid CBZ, OXC and PHT for the HLA-B*15:02 carrier, while 
LTG should be used with caution (Hung et al., 2010). 
  Genetic predisposition is specific for the phenotype 
It should be kept in mind that the association of HLA-B*1502 allele is only valid 
for CBZ-induced SJS/TEN, but not for other types of CBZ hypersensitivity like 
maculopapular reactions or DRESS (Li and Uetrecht, 2009, Pichler, 2003). These 
conditions are associated with HLA-A*31:01 carriage in individuals of European 
and Japanese ancestry.   
HLA-B*1502 is more prevalent in Han Chinese while HLA-A*3101 is more 
prevalent in Europeans and Japanese ancestry. Consequently, the CBZ-induced 
reactions profile varies with location (i.e., SJS and TEN are more common in 
Thailand) (Hsiao et al., 2014).     
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1.4.7 Clinical features of drug hypersensitivity 
It is important to realize that most immune responses to drugs are silent, i.e. in 
most cases of contact with the drug under investigation there is no overt clinical 
presentation of drug hypersensitivity. In patients that develop clinical 
manifestations, diagnosis is dependent on several clinical features that suggest 
an immunological event: 
1. Wide spectrum of clinical presentation in terms of both magnitude and nature 
of the tissue injury to the same drug (Table 1.4) (Bugelski, 2005). The famous 
example is halothane, which can cause two forms of drug-specific hepatic 
damage. Reductive metabolism leads to a mild form of self-limiting tissue 
injury referred to as type I hepatitis (in up to 20% of patients). On the contrary, 
oxidative metabolism may result in the production of acyl halide metabolites 
that bind to protein and lead to the development of immune-mediated 
hepatotoxicity (type II hepatitis). Although the latter is less common than type 
I hepatitis, it is more severe and has a higher mortality (Naisbitt, Pirmohamed 
and Park, 2003)    
2. Constitutional symptoms of fever, rash, eosinophilia, arthralgia and 
lymphadenopathy. 
3. Latency period of about two weeks for the reactions to manifest. 
4. On re-exposure to the provoking agent, the reactions appear more rapidly and 
are more severe. 
5. Resolution of the reactions after drug withdrawal. Moreover, reactions can be 
averted by the gradual increase in the dose over time; a process that indicates 
the development of tolerance (Naisbitt et al., 2003a). 
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1.4.8 Clinical presentation of IDRs: 
 Autoimmunity:  
Autoimmunity is the inability of an organism to identify its constituent parts as self. 
This results in the action of its own immune system against these cells or tissues.  
Autoimmunity involves the development of autoantibodies and/or effector T-cells 
with specificity against self-proteins. The clinical presentation is broad and can be 
classified into either a generalized autoimmune reaction (e.g. idiopathic lupus) or 
organ specific reactions such as auto immune hemolytic anemia, autoimmune 
hepatitis and pemphigus vulgaris (Pichler, 2003). 
Accordingly, the autoantibodies may develop against the nuclear antigen, 
erythrocytes or other protein antigens. These autoantibodies do not disappear 
immediately after withdrawal of the drug but they take several weeks to do so 
since the autoantigen is still present. Many drugs are known to produce 
Table 1.4. Expression of Immune Mediated Adverse Effects. Adapted from (Bugelski, 
2005) 
Severity of 
Response 
Effector 
Mechanisms 
Clinical presentation Examples 
No overt signs 
or symptoms 
Cell mediated 
Humoral 
In vitro proliferation of 
lymphocytes antidrug 
antibodies 
Sulfamethoxazile 
,Nomifensin and 
amodiaquin 
Trivial or mild 
Cell mediated 
Humoral 
Maculopapular 
exanthema, Urticaria 
Amoxicillin   
 Cephalosporins 
Moderate 
Cell mediated 
Humoral 
Bullous exanthema, 
Anticonvulsant 
hypersensitivity 
syndrome 
Amoxicillin   
 Phynetoin 
Severe 
Cell mediated 
Humoral 
Epidermal necrolysis 
Haemolytic anemia 
Sulfamethoxazole 
Penicillin 
Life threatening 
Cell mediated 
Humoral 
Hepatic failure 
Anaphylaxis, 
Halothane 
Penicillin 
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generalized autoimmune reactions (Fritzler and Tan, 1978). However, the clinical 
and the laboratory features of these reactions overlap with the idiopathic form so 
after drug withdrawal it is hard to differentiate between them (Wiik, 2008). 
Common clinical presentations of drug-induced lupus include fever, myalgias, 
arthritis, and serositis involving the pleura and/or the pericardium. Drugs known 
to induce lupus include biological agents such as anti-TNF-α, (IFN)-α and various 
cytokines. Autoimmunity often develops around one year after starting treatment 
in spite of the fact that antibodies and specific T-cells are detectable much earlier 
(Woosley et al., 1978). The detection of an antigen-specific response ex vivo is 
an essential characteristic for the diagnosis (Zhang et al., 2011). 
  Skin rashes 
These are the most common clinical feature of drug hypersensitivity. In contrast, 
other reactions like allergic hepatitis, nephritis and agranulocytosis occur much 
less frequently (Bugelski, 2005).  
The skin rashes induced by drugs ranging in severity from the mild maculopapular 
rash to life-threatening Steven Johnson Syndrome (SJS) and toxic epidermal 
necrolysis (TEN).  
1.4.8.2.1 Drug induced urticaria 
It represents only 5% of all cutaneous drug reactions (Nigen et al., 2003). 
Urticarial lesions also known as “hives” are itchy, red, blotches or wheals, which 
are pale in the centre while red around the rim. They are widely distributed over 
the body and sometimes associated with swelling of the subcutaneous tissues 
known as “angioedema”. These lesions disappear within few hours without a 
remnant trace. β-lactam antibiotics are common causes of urticaria. Binding of the 
β-lactam ring to proteins and the production results in immune activation and the 
generation of IgE antibodies with specificity against the drug modified proteins 
(Levine and Price, 1964). It should be kept in mind that not all drug-induced 
urticarias are caused by antibodies. For example, the inhibition of kinin 
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degradation that is caused by angiotensin converting enzyme inhibitors, the 
altered arachedonic acid metabolism caused by aspirin and other NSAIDS 
(Mathelier-Fusade, 2006). These are two examples of pseudoallergic (non-
allergic) reactions.           
1.4.8.2.2 Maculopapular drug eruptions 
Maculopapular eruptions are the most common IDRs. Usually these reactions 
develop within 1-2 weeks after drug exposure and more rapidly on rechallenge or 
if the patient is previously sensitized (Torres et al., 2009). Maculopapular rashes 
are T-cell-mediated. Histological analyses have shown a cellular perivascular 
infiltration of T-cells (mainly CD4) in the dermis together with the expression of 
skin homing receptors like cutaneous lymphocyte antigen (CLA), the chemokine 
receptors like CCR6 and CCR10 and an elevated expression of their ligands 
(CCL20 and CCL27 respectively) in skin. T-cells secrete cytokines and cytolytic 
molecules when activated with the drug and chemokines that attract other cells 
inflammatory cells that contribute towards the tissue injury. 
1.4.8.2.3 Fixed Drug Eruption (FDE) 
Fixed drug eruptions are characterized by the development of erythematous 
round lesions with brown to dusky purple or red colour plaques and sometimes 
feature blisters, which develop days or weeks after taking the causative drug. 
These lesions are associated with itch and/or burning sensation in the affected 
area. Usually specific areas of the skin are affected. These include the feet, hands 
and mucosal surfaces. The site of the eruption is fixed, which means that the 
patient develops the same eruption at the same site, after re-exposure to the drug. 
The eruption heals 7-10 days after drug withdrawal; however, hyperpigmentation 
may be permanent (Pal et al., 2014). It is believed that the FDE is mediated by 
intraepidermal resident memory effector CD8+ T-cells. Weak HLA associations 
have been described with some drugs such as sulfonamides, tetracyclines and 
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NSAIDs (Pavlos et al., 2012). Patch test has been reported to be +ve at the site 
of the lesion but reliability of the assay is drug dependent (Andrade et al., 2011).  
  Drug reaction with eosinophilia and systemic symptoms 
(DRESS) 
The DRESS syndrome is characterized by the development of fever with a wide-
spread maculopapular rash and multi-organ involvement. Furthermore, white cell 
abnormalities such as eosinophilia are common features of DRESS. 
Lymphadenopathy is common and often misdiagnosed as viral infection. 
80% of cases with DRESS affect the liver, 40% kidneys and 38 % lungs. The heart 
and pancreas are involved less commonly (Walsh and Creamer, 2011). Research 
has shown some association with the reactivation of human herpes viruses 
especially HHV-6 and cytomegalovirus (CMV). DRESS features can occur 2-6 
weeks after the discontinuation of the culprit drug. It has been hypothesized that 
specific-specific T-cells are the initial mediators of the syndrome. Viral-specific T-
cells are activated at a later time-point and are thought to be responsible for 
extending the duration of the disease (Choudhary et al., 2013). Drugs commonly 
associated with DRESS include carbamazepine, phenobarbital, phenytoin and 
sulfonamides (Seishima et al., 2006). Laboratory findings show antithyroglobulin 
and antithyroid peroxidase antibodies in 30-40% of patients (Gupta et al., 1992). 
In addition to hematological abnormalities in the form of eosinophilia, 
thrombocytopenia, and atypical lymphocytosis. Reactivation of HHV-6 has been 
added to the scoring criteria of screening for DRESS in Japan (Shiohara et al., 
2006).  DRESS has a 10% mortality rate (Walsh and Creamer, 2011). 
1.4.8.3.1 Steven Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) 
These are life threatening skin rashes characterized by the development of fever, 
keratinocyte apoptosis and prominent blistering of the skin.  The two conditions 
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are thought to be mediated via the same immunological mechanism; and the main 
different being the disease severity. SJS is associated with epidermal detachment 
of up to 10% of the skin surface area, while in TEN more than 30% skin 
detachment is observed. Mortality rates in patients with TEN exceed 30%. 
Detachment of 10-30% of the skin is referred to as transitional SJS-TEN 
(Mockenhaupt, 2009). The pathology of both SJS and TEN is characterized by 
extensive keratinocyte apoptosis resulting in the separation of the dermis from the 
epidermis, which is thought to be caused by T-cells. One possible mechanism 
involves the interaction of Fas ligand with its receptor on target cells. Another 
possible mechanism involves cytolytic molecules such as perforin and granzyme 
B that are released by T-cells. Most recently, granulysin has been found in high 
levels in blister fluid of patients with TEN indicating that it may be an important 
mediator of tissue injury (Chung et al., 2008). 
  Hematologic Idiosyncratic Adverse Reactions 
1.4.8.4.1 Drug induced hemolytic anemia  
Is characterized by increased red cell destruction through the effect of antibody 
mediated complement activation (Aster, 2010).  
One of the famous drugs known to be associated with the production of antibodies 
is penicillin especially if it is given in high doses for more than 10 days (Garratty, 
1993). 
1.4.8.4.2 Drug induced thrombocytopenia 
Thrombocytopenia occurs when the platelet count is lower than (150000 
platelets/µL). When the count drops to less than (10000 platelet/µL) the patient is 
at high risk of life-threatening hemorrhage (Aster, 2010). The commonest 
manifestation of thrombocytopenia is spontaneous bruising, which is usually 
present after a week or more of the offending treatment (Aster and Bougie, 2007). 
A famous example of the drug-induced thrombocytopenia is heparin. Antibodies 
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against the heparin–platelet factor 4 complex have been detected in patients with 
thrombocytopenia (Warkentin, 2003)(Warkentin, 2003). Although these reactions 
are immune mediated, they are not necessarily associated with immune memory 
which is a common feature of immune-mediated reactions (Zhang et al., 2011). 
Therefore, if a patient with a known history for heparin-induced thrombocytopenia 
is rechallenged with heparin he may not essentially develop thrombocytopenia or 
even if he did so it does not occur more rapidly (Warkentin and Kelton, 2001). 
1.4.8.4.3 Drug induced agranulocytosis 
Agranulocytosis is defined as a neutrophil count less than 500 neutrophils/µL of 
blood. This makes the patient a high risk of acquiring a serious and potentially 
fatal infection. Agranulocytosis is induced by a large group of drugs including 
analgesics, antipsychotics, antithyroid medications and anticonvulsants (Andres 
et al., 2006). Cancer chemotherapy is also a well-known cause of 
agranulocytosis, but it is usually not idiosyncratic. The drugs mentioned above do 
cause idiosyncratic agranulocytosis and in several cases the reactions are 
believed to be immune mediated (Tesfa et al., 2009).   
Clozapine induced agranulocytosis is the most widely studied form of 
agranulocytosis. A weekly blood count is performed in patients receiving the drug 
to prevent agranulocytosis. Drug-dependent antibodies have not been detected 
in patients on clozapine therapy. However, clozapine induced neutropenia is 
related to neutrophil metabolism. Clozapine is oxidized by myeloperoxidase to a 
nitrenium ion metabolite that binds to neutrophils causing activation of the 
apoptotic cascade (Williams et al., 2000).  
The covalent adducts formed in neutrophils have the potential to initiate an 
immune response. One study has shown that there is a weak association between 
clozapine induced agranulocytosis and the presence of certain HLA genotypes in 
Ashkenazi Jewish population. These HLA genotypes include DRB1*04:02, 
DQB1*03:02, and DQA1*03:01. While in non in non-Jewish patients there was an 
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association with HLA-DR*02, DQB1*05:02, DQA1*01:02 (Yunis et al., 1995) , 
HLA-DQB1 (126Q) and an amino acid change in the extracellular binding pocket 
of HLA-B (158T) (Goldstein et al., 2014). The time needed to elicit clozapine 
agranulocytosis is relatively short 6-12 weeks and this period does not shorten on 
rechallenge so this may suggest an autoimmune mechanism (Uetrecht, 2009).  
1.4.8.4.4 Drug induced aplastic anemia 
Aplastic anemia is relatively rare in comparison to drug induced agranulocytosis, 
but its severity had limited the use of several drugs including chloramphenicol and 
felbamate (Young et al., 2008). It has been suggested that cytotoxic T 
lymphocytes cause bone marrow destruction. The dramatic response seen in 
patients exposed to immuno-suppressive therapy suggests that the etiology is 
immune mediated (Young, 2002).  
  Idiosyncratic liver toxicity 
The liver is a major site for the drug metabolism. Realising that IDRs may involve 
a role mediated by reactive metabolites, it is not surprising that the liver is the 
target of many reactions. In USA, it has been reported that idiosyncratic drug 
induced liver injury (IDILI) accounts for about 13% of acute liver failure cases 
(Ostapowicz et al., 2002). Moreover, it is the most common cause of drug 
withdrawals from the market (Temple and Himmel, 2002). The mechanisms of 
IDILI are not well understood and the immune system involvement is more 
controversial than other types of IDRs (Zhang et al., 2011). 
In comparison to other types of IDRs, there is a time interval between the 
exposure to the drug and the development of the IDILI. Usually, this takes about 
1-3 months, but sometime the delay may be significantly longer. For certain drugs, 
the time between initial exposure and the development of IDILI is than one year 
(Lawrenson et al., 2000). In some cases, there is rapid development of symptoms 
when the drug is re-administered but this is not universal. In a few cases, IDILI is 
associated with fever, rash, eosinophilia. Such findings provide the clinical 
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evidence that the reactions may involve the adaptive immune system 
(Zimmerman, 1999). Moreover, antidrug antibodies or autoantibodies have been 
detected in the serum of patients with IDILI but little is known about their 
significance in the pathogenesis of liver injury (Liu and Kaplowitz, 2002). The 
histology of IDILI is similar to any other types of liver injury. The most common 
comparison is with viral hepatitis. Both conditions involve mild to moderate 
inflammation and lymphocytic and eosinophilic infiltration (Kleiner, 2009). IDILI 
caused by drugs such as isoniazid and ketoconazole are classified as metabolic 
idiosyncrasy (Zimmerman, 1999). 
A study has shown that HLA association with IDILI (that is induced by structurally 
diverse drugs: flucloxacillin, co-amoxiclav, ximelagatran, lapatinib, lumiracoxib) 
reside on common HLA haplotypes (B*57:01, DRB1*15:01, DRB1*07:01, 
DQA1*02:01 and DRB1*15:01 respectively) which were present in populations of 
diverse ethnicity (Alfirevic et al., 2012). 
1.4.9 Diagnostic tests 
In some cases of drug hypersensitivity there may be laboratory findings that 
provide clues for the underlying mechanisms. These tests also provide a more 
solid ground for diagnosis. 
In vivo diagnostic tests include skin tests and analysis of the eosinophil count and 
the presence of autoantibodies. In vitro, it is possible to detect drug-specific T-
cells and the presence of certain cytokines secreted from drug-stimulated PBMCs 
(Gómez et al., 2012). Specific tests and their applicability domain are discussed 
in detail below. 
  In vivo tests 
1.4.9.1.1 Serum tests 
These include a variety of markers like tryptase level and histamine level. These 
markers are of value in diagnosing type I hypersensitivity reactions (Pichler, 2007) 
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1.4.9.1.2 Skin tests 
These include prick, intradermal and patch tests (Bernstein et al., 2008). These 
tests give variable results depending on the type of reaction and the drug.  They 
were shown to be of high sensitivity 70% and specificity 97-100% for benzyl 
penicillin type I reactions (Kranke and Aberer, 2009). On the other hand, low 
sensitivity and specificity was found with non-immediate β-lactam reactions in 
patients with cystic fibrosis (Whitaker et al., 2012).  Padial et al. showed that only 
9% of patients with non-immediate β-lactam hypersensitivity reactions had 
positive delayed intradermal tests (Padial et al., 2008). Although skin tests do not 
offer a predictive value for the β-lactam non-IgE dependent reactions, they are 
useful to exclude concomitant type I hypersensitivity reaction (Khan and Weiss, 
2013). 
1.4.9.1.3 HLA typing 
Significant advances have been made in pharmacogenomics over the last 
decade. Most significantly, several forms of hypersensitivity are now known to be 
exquisitely linked to expression of a single HLA allele.   
HLA phenotype is important when there is high linkage disequilibrium that yields 
high positive and negative predictive values. The famous example for HLA 
phenotype implementation is abacavir hypersensitivity and the association with 
HLA-B*57:01. HLA-B*57:01 testing is associated with a positive predictive value 
47.9% and negative predictive value 100% (Mallal et al., 2008). Thus, identifying 
an HIV patient with HLA-B*57:01 leads to avoiding abacavir and prescribing a 
safer alternative. This has eliminated abacavir hypersensitivity. 
1.4.9.1.4 Drug provocation test (DPT) 
This test provides the gold standard to confirm or exclude the drug hypersensitivity 
as the patient is re-exposed to the suspect drug. However, its use in patients with 
positive skin tests is limited by ethical reasons as there is a risk that the patient 
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may generate a severe systemic reaction (Aberer et al., 2003). Moreover, the 
evaluation of the test result for management decision is still controversial 
(Romano et al., 2004).  
  In vitro tests 
In vitro tests have the advantage over the in vivo tests that they are free of risk to 
the patient; however, the sensitivity and specificity of the assays have not been 
defined, which limits their use as for diagnosis.   
1.4.9.2.1 Lymphocyte transformation test (LTT) 
This test depends on proliferative responses of patients T-cells in response to 
drug. PBMCs are incubated for 6 days in a 5% CO2 ventilated incubator at 37ºC 
in the presence and absence of the culprit drug. Radioactive thymidine is added 
for the last 16 hrs. Later, radioactivity in drug-treated and control wells is counted 
which represents the degree of thymidine incorporation to DNA. Stimulation index 
(SI) is the ratio between the proliferative response of in drug-treated wells over 
the proliferative response of the medium control. SI≥2 is usually regarded as 
positive (Pichler and Tilch, 2004).  
One research has assessed the sensitivity of LTT to be (74%). This is significantly 
higher than that of skin tests while the specificity to be 85% (Blanca et al., 2009). 
Other studies have confirmed the reliability of this test in the diagnosis of β-lactam 
allergy. (Nagao-Dias et al., 2009). 
3H-thymidine uptake proliferation assay is a simple modification of LTT in 
which the tested cells are primed (memory) T-cells clones (TCCs). Therefore, the 
proliferative response is expected to be much faster and so the incubation is 
restricted to (48hrs).       
More recently, modifications have been made to the LTT. Specifically, multiple 
readouts have been used to analyse different aspects of the T-cell response.  
These include pulsing APCs, MHC blocking and others. 
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1.4.9.2.2  Enzyme Linked Immunospot Assay (ELISPOT) and 
Intracellular Cytokine Staining (ICS) 
Both assays are used to study different phenotypes of type IV hypersensitivity 
reactions (Scheibenbogen et al., 1997). 
They are qualitative and quantitative tools to measure release rate of target 
cytokine(s) by specific T-cells in response to pharmacological doses of a specific 
drug. 
 ELISPOT assay  
The T-cells are incubated with autologous antigen presenting cells and the drug 
together in a membranous plate that is coated with an anti-cytokine antibody. The 
antibody binds the cytokine when it is released from the T-cells. Subsequently a 
second antibody is added to allow visualization of the bound antibody. Following 
addition of an enzyme substrate,  dark coloured spots representative of a drug-
reactive cell are visualized (Kalyuzhny, 2005). It has been estimated that 
ELISPOT can detect 1 in 100000 cells (Asai et al., 2000).  
  Intracellular Cytokine Staining (ICS) 
It is an assay that is reliant on flow cytometry. The assay allows the analysis of 
individual cells in mixed populations.  T-cells are stimulated with antigen in the 
presence of protein transport inhibitor, which prevents cytokine release from the 
cells. Cells are then washed then anti-cytokine antibodies are added. Cells 
expressing the cytokine are counted using fluorescence labelled antibodies (Rive 
et al., 2013). The flow cytometer uses laser beams of different wavelengths to 
detect the fluorochromes and so by using different fluorochromes labelled with 
different antibodies we can detect multiple cytokines simultaneously (Freer and 
Rindi, 2013). 
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1.4.9.2.3 Flow cytometry  
Flow cytometry has gained great importance over the last decade after the new 
advances, which added more capabilities for this technology. In addition, it 
enables us to quantify cell proliferation using CFSE staining methods (Boks et al., 
2010). Moreover, it can sort cells and thus, we can enjoy having cells of specific 
criteria with high purity that can be utilized later in cloning assays. 
1.4.9.2.4 T-cells priming and/or cloning assays 
Over the last two decades, we have witnessed great leaps in our knowledge of T-
cell physiology and its role in immunity, which enabled us to develop new 
techniques to prime naïve T-cells and/or make clones from memory T-cells. These 
techniques are of value when the primed (memory) drug-specific T-cells are low 
in number in patient blood or tissue when polyclonal T-cell responses are not 
detectable. Furthermore, T-cell cloning assays are of value when the anticipated 
drug reaction is so serious e.g., SJS and therefore any trial to induce such reaction 
in vivo would be unethical.   
In addition, drug specific clones provide us with valuable chance to study the 
phenotype and function of T-cells under controlled fixed conditions and thus 
avoiding any bias that may ensue in vivo due to interaction of the patient with the 
environment.       
1.4.9.2.5  Others 
Other in vitro tests include radioallergosorbent testing (RAST), enzyme linked 
immunosorbent assay (ELISA) or fluoroenzyme immunoassay (FEIA) and 
basophil activation test. These tests are all designed to measure the level of 
the IgE expressed in response to an allergen. Hence, they are of no value in 
diagnosing non-immediate drug hypersensitivity reactions (Rive et al., 2013). 
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1.4.10 Diagnostic approach 
Type B drug reactions are a cause of significant morbidity and mortality; 
moreover, they are unpredictable. Type I and type IV reactions are the most 
common in clinical practice. Careful clinical history and phenotyping are the main 
pillars for diagnosis and patients’ stratification and are of value to direct the choice 
of diagnostic tests with the outcome of identifying patients with true 
immunologically mediated drug reactions.  
The gold standard for evaluating type I reactions involves in vivo testing such as 
prick and intradermal tests with validated reagents and drug provocation test. 
Type IV delayed reactions are T-cell mediated involving a variety of cell types and 
multiple cytokines in addition to variable presentation both in type and magnitude. 
In vivo tests such as patch testing and intradermal testing are conducted with 
delayed readings together with ex vivo testing such as LTT and ELISPOT to 
support the diagnosis of immunologically mediated drug reactions to a specific 
drug. However, the sensitivity of these tests are less than 100% and so given the 
severity of these adverse drug reactions the patients are advised to avoid using 
the suspect drug and to replace it with a safer prescribed one (Rive et al., 2013). 
1.4.11 The outcome of screening and diagnostic testing for 
immediate and delayed drug hypersensitivity reactions 
Combination of the tests mentioned above are useful clinical tools for the 
delineation of the nature of the drug reaction, clarifying or removing the label of 
immediate drug reaction and providing the patient with specific valuable 
information about which drugs or classes of drugs can be safely taken in future. 
Clinical studies have highlighted that most patients labelled with immediate drug 
hypersensitivity can safely take the culprit drug at some time after. The most 
common reason is that the initial presentation was not an IgE mediated reaction; 
moreover, the reaction is not permanent and there is an attrition with time. 
Approximately, 10% of patients annually lose skin test reactivity to penicillin and 
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80% of patients over 5 years lose skin reactivity to amoxicillin. So, false labelling 
of patients as drug allergic imply that these patients may need to take more toxic 
and more expensive drugs which are actually unnecessary (Rive et al., 2013). 
1.5 Overview on the immune system 
1.5.1 Immunology 
Immunology is the study of the body’s defence against infection. Its origin is 
attributed to Edward Jenner who observed in the 18th century that the mild disease 
of cowpox or vaccinia could confer a protection from the fatal version of the 
disease. Although Jenner introduced vaccination, he knew nothing about the 
causative agent. It was not until late the 19th century when Robert Koch 
demonstrated that the disease is caused by specific microorganisms (Murphy, 
2012) 
1.5.2 The immune response 
The immune response can be divided into two types: innate and the adaptive 
immune responses: 
  Innate immune response 
The innate response is characterized by being immediate, non-specific and 
incapable of developing an immunological memory that can identify the 
pathogenic microorganisms when they re-attack the body.  
Components of the innate immunity 
 Physical barriers  
These include the skin, mucous membranes, epidermis and dermis. In addition to 
being a physical barrier ,the skin provides low pH due to the presence of lactic 
and fatty acids, while the dermis produces sebum with a low ph. (Khan, 2008). 
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 Chemical barriers 
Chemical barriers include endogenous chemicals like the hydrolytic enzymes 
within saliva and the low pH of the stomach and the vagina. One of the main 
elements in the innate immune response is the complement system which plays 
a tremendous role in combatting infections through several mechanisms which 
include:  opsonisation, chemotaxis , cell lysis and clumping of antigen bearing 
agents (Parham, 2009).  In addition to that there are other  chemicals that mediate 
immunological action like the cryptidins, α-defensins, β-defensins, interferons 
(IFNs), and surfactant proteins A and D (Khan, 2008).  
 Cellular barriers 
Several cell groups are responsible for combatting the invading microorganisms. 
These are the natural killer cells, macrophages, monocytes, granulocytes (which 
include neutrophils, eosinophils and basophils) and dendritic cells (Murphy, 
2012;Khan, 2008).  These cells engulf the offending agent by the mechanisms of 
pinocytosis, receptor mediated endocytosis, and phagocytosis. While endocytosis 
is not cell specific and is carried out presumably by all cells, phagocytosis is more 
cell-specific and results in the ingestion of the particulate as well as the whole 
microorganism. The cells that are involved in the phagocytosis are the 
macrophages, monocytes, neutrophils and dendritic cells (Khan, 2008). 
 Innate mechanisms 
The recognition of the microbes by innate mechanisms is dependent upon 
common microbial patterns, which trigger the activation of innate immune cells. 
These include: lipopolysaccharides (LPS), mannose, fucose, teichoic acid and N-
formyl peptides. These common microbial patterns are called pathogen 
associated molecular patterns (PAMPs) (Khan, 2008). These PAMPs are 
recognized by Toll like receptors (TLRs) that are expressed by the cells of the 
innate immune response in addition to other types of cells like the fibroblasts or 
the endothelial cells (Alegre et al., 2008). This mechanism enables the innate 
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immune response cells  to react effectively against a wide spectrum of invading 
pathogens ranging from viruses to parasites (Lemaitre et al., 1996). 
Upon the recognition of the pathogen by the TLRs, normally by cells residing in 
the proximity of the infection site, the cells start to secrete chemokines (which are 
defined as soluble proteins that act as a chemotactic factor for immune cells). An 
example includes CCL5 (Bachmann et al., 2006). Moreover, the activated 
resident cells and macrophages secrete soluble mediators known as cytokines 
such as the tumour necrosis factor (TNF-α) and the interleukins. These molecules 
can affect the behaviour of the cells and boost the phagocytic ability of cells of the 
innate immune system. As a result of the high levels of the cytokines and the 
chemokines, cells and plasma proteins accumulate at the site of infection causing 
the classical signs of inflammation which are swelling, redness, pain and heat 
(Moser and Leo, 2010).  
  Adaptive immune response 
Although it is slower in onset in comparison to the innate immune response, the 
adaptive response is more efficient. In addition to that, the adaptive immune 
response is characterized by its unique feature of generating immunological 
memory, which entails that the second exposure of the body to the offending 
agent would trigger a stronger and quicker specific response in comparison to the 
1st exposure (Murphy, 2012). The adaptive immune response is mediated by 
humoral and cellular mechanisms that are designed specifically to eliminate the 
pathogen (Khan, 2008). For a comparison between innate and adaptive immunity 
(Table 1.5). 
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 Humeral mechanisms (antibodies)  
Antibodies (also called immunoglobulins) are glycoproteins produced by activated 
B-cells during the immune response. They are synthesized in response to specific 
antigens and the can bind only the antigen which they are produced for. 
Antibodies can be circulating either freely or in a bound form attached to cells by 
the Fc receptors (Gordon Betts J, 2016). The antibody molecule (monomer) is a 
Y-shaped structure that is composed of two identical light (L) and heavy (H) chains 
that are connected by disulfide bonds. Both light and heavy chains are composed 
of constant and variable regions. Papain splits the immunoglobulin molecule into 
three fragments of equal size. Two are the antigen binding fragments (Fab) and 
the third fragment is the crystallisable fragment (Fc). Antibodies are highly diverse 
molecules due to high variability in the Fab fragment. This variability enables each 
antibody to bind to a specific antigen. There are five different classes of heavy 
chain. The constant region of the heavy chain is identical in all antibodies of the 
same class. The antibodies are different according to the heavy chain of the Fc 
region and this difference is responsible for the functional variability of the different 
classes of antibodies (Khan, 2008).  
Table 1.5: Comparison between the innate and adaptive immunity.       
 Innate Adaptive 
Stimulation 
Not required (ready for 
immediate action) 
Required (needs a previous 
exposure) 
Specificity Minimal 
Highly specific 
Self vs non-self-discrimination 
Receptor mediated 
Response 
Within minutes 
No change in quality and 
quantity over time 
Develops over days 
Improved by previous exposure 
Memory No Yes 
Soluble 
factors 
Lysozyme, complement, 
acute phase proteins, 
interferons, cytokines 
Antibodies, cytokines, interferons 
Cells 
Phagocytic leukocytes, 
natural killer cells 
T-cells, B-cells 
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Antibodies have two main roles. The first is to bind to the its specific antigen such 
as the virus or bacteria rendering it non-pathogenic. The second is that it triggers 
the recruitment of other cells or molecules to destroy the antigen bound to the 
antibody (Moser and Leo, 2010). See Table 1.6. 
 Cellular mechanisms 
The main cells involved in the adaptive immune response are B and T 
lymphocytes. Their classification and function is discussed below.        
1.5.3 The immune system cells 
The immune system is composed of various cell types with different roles. The 
phagocytes are involved in eliminating pathogens in both the innate and the 
Table 1.6: The 5 classes of antibodies. Adapted from (Gordon Betts J, 2016). 
 IgM IgG IgA IgE IgD 
Heavy chain µ γ α ε σ 
Number of 
antigen 
binding sites 
10 2 4 2 2 
Percentage of 
total antibody 
in serum 
6% 80% 13% 0.002% 1% 
Crosses 
placenta 
no yes no no No 
Fixes 
complement 
yes yes no no No 
Fc binds to  phagocytes  
Mast cells 
and 
basophils 
 
Function 
Main antibody 
for primary 
response and 
fixes 
complement 
Monomer 
form is a 
receptor for 
the B-cells 
Main antibody 
for secondary 
response, 
opsonisation, 
neutralises 
toxin 
Secreted into 
mucous 
tissues, saliva 
and colostrum 
For allergy 
and 
antiparasitic 
effect 
B-cell 
receptor 
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adaptive immune response, while the lymphoid cells confer the highest degree of 
specificity in recognising the self-antigens and mediating the adaptive immune 
response that combats the offending pathogens. All immune cells originate from 
the pluripotent stem cells and they develop  into lymphoid cells, myeloid cells and 
other cells (Khan, 2008). 
  The lymphoid lineage 
They constitute 20-25% of leukocytes in blood and they are divided into (Setty, 
2006): 
1.5.3.1.1 B-cells 
They constitute 20-25% of total lymphocytes in blood (Tomasek et al., 2013). They 
are lymphocytes that have the unique ability to form antibodies. They develop in 
the bone marrow. The cell surface of the B-cell contains receptors called B-cell 
receptors (BCRs) that have membrane bound immunoglobulins which binds to 
their specific antigen. After binding of the antigen with its cognate receptor and 
the activation that is mediated by the helper T-cell, the B-cell transforms into 
plasma cell or memory cell according to the type of the signals they receive 
(Moser and Leo, 2010). 
 T-independent B-cell activation: Antigens like the bacterial 
lipopolysaccharides activate the B-cells through cross linking of BCRs (1st 
signal). In addition, B-cells receive a 2nd signal from antigen binding with 
TLRs. B-cells activation leads to proliferation and the production of IgM 
antibodies mainly in a T-cell independent pattern. Such IgM antibodies 
have low affinity and thus display an innate stereotyped pattern. Overall, 
this type of immune response is poorly effective and emphasize the pivotal 
role of the T-cells in activating the B-cells to mount a potent and more 
specific immune response (Vos et al., 2000).      
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 T-dependent B-cell activation: Antigens bind to BCRs providing the 1st 
signal for B-cells. The typical secondary immune response develops on 
multiple exposures to the same antigen and requires APCs such as the 
dendritic cells or macrophages that activate the Th2 cells to the specific 
antigen. Then the activated T-cells play an important role in activating the 
B-cells (2nd signal) by producing signals (both soluble and humoral) 
(Fazilleau et al., 2007).  Because of this activation, the B-cells differentiate 
into plasma or memory cells. Moreover, Plasma cells start the production 
of large amounts of IgG, IgA and IgE antibodies in a process known as 
class switching. Such antibodies have a higher affinity with diverse 
functions  in comparison to IgM  produced by the T-cell independent 
activation (Allen et al., 2007). See Table 1.6.       
 
Figure 1.6. (A) T-independent B-cell activation: Bacterial antigens like the polysaccharides 
are able to stimulate the B-cell directly through antigen mediated cross-linking BCRs (1st signal). 
Moreover, such antigens bind with TLRs (2nd signal). Such activations lead to the maturation to 
the plasma cell, which produces IgM antibodies. 
(B) T-dependent B-cell activation:  B-cells receive a (1st signal) from antigen mediated cross-
linking BCRs. In addition, T-cells are activated by the antigen presenting cells to express CD28, 
CD40L and cytokines to activate the B-cells (2nd signal). Thus, B-cells mature to become plasma 
cells or memory cells according to the type of the signals they receive.          
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1.5.3.1.2 T-cells 
They constitute 75-80% of total lymphocytes in blood (Tomasek et al., 2013). T-
cells are produced in the thymus; however, their precursors are found in the bone 
marrow. The cells that migrate to the thymus do not express CD4 or CD8+ 
receptors (double negative T-cells). Subsequently, they start to develop in the 
thymus and the expression of CD4 or CD8 receptors increase. At the same time, 
they become able to differentiate self from non-self peptides. The cells, which 
don’t  bind to the MHC/antigen complexes weakly, die by apoptosis and so the 
rest of the cells will undergo positive selection (Male et al., 2012). 
Simultaneously, cells that respond to the MHC class II will retain the CD4 receptor 
and lose the CD8 receptor and so become T helper cell. On the other hand, the 
cells which respond to the MHC class I receptor will retain the CD8 receptor and 
lose the CD4 type and so become cytotoxic T-cells. The cells then will undergo 
the process of negative selection in which the cells that bind strongly to the 
MHC/self-peptide will undergo apoptosis. This process is important to get rid of 
these cells which may mediate autoimmunity if they still present in the body. The 
net result is that the cells that bind weakly to the MHC/self-antigen will be allowed 
to leave the thymus (Rhoades and Bell, 2009). The output cells are naïve T-cells 
(Th0) which are T-cells that are considered mature but unlike the activated or 
memory T-cells have not encountered their specific antigen (Reviews, 2014). 
These cells are characterized by the expression of L-selectin (CD62L); the 
absence of the markers of activation CD25, CD44 or CD69; and the absence of 
memory CD45RO marker (De Rosa et al., 2001). They are characterized by the 
presence of unique receptor which is known as the T-cell receptor (TCR) which 
distinguishes the T-cells from other types of lymphocytes  (Parham, 2009). 
T-cells are divided according to the structure of the TCR molecule into two types: 
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1.5.3.1.2.1 TCR-1 (γδ cells)  
The TCR molecule is composed of γ and δ polypeptides and constitutes 5% of 
the T-cells in general and 10% of intraepithelial T-cells (Khan, 2008). Unlike the 
αβ cells the γδ cells are not restricted to the recognition of peptide antigens 
presented by the MHC molecules and their role in the immune response is less 
well defined than that of the αβ cells (Parham, 2009). 
1.5.3.1.2.2 TCR-2 (αβ cells): 
The TCR molecule is composed of α and β polypeptides that constitutes 95% of 
T-cells. They are subdivided into two groups of cells: Th (T-helper cells) that are 
CD4+ and the Tc (cytotoxic T-cells) that are CD8+. Th cells recognize the antigens 
that are presented by MHC class II, while the Tc cells recognise the antigens 
presented by MHC class I. Th cells can be subdivided into: Th1 , Th2 , Th9 ,Th17, 
Th22 , T follicular helper cells (Tfh) and T regulatory (Tregs) according to their 
cytokine secretion profile  (Murphy, 2012). 
 Th1 cells: 
They secrete IL-2, IL-3, IFN-γ, TNF-α, TNF-β and GM-CSF (Khan, 2008). These 
cells have an important role in immune response against bacteria enclosed inside 
vesicles inside the macrophages. Following recognition, antigen uptake results in 
activation of the macrophages and an increase in their intracellular killing 
capacity. Th1 cells play an important role in inflammation, cytotoxicity and 
delayed-type hypersensitivity (Murphy, 2012). 
 Th2 cells: 
They secrete IL-4, IL-5, IL-6, IL-10, IL-13, TNF-β and GM-CSF. Moreover they 
support B-cell activation, isotype switching and IgE production (Khan, 2008). They 
are specialised in mounting immune responses at mucosal surfaces and 
particularly against parasitic infections. The protective mechanisms that are 
produced are shared with what is commonly known as “allergic responses” which 
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are characterized by the production of mucous, recruitment of eosinophils and the 
production of IgE antibodies (Murphy, 2012). While most of the Th1 cells leave 
the lymph nodes and travel to the site of the inflammation,Th2 cells remain in the 
lymph nodes (Parham, 2009).  
  Follicular helper T-cells (Tfh): 
These cells  were first found in human tonsils (Breitfeld et al., 2000), in which there 
is a continuous exposure to antigens. Bcl6 was recognized as a master regulator 
for the Tfh differentiation (Johnston et al., 2009). Tfh cells are recognized by their 
constitutive expression of B-cell follicle homing receptor CXCR5 (Fazilleau et al., 
2009). It has been shown that IL6/IL21 promotes Tfh differentiation through 
activation of STAT3 signalling pathway. Tfh cells are important for the 
development of germinal centres and the differentiation of B-cells to plasma or 
memory cells (Baumjohann et al., 2013). 
 Th9 cells: 
They are a group of CD4+ helper T-cells that express IL-9, IL-10, IL-21, CCL17, 
and CCL22. Following activation, naive CD4+ T-cells differentiate into Th9 cells 
in the presence of TGF-beta and IL-4. However, unlike Th2 cells, Th9 cells do not 
express IL-4, IL-5, or IL-13. Th9 cells play an important role in host defence 
against helminthic infections, yet they may have detrimental effects in the form of 
the development of chronic allergic inflammation, airway remodelling, and 
autoimmune disease (Kaplan et al., 2015) , pulmonary fibrotic diseases like cystic 
fibrosis (Wilson and Wynn, 2009). 
 Th17 cells: 
Th17 cells play an important role in autoimmune diseases like rheumatoid arthritis 
psoriasis, inflammatory bowel disease and ankylosing spondylitis (Korn et al., 
2009). Th17 cells count in the peripheral blood has been found to be inversely 
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correlated with poor lung function in patients with cystic fibrosis (Mulcahy et al., 
2015).  
There are two subtypes: pathogenic Th17 (that have been induced by IL-1β and 
IL-23) (Singh et al., 2013), non-pathogenic Th17 cells (induced by TGF-β and IL-
6) (Lee et al., 2012).   
These cells produce distinct cytokines that result in responses promoting the 
recruitment of neutrophils, which are effective in dealing with extracellular 
bacteria. These include IL-17A, IL-17F, IL-21, and IL-22 (Zambrano-Zaragoza et 
al., 2014).  
 Th22 Cells: 
These are a subset of CD4+ effector T-cell that do not express IL-17, CCL20, IL-
23 R, CD161 (Th17 markers), IL-4 (Th2 marker), or IFN-gamma (Th1 marker). 
Instead, they have a noticeable secretion of IL-22, IL-13 and TNF-α (Eyerich et 
al., 2009). These cells also express CCR4, CCR6, and CCR10, which allow them 
to reside in the skin (Duhen et al., 2009). Activated naïve CD4+ cells, may 
differentiate into Th22 cells in the presence of IL-6 and TNF-α. Extensive research 
have shown that these cells may be involved in the pathogenesis of psoriasis, 
eczema and allergic contact dermatitis (Eyerich et al., 2009).  
 Regulatory T-cells:  
These are a subset of CD4 that constitutively express CD25 and the Foxp3 
transcription factor. Regulatory T-cells are involved in limiting the immune 
response and preventing the autoimmune diseases by blocking the activity of 
helper, effector and APC cells. They are divided into natural (develop in thymus) 
and induced Tregs (develop from naïve T-cells in periphery) (Sakaguchi et al., 
2008). 
They suppress the immune response by various mechanisms: They produce 
adenosine (which acts as a suppressive molecule), cAMP (which suppresses the 
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TCR-induced Ca2 +, NFAT, and NF- κB signalling). They also secrete suppressive 
cytokines (TGFβ, IL-10 and IL-35). They suppress the secretion of IL-2 and they 
cause cell death via perforin and granzyme-B (Schmidt et al., 2012).        
 Natural Killer T-cells (NKT cells):  
These are T-cells that express both αβ TCR and markers that are expressed by 
the NK (natural killer) cells such as NK1.1.  However, the term is used to describe 
a large variety of cells including NK1.1+, NK1.1–, CD4+, CD8+, CD4– and CD8– 
cells. They are not restricted to MHC-dependent antigen presentation, instead 
they recognise antigens that are glycolipids and require the CD1d. NKT-cells are 
a bridge between the innate and acquired immune responses. Other markers that 
are expressed by these cells include CD16 and CD56.  Activation of natural killer 
T (NKT) cells results in functions similar to CD4+ and CD8+ T-cells. These cells 
are cytotoxic in nature and they release cytokines like IL-4, IFN-γ, GM-CSF and 
others. It has been found that abnormal NKT-cell function may be associated with 
the development of certain cancers and autoimmune disease (Khan, 2008). 
 Memory T-Cells: 
Memory cells persist after the invading pathogen has been eliminated and they 
have the ability to mount a quick and stronger immune response following 
secondary exposure of the pathogen. Memory T-cells differ from the naïve T-cells 
in two features: First, they recirculate through peripheral tissues rather than 
through the secondary lymphoid organs and thus are activated at the site of 
contact with the allergen by the dendritic cells and macrophages. 
Second: The activation requirements are less than those of the naïve T-cells since 
they do not require the stringent co-stimulatory signalling that is needed to activate 
naïve T-cells (Parham, 2009). 
When naïve T-cells, which are CD45RO-, encounter an antigen presented by 
antigen presenting cells they become activated and transform into effector cells. 
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Some of effector cells are long-lived memory cells expressing CD4+ or CD8+ and 
the characteristic receptor CD45RO. Memory cells require the presence of IL-7 
and IL-15 for survival. Moreover, they require contact with self-peptides (i.e. self-
MHC peptide complexes) to proliferate otherwise they undergo apoptosis. 
Memory T-cells subdivide into two types of memory cell, which are known as 
central and effector memory T-cells. Central memory T-cells express CCR7 and 
secrete IL-2; they remain in peripheral lymphoid tissues after restimulation. In 
contrast, effector memory T-cells migrate to tissues; they lack the expression of 
CCR7 but they express CCR3 and CCR5. Following activation, effector memory 
T-cells secrete large amounts of cytokines including IFN-γ, IL-4 and IL-5 (Murphy, 
2012). 
1.5.3.1.3 Natural killer cells (NK cells) 
Natural killer cells are a group of lymphocytes identified on their ability to combat 
tumour cells. They develop in the bone marrow and they lack CD3 receptors 
expressed on T-cells and the immunoglobulin receptors on B-cells. However, they 
express CD56 and CD16, which is a receptor for IgG immunoglobulin. This 
receptor upon binding with the IgG is important in mediating antibody-dependent 
cellular cytotoxicity. They have an important role in innate immunity (Khan, 
2008).  
  Antigen presenting cells   
1.5.3.2.1 B-cells: See 1.5.3.1.1 
1.5.3.2.2 Macrophages 
They are large cells that differentiate from circulating monocytes after they enter 
tissues. In contrast to monocytes, which circulate in blood, macrophages reside 
in tissues. Macrophages kill the invading microorganisms by generating reactive 
oxygen species and through the activation of proteolytic enzymes. Moreover, 
macrophages secrete several cytokines that attract leukocytes to the site of 
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inflammation and initiate the acute inflammatory response. Macrophages also act 
as antigen presenting cells, presenting antigens to T-cells. Thus, macrophages 
are able to bridge innate and adaptive immunity (Rhoades and Bell, 2009). In 
addition to their role in the immune response, they play an important role in tissue 
repair and aging.  The expression of MHC class II and  co-stimulatory molecules 
increase dramatically in case of infection (Khan, 2008). 
1.5.3.2.3 Dendritic cells 
They are very important antigen presenting cells. They are distributed in small 
numbers in different tissues that encounter various antigenic stimuli like the skin, 
lining of the nose, lungs and stomach. Following activation, dendritic cells migrate 
to the lymph nodes to initiate acquired immune response by their interaction with 
B and T-cells. The dendritic cells can be divided into myeloid dendritic cells and 
lymphoid dendritic cells which looks like the plasma cells and so called 
plasmacytoid (Murphy, 2012). Myeloid dendritic cells secrete IL-12. They can be 
divided into two subsets, which are MDC1 and MDC2. MDC1 stimulate T-cells, 
while the MDC2 have a role in fighting wound infections. The lymphoid dendritic 
cells are similar to plasma cells and produce large amounts of IFN-α (Khan, 2008). 
  Granulocyte cells 
1.5.3.3.1 Neutrophils 
They constitute 60-70% of blood leukocytes in healthy individuals. These cells are 
phagocytic by employing a number of bactericidal substances and lytic enzymes 
to kill the microbes. They have granules, which contain substances like 
myeloperoxidase, defensins, cathepsin-G and bactericidal/permeability-
increasing protein, lactoferrin, cathelicidin and gelatinase. Neutrophils can 
regulate the function of monocytes and other lymphoid cells via the release of 
various cytokines including IL-1β, IL-1ra, IL-8, TGF-β, and TNF-α. The production 
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of cytokines by the neutrophils is highly variable and dependent on the nature of 
the stimulus (Khan, 2008).  
1.5.3.3.2 Eosinophils 
They comprise 2% of the blood leukocytes in non-atopic individuals. They play a 
pivotal role in immunity to helminthic infections. Eosinophils are also capable of 
phagocytosis and killing ingested microorganisms but this is not their main 
function. Their immune function is mediated via production of reactive oxygen 
species (De Paulet et al., 2012), leukotrienes, prostaglandins, elastase, a plethora 
of cytokines (IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-13, TNF-α). They are present in 
thymus, spleen, lymph nodes, uterus and lower GI tract, but they are not present 
in the skin, esophagus or lungs. Eosinophils are attracted by mediators released 
by T-cells, mast cells and basophils. Eosinophils secrete histaminase and aryl 
sulfatase, which inactivates histamine and slow reacting substance of anaphylaxis 
(SRS-A). This will result in anti-inflammatory effects and inhibition of granulocyte 
migration to the site of inflammation (Khan, 2008). 
 
Figure 1.7: Roles of different types of immune cells in the development of immune 
reactions. 
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1.5.3.3.3 Basophils and mast cells 
Basophils are found in very small numbers in the circulation (0.01–0.3% of 
leukocytes). They develop in the bone marrow. Mast cells are similar to the 
basophils but they develop from different precursor cells in the bone marrow 
(Khan, 2008). Both the mast cells and the basophils release heparin. The mast 
cells and the basophils also release histamine and serotonin, bradykinin and the 
slow reacting substance of anaphylaxis. The basophils and the mast cells play a 
great role in mediating type I hypersensitivity reaction due to the IgE antibody that 
is attached to the cell membrane of these cells. So when a specific antigen binds 
to IgE antibody this will cause the release of large quantities of mediators (Figure 
1.7) which causes local vascular and tissue reactions that are translated into 
various allergic manifestations (Hall, 2010). 
1.5.4 Antigen presentation:  
  MHC structure 
 MHC class I molecule is a transmembrane glycoprotein with a molecular 
weight of 43kDa. For antigen presentation it must be expressed on the cell 
membrane of antigen presenting cells (Coico and Sunshine, 2015). See 
Figure 1.8. It is associated with small invariant polypeptide called β2-
microglobulin (β2m) that is encoded by chromosome 15 (Faber et al., 
1976). MHC class I molecules are composed of three extracellular 
domains: α1, α2 and α3. The α1 pairs with α2 on the exterior of MHC I 
molecule while the α3 pairs with β2m closer to cell membrane (Coico and 
Sunshine, 2015).       
 MHC class II molecule is a transmembrane glycoprotein that is composed 
of two chains; α and β with a molecular weight of 35 and 28 kDa 
respectively. See Figure 1.8. The structure (like MHC class I) has four 
extracellular components which entails α1 pairing with β1 on the exterior 
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while α2 pairs with β2 on the interior. Both α and β chains have cytoplasmic 
tails (Coico and Sunshine, 2015).  
 
  MHC class I antigen presentation  
MHC class I molecules present protein fragments of intracellular origin e.g. viral 
proteins. Antigens are degraded into small peptide sequences by cytosolic and 
nuclear proteasomes. Then, by the action of the transporter associated with the 
antigen presentation (TAP) these peptides are translocated to the endoplasmic 
reticulum (ER). See Figure 1.9.  In the ER, the MHC class I heterodimer is 
composed from heavy and light chains and the peptide is the third component that 
is needed for stability. MHC class I complexes are transported from the ER to the 
cell surface for presentation to the T-cell receptor of the CD8+ (cytotoxic) T-cells  
(Neefjes et al., 2011). MHC I molecules that fail to associate with the peptides in 
the ER are returned to the cytosol for degradation (Hughes et al., 1997). 
 
Figure 1.8: Structure of MHC molecules I and II. MHC I is composed of heavy chain and β2-
microglobulin invariant chain. The heavy chain is composed of three subunits which are α1, α2 
and α3, while the MHC class II is composed of two chains α and β. Each of them are composed 
of two subunits. The peptide binding groove of MHC class I is between α1, α2 subunits of the 
heavy chain while –it is between α1, β1 subunits of MHC class II.   
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Figure 1.9: Antigen presentation by MHC I (right).    Intracellular antigens are degraded by 
the aid of cytosolic and nuclear proteasomes into small peptides. Then, by the action of the 
transporter associated with the antigen presentation (TAP) these peptides are translocated to 
the endoplasmic reticulum (ER). In the ER, the MHC class I heterodimer will combine with the 
peptide. MHC class I complexes leave the ER to the cell surface to be presented to the T-cell 
receptor TCR of the CD8+ (cytotoxic T-cells).  
Antigen presentation by MHC II (left): The transmembrane α and β chains of the MHC class 
II molecules are assembled with the invariant chain (li) in the ER. Then, the resulting complex 
is transported to an endosome where it would be digested leaving residual class II‑associated 
Ii peptide (CLIP) in the peptide-binding groove of the MHC class II heterodimer. Consequently, 
HLA-DM facilitates the exchange of the CLIP fragment for a specific peptide derived from a 
protein degraded in the endosome. Finally, the MHC class II molecules are transported to the 
cell surface to present their antigen to the TCR of the CD4+ (helper) T cells. Image provided 
courtesy of Abcam Inc. Image copyright©2015 Abcam. 
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  MHC class II antigen presentation 
MHC class II molecules are concerned with the presentation of exogenous 
antigens to CD4+ T-cells. Previous research has shown that the transmembrane 
α and β chains of the MHC class II molecules are assembled with the invariant 
chain (li) in the ER. See Figure 1.9. Then, the resulting complex is transported to 
the endosomal compartment. Here the complex is digested leaving residual class 
II‑associated Ii peptide (CLIP) in the peptide-binding groove of the MHC class II 
heterodimer. Consequently, HLA-DM facilitates the exchange of the CLIP 
fragment for a specific peptide derived from a protein degraded in the endosome. 
Finally, the MHC class II molecules are transported to the cell surface to present 
their antigen to the T-cell receptor expressed on CD4+ (helper) T-cells (Neefjes 
et al., 2011). 
  Cross presentation 
Cross presentation acts like an intersecting mechanism between the classical two 
mechanisms mentioned above. It involves the presentation of exogenous 
antigens by the MHC class I molecules. Cross presentation is an essential 
mechanism for triggering the immune response against viruses that do not infect 
the antigen presenting cells in addition to tumours (Rock, 1996). 
 
1.5.5  The role of T-cell receptor (TCR) in mediating immune 
response 
  TCR structure and diversity 
The TCR molecules found on the surface of T-cells have an important role in 
recognition of antigens and T-cells activation. The pairs of α/β or γ/δ develop from 
the somatic DNA recombinations of germline gene segments during T-cell 
development. 
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The human T-cell α and δ chains genes loci are on chromosome 14 while the β 
chain and the γ chains genes loci are on chromosome 7 (Boehm and Rabbitts, 
1989). 
The available pool for the αβ TCR comprises of 42 variable (V) and 61 joining (J) 
segments in the α locus and 47 V, two diversity (D), and 13 J segments in the β 
locus (Arstila et al., 1999). Each chain is composed of two extracellular domains: 
Variable (V) region and a Constant (C) region, both of which belong to the 
Immunoglobulin superfamily (IgSF) domain. The Constant region is proximal to 
the cell membrane, followed by an anchoring transmembrane region and a short 
cytoplasmic tail, while the variable region binds to the peptide/MHC complex. See 
Figure 1.10.  The variable domain of both the TCR α-chain and β-chain each 
have three hypervariable or complementarity determining regions (CDRs), 
whereas the variable region of the β-chain has an additional area of 
hypervariability (HV4) that does not normally contact antigen and, therefore, is not 
considered a CDR.   
The most important CDR is CDR3 which is responsible for recognizing processed 
antigen. However, CDRl of the α chain interacts with the N-terminal of the 
antigenic peptide while the CDRl of the β chain interacts with the C-terminal of the 
peptide. CDR2 is thought to recognize the MHC molecule. 
The presence of multiple V/D/J gene segments in germline DNA leads to 
enormous diversity in TCR composition. Moreover, the insertions and 
combinations of template independent nucleotides at Vβ-Dβ, Dβ-Jβ and Vα-Jα 
junctions would add to the diversity. Consequently, most of the diversity will 
accumulate in the complementarity-determining region 3 (CDR3) which is 
encoded by the V(D)J junction and interacts with the antigenic peptide presented 
by the major histocompatibility complex molecule (Stauss and Xue, 2011). 
αβ cells constitute approximately 95% of T-cells in human body (Girardi, 2006). 
Moreover, diversity in CDR3 of TCR-Vβ accounts for most of the total diversity of 
TCRs in an individual (Laydon et al., 2015); thus, Vβ sequence of CDR3 is a more 
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suitable and reliable marker for clonotypic analysis of T-cells than the Vα 
sequence.    
 
 The CD3 receptor complex 
For the TCR to be fully functional in it must be assembled with the CD3 multi 
protein complex on the T-cells. The CD3 is composed of distinct chains (γ, δ, and 
ε) in mammals and the ζ-chain. These chains (γ, δ, and ε) have 44-81 amino acid 
sequences on their intracellular site that are called immunoreceptor tyrosine–
based activation motifs (ITAMs) which are responsible for intracellular signal 
transduction. The ζ-chain has three ITAMs (Flaherty, 2012). 
 
Figure 1.10: T-cells receptor (TCR), CD3 and CD4/CD8 structures. The T-cell receptor is 
composed of α and β chains in αβ T-cells while it is composed of γ and δ chains in γδ T-cells. 
Antigen binding site is at the end of the variable region, which has the complementarity 
determining regions (CDRs). CD3 receptor is composed of two couples of chains ε and γ, ε and 
δ. CD4 and CD8 molecules are attached to p56lck, which is a tyrosine kinase that is involved 
in T-cells signalling. In addition, there are two ζ chains. 
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  Stabilizing molecules  
The binding of the TCR to MHC molecules is of low affinity and so additional other 
molecules are required to stabilize the interaction. Research have shown that 
CD4 and CD8 molecules stabilize the interaction between the TCRs and the MHC 
class II and I respectively. The CD4 and CD8 molecules have a cytoplasmic tail 
that is capable of signal transduction to the nucleus through the phosphorylation 
of serine residues which triggers the activation of the p56lck kinase which in turn 
plays an important role in the activation of T helper and T cytotoxic cells (Flaherty, 
2012). 
  Co-stimulatory and co-inhibitory molecules 
After T-cells are activated by the first signal (i.e. an antigen specific interaction of 
the TCR with an antigen loaded MHC molecule), they require a second signal to 
amplify or attenuate the response (Pacheco et al., 2005). This signal which is 
antigen nonspecific is mediated by the interplay of co-stimulatory and co-inhibitory 
molecules expressed on both the APCs and the T-cells. See Table 1.2. These 
molecules interact actively to shape the final outcome of the immune response; 
either an effective immune response or anergy (Bour-Jordan et al., 2011). 
  Cytokines 
Cytokines are polypeptides secreted by leukocytes and other cells to act 
principally on hematopoietic cells. The modulation of receptors with specificity for 
individual cytokines results in modulation of immune and inflammatory responses. 
Cytokines are known to control the quality and magnitude of an immune response 
to a given pathogen. Th1 secreting cells release IL-2 and IFN-ƴ. In contrast, Th2 
secrete interleukins such as IL-4, IL-5, IL-6, IL-10 and IL-13. Other cytokines like 
TNF-α and GM-CSF are secreted by both Th cell types (Ucytech.com, 2015). 
Chemokines are cytokines with chemotactic action. Cytokines and chemokines 
may mediate their function on the cells which secrete them (autocrine), or the 
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adjacent cells (paracrine) or in some examples on distant cells (endocrine) (Zhang 
and An, 2007).  
  TCRs in drug hypersensitivity 
 TCR signalling 
The interaction of MHC-antigen complex with the specific TCR leads to complex 
chain of signalling pathways mediating T-cells proliferation, differentiation and 
cytokine secretion. The interaction of APCs and T-cells though accessory 
molecules CD4 or CD8 receptors lead to the aggregation of TCRs on the T-cell 
membrane with the subsequent activation of T-cells (Choudhuri et al., 2005). 
The process starts with the phosphorylation of tyrosine proteins by Src kinases 
and Lck (Nel, 2002). TCR phosphorylation by Lck creates a binding site for the 
action of another tyrosine kinase called ZAP-70 (zeta chain associated protein of 
70 kDa) (Smith-Garvin et al., 2009). Then, ZAP-70 phosphorylates another two 
important proteins namely SLP76 (SH2-domain containing leukocyte protein of 
76kDa) and LAT (linker for T-cells activation). Both trigger Ca2+ and diacylglycerol 
(DAG) release with the subsequent activation of T-cells (Li and Rudensky, 2016). 
 Selective TCR expression in drug hypersensitivity: 
The first notion for the preferential TCR expression was mentioned in the 
pioneering analytic study of Pichler on the TCR subsets of penicillin stimulated T-
cells in 1997, which showed the presence of αβ T-cells in the blood of drug allergic 
individuals. Pichler suggested that the preferential expression of TCR may occur 
in drug hypersensitivity reactions (Pichler et al., 1997). A study conducted using 
bacampicillin showed the TCR-Vβ profile shifted towards Vβ -2, Vβ-3, Vβ-5.1 
and/or Vβ-14 when T-cells were activated with the drug antigen in vitro 
(Cederbrant et al., 2000). Moreover, in lamotrigine induced hypersensitivity there 
was a marked dominant clonal expansion of Vβ-5.1 T-cells. These studies 
suggest that the polymorphism within the TCR genes may serve as determinants 
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of susceptibility (Naisbitt et al., 2003b) and that the preferential expression of TCR 
may play an important role in hypersensitivity reactions (Ko and Chen, 2012). 
 Restricted TCR expression in carbamazepine SJS/TEN versus 
polyclonal expression in abacavir hypersensitivity  
Researchers used the strong HLA–B*15:02 predisposition in carbamazepine 
(CBZ)-SJS/TEN as a model to explore the repertoire of TCR expressed on CBZ-
specific T-cells).  A restricted and the common TCR expression of Vβ-11-ISGSY 
was identified as the predominant clonotype in many individuals that developed 
hypersensitivity. This clonotype was present in 16 out of 19 (84%) patients with 
SJS/TEN, but not at all in 17 drug-tolerant patients. The clonotype was present at 
  
A. Restricted TCR Vβ expression in 
carbamazepine hypersensitivity 
B. Polyclonal TCR Vβ expression 
abacavir hypersensitivity   
Figure 1.11: A comparison between the TCR Vβ expression profile of (A) carbamazepine 
and (B) abacavir. In the case of (A)  carbamazepine the TCR-Vβ expression is  restricted (Ko 
et al., 2011). While in case of (B) abacavir, it is polyclonal and there is no major TCR-Vβ 
skewing in TCR-Vβ expression profile from naive to primed T-cells.  Reprinted by permission 
from Macmillan Publishers Ltd:[Nature],(Illing et al., 2012), copyright (2016). 
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low frequencies in healthy individuals (four out of 29; 14%) ( A). Furthermore, T-
cells obtained from the peripheral blood of healthy donors who were carriers of 
HLA-B*15:02 and Vβ -11-ISGSY showed reactivity toward CBZ  
in vitro. Subsequently, the T-cell response was blocked by the addition of an anti-
TCR- Vβ-11 antibody. Consequently, these data have highlighted the pivotal role 
of the TCR in the development of SJS/TEN and provided an explanation for why 
certain HLA-B*15:02 carriers tolerate CBZ (Ko and Chen, 2012).    
On the other hand, analysis of the TCR Vβ expression for the abacavir-reactive 
CD8+ T-cells from HLA-B*57:01 positive healthy blood donors revealed a 
polyclonal pattern ( B). Moreover, comparison of TCR-Vβ expression on naïve T-
cells to that of the primed T-cells did not reveal a major skewing of the TCR-Vβ 
profile. 
 Clinical implications of drug-restricted TCR Vβ in comparison to the 
polyclonal expression  
 A strong association in Han Chinese between CBZ-SJS/TEN and HLA-B*15:02 
has been observed. HLA-B*15:02 was present in 98% of patients (59 of 60 
patients) with CBZ-SJS, but in only 4.2% of CBZ-tolerant patients and in 8.6% of 
the general population (Hung et al., 2006). Similar observations were obtained 
from studies on patients from Hong Kong, Singapore, Thailand, Malaysia and 
India, where the allele is prevalent (Man et al., 2007;Mehta et al., 
2009;Locharernkul et al., 2008). Moreover, in a large-scale prospective study, the 
use of HLA-B*15:02 screening before patients were administered with CBZ 
showed that the screening can effectively reduce the incidence of CBZ-SJS/TEN 
(Chen et al., 2011). It has been found that the HLA-B*15:02 screening has a 
negative predictive value of 99.9% and a relatively low-positive predictive value 
of 5.6% (Hung et al., 2006;Chen et al., 2011). This is due to the fact that many 
patients carrying high-risk alleles do not develop SJS. This observation has led to 
the conclusion that another factor may be implicated in the T-cell mediated 
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immune reactions which may contribute to CBZ-SJS/TEN development. This 
factor is likely to be the specific TCR clonotype that recognizes the 
HLA/peptide/drug complex. 
Furthermore, it has been found that the clinical stage of the CBZ-SJS correlates 
with expression level of the dominant TCR clonotypes (CBZ-specific CDR3 
sequences) in the peripheral blood mononuclear cells, suggesting that these 
clonotypes may be useful in evaluating the stage of the disease. Another 
interesting finding is that the CBZ-restricted clonotypes were undetectable in 
CBZ-tolerant individuals. This provides the explanation which explains why some 
HLA-B*1502 carriers do not develop SJS when taking CBZ (Ko et al., 2011). 
The HLA-B*1502 has a low positive predictive value (5.6%) which means that 
many patients are unnecessarily withheld from the treatment with CBZ. Using 
screening with the specific TCR clonotype of the peripheral blood mononuclear 
cells from the HLA-B*1502-positive carriers could significantly improve the 
positive predictive value of identifying the high-risk individuals. Theoretically, 
positive predictive values of 100% could be achieved if all the specific TCR 
clonotypes were identified. Nevertheless, the drug specific TCR clonotypes are 
not present in all patients. Two of 19 with the CBZ-SJS patients did not express 
the specific clonotypes associated with CBZ-SJS (Ko et al., 2011). This finding 
would obviously lower the negative-predictive value.  
Another famous example describing a role for TCR in drug hypersensitivity is the 
preferential expression of the TCR-Vβ 17 on the peripheral blood T-cells and 
NiSO4 responsive T-cells isolated from inflamed tissue (Budinger et al., 2001). 
These data provides the evidence that T-cells carrying this particular TCR may be 
involved in nickel hypersensitivity (Ko and Chen, 2012). 
In summary, identifying a restricted pattern of TCR-Vβ expression for a culprit 
drug can pave the way for designing new diagnostic techniques or tests to identify 
patients at risk of developing drug hypersensitivity reactions. Moreover, it opens 
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the prospect for treating drug reactions effectively through the use of specific anti-
TCR-Vβ antibodies for the specific clonotypes of the culprit drug.   
1.6 Cystic fibrosis (CF) 
CF is an autosomal recessive disorder caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene which is situated on 
chromosome 7. The CFTR gene codes for the CFTR protein that controls the 
chloride ion transport across epithelial cells. Research has shown that there are 
more than 1900 different mutations affecting this gene (Ferec and Cutting, 2012). 
The result of these mutations is reduced secretion of chloride and increased 
absorption of sodium causing thick viscous secretions (Clunes and Boucher, 
2007) and blockade of secretory tubes and the affected organs such as the 
pancreas, salivary glands, gonads and the liver. The most significant effect is in 
the lung where the mucocilliary clearance of the bacteria is impaired. Patients with 
CF commonly present with chest infections usually Staphylococcus aureus and 
Pseudomonas aeruginosa (Chinen and Shearer, 2008;Konstan et al., 2012). 
Moreover, the patients have difficulty in gaining weight and height (Hardin, 2004). 
Antibiotic treatment is regarded as a cornerstone in the therapy of the recurrent 
infections but their use is limited by a higher prevalence of allergic reactions which 
could be attributed to the high doses and long duration of use (Parmar and 
Nasser, 2005).  
Acute chest infections are usually dealt with using intravenous antibiotics (I.V.). A 
β-lactam is normally used for treatment alongside either tobramycin or colistin. 
The most widely used drugs are piperacillin-tazobactam, aztreonam, meropenem 
and ceftazidime. Patients with CF have a higher volume of distribution and more 
rapid drug clearance. Moreover, the β-lactams fail to perfuse the bronchial 
secretions in sufficient concentrations (15% of blood levels) (Bergogne-Berezin, 
1987). Consequently, the patients require higher doses and longer durations of 
antimicrobial therapy compared to standard treatments. 
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1.7 β-lactams hypersensitivity in patients with CF 
Several studies have shown that the prevalence of β-lactam hypersensitivity is 
higher in patients with CF; 26-50% in patients with CF, compared with 1-10% in 
the general population (Koch et al., 1991;Parmar and Nasser, 2005). 
Hypersensitivity reactions to β-lactams are mostly non-immediate with an average 
delay of 9.1 days (Pleasants et al., 1994). The reactions consist of maculopapular 
rash, fixed drug eruptions, arthralgia, fever and/or flu–like symptoms, while 
Steven Johnson Syndrome and toxic epidermal necrolysis, and anaemia are 
extremely rare. On the other hand, immediate allergic reactions (IgE dependent) 
i.e. anaphylaxis and/or urticaria represent only 6% of the cases (Whitaker et al., 
2012).  
Piperacillin consistently has the highest rates of hypersensitivity, occurring in 30-
50% of cases while other antibiotics such as mezocillin (17%), carbenicillin (7%), 
and imipenem (3%) have lower rates of reaction (Wills et al., 1998;Pleasants et 
al., 1994;McDonnell and FitzGerald, 1984). Previous research has shown that an 
accelerated response ensues upon re-exposure to the culprit drug, suggesting an 
immunological memory rather than direct toxicity. Hypersensitivity reactions to 
multiple β-lactam antibiotics are a common problem. Whitaker et al (2012) 
showed that 30% of patients had more than two previous β-lactam reactions, 
while 20% of patients had a single β-lactam reaction. Such patients tend to show 
lower lung function tests and a history of multiple and longer exposure to 
antibiotics  (Whitaker et al., 2012). 
1.7.1 Cross reactions between β-lactam antibiotics 
Cross reactivity between β-lactam antibiotics has been shown to be less 
problematic than it was thought from early studies focussing solely on similarities 
between structures (Ramesh and Ramesh, 2002). This picture of low cross 
reactivity in patients with CF is similar to that seen in patients without CF. For 
example, a study has shown that cross reactivity between imipenem and 
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meropenem in penicillin allergic patients is less than 1% (Romano et al., 2006).  
Aztreonam does not have the bicyclic core structure (Figure 1.12) of the 
penicillins, cephalosporins or carbapenems and therefore does not does not 
activate T-cells responsive to other drugs.  
However, aztreonam has a side chain in common with ceftazidime, which signifies 
that a percentage of patients with ceftazidime hypersensitivity might develop a 
second hypersensitivity reaction when exposed to aztreonam. From a practical 
point of view, aztreonam is well tolerated. Only two case reports describe patients 
who reacted to both drugs (Moss et al., 1991;Jensen et al., 1987). 
The results of several studies of cephalosporin administration in penicillin skin test 
positive patients have shown that there was an incidence of 4.5% of cross 
reactivity. The majority of reactions to cephalosporins were with drugs with similar 
or identical side chains (Sheppard and Welsh, 1999;Novalbos et al., 
2001;Audicana et al., 1994).  
 
Figure 1.12. Diagrammatic presentation showing the chemical structure of the main 
antibiotic classes (Penicillins, monobactam, cephalosporins and carbapenems) used in 
patients with CF.  Penicillins, cephalosporins and carbapenems share a similar bicyclic core 
which may explain the cross-reactivity between these antibiotics. On the other hand, 
monobactams have a single central cyclic structure.    
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1.7.2 Risk factors 
A previous history of hypersensitivity reactions to penicillin accentuates the 
likelihood of subsequent reactions to other penicillin antibiotics by up to six fold 
(Ramesh and Ramesh, 2002). Despite this, there are no well-defined factors that 
predict the risk of developing drug hypersensitivity reactions in patients with CF. 
A possible hypothesis is that atopic children with CF who are skin prick positive 
to aeroallergens are more likely to be infected with Pseudomonas. Consequently, 
they need more frequent high doses of I.V. antibiotics that leads to a higher 
incidence of allergic reactions (Warner et al., 1976). Alternatively, antibiotics are 
commonly administered I.V. in a high dosage and for prolonged durations in a 
repeated schedule. Thus, increased exposure might influence susceptibility. It is 
possible that there is role for additional factors such as endogenous danger 
signals which are common in patients with CF. These include TNF-α and IL-1 
which are capable of triggering dendritic cells maturation. The immune status in 
patients with CF is in the stage of chronic acute response due to repetitive 
infections; thus, it is characterized by high number of neutrophils in addition to 
cytokines including IL-8, IL-1B, IL-6, IL-17 and TNF-α. (Sagel et al., 2001;Bonfield 
et al., 1999;McAllister et al., 2005). 
It is unclear whether CFTR mutations themselves mediate a pro-inflammatory 
state. Previous research has shown that CFTR knockout mice develop 
exaggerated cytokine responses after challenge with bacteria (Heeckeren et al., 
1997). CFTR deficient cells have a higher tendency to express exaggerated Th2 
responses when exposed to Aspergillus fumigatus where it is shown that these 
mice express higher levels of IgE, IL-4 and IL-13 when compared with controls 
(Mueller et al., 2011). This may explain the high prevalence of allergic 
bronchopulmonary aspergillosis (ABPA) in patients with CF (Skov et al., 1999). 
This may offer another mechanism explaining the high prevalence of drug 
hypersensitivity in patients with CF. 
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1.8 Piperacillin 
Piperacillin is an extended spectrum β-lactam antibiotic of the ureidopencillin 
class (Figure 1.13). It has a wide spectrum activity against many pathogens 
including Pseudomonas aeruginosa which is one of the main life threatening 
infections in patients with CF (Tan and File, 1995). It is also recommended for the 
treatment of infections caused by most Gram +ve and Gram –ve bacteria (Perry 
and Markham, 1999). 
Commonly piperacillin is used in combination with tazobactam (β-lactamase 
inhibitor) in a formulation known as Zosyn™. 
1.8.1 Pharmacokinetics 
Piperacillin is poorly absorbed from the gastrointestinal tract as is tazobactam and 
so they are both administered I.V. 
Thirty percent of piperacillin binds via non-specific adsorption (non-covalent 
binding) to protein (Sörgel and Kinzig, 1993). The same applies for tazobactam. 
Protein binding of piperacillin or tazobactam is not affected by binding of the other 
compound. Piperacillin is widely distributed into body fluids and tissues. Mean 
tissue concentrations are usually 50-100% of the plasma concentration (Grayson 
et al., 2010).  
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Piperacillin is excreted mainly by renal system and to a less extent through the 
bile (Westphal et al., 1997).  Most of the administered dose (80%) is excreted as 
unchanged drug while the rest is excreted as desethyl-piperacillin or desethyl 
piperacillin glucuronide (FDA, 2009). 
Notably, the pharmacokinetics of piperacillin in patients with CF show that there 
is a moderate increase in volume of distribution but the clearance rate is very high 
which implies the need for more aggressive dosing regimens (Hayashi et al., 
2010). 
There is little role for metabolism in the clearance of piperacillin. Hepatic 
degradation of piperacillin leads to cleavage of the β-lactam ring and the formation 
of a minor active metabolite (N-desethylpiperacillin) (Wise et al., 1991).            
N-desethylpiperacillin by itself is metabolized in liver to N-desethylpiperacillin 
glucuronide. Both N-desethylpiperacillin and its metabolite N-desethylpiperacillin 
glucuronide are detected in urine and bile (Ghibellini et al., 2007). 
Piperacillin as well as its metabolite N-desethylpiperacillin are believed to form 
functional antigens capable of activating T-cells and mediating hypersensitivity 
reactions (Whitaker et al., 2011).   
 
Figure 1.13: Piperacillin chemical structure.       
General Introduction  Chapter 1 
 
 
 
80 
 
Tazobactam metabolism yields a single metabolite that does not show any 
pharmacological or antibacterial activities (Grayson et al., 2010). 
 Administration and dosage 
Since it is poorly absorbed from intestine, it is administered either I.M or I.V. The 
usual dose is 3-4g every 4-6 hr but the maximum daily dose for adults could reach 
200-300 mg/kg in divided doses daily via I.V. injection in serious infections 
(Hamilton, 2011). 
The mean peak plasma concentration is 134, 242 and 298 µg/mL following the 
administration of 2, 3, and 4 g piperacillin doses respectively. 
 Why do we investigate mechanisms of piperacillin 
hypersensitivity? 
Piperacillin is a β-lactam antibiotic that is frequently used to combat bacterial 
infections in patients with CF. However; its use is associated with a high incidence 
of delayed-type hypersensitivity reaction. The reactions consist of maculopapular 
rash, fixed drug eruptions, arthralgia, fever and or flu–like symptoms, while Steven 
Johnson Syndrome and toxic epidermal necrolysis, and anemia are extremely 
rare (Drugs.com, 2015). Thus, the problem of these reactions is not increased 
mortality. The main problem is the necessity to abandon the drug as a treatment 
option. Piperacillin has been found to be associated with the highest rates of 
hypersensitivity reactions in comparison to other β-lactams.  
Our previous studies have identified lymphocyte proliferative responses and 
cytokine secretion from PBMCs isolated from approximately 75% of 
hypersensitive patients (Whitaker et al., 2011). In contrast, PBMCs from tolerant 
controls are not specifically activated (Monshi, 2013). To our knowledge, there is 
no evidence that tazobactam or its metabolite has any role in mediating 
hypersensitivity reactions in patients with CF treated with tazocin. 
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1.9 Hepatitis C 
Hepatitis C: is a hepatic disease caused by hepatitis C virus (HCV) infection. This 
infection can cause both acute and chronic hepatitis infection that varies from mild 
illness that lasts few weeks to lifelong disease.  
It is a blood borne transmitted disease mediated by transfusion of unscreened 
blood and blood products, careless injection practices and poor sterilization of 
medical equipment. Sexual transmission and transmission from mother to baby 
are much less common. 
HCV virus infection represents a global health problem affecting 130-150 million 
individuals worldwide (WHO, 2015). HCV is a major cause for chronic hepatitis, 
cirrhosis and hepatocellular cancer. Moreover, it is the commonest indication for 
liver transplantation in USA (Verna and Brown, 2006).  
Clinical presentation 
The virus has an incubation period of 2-6 months. Approximately 80% of patients 
are asymptomatic (WHO, 2015). Acute symptoms usually include: fever, nausea, 
vomiting, dark coloured urine and faeces, jaundice, fatigue and joint pain. 
Because the disease is largely asymptomatic in the acute stage, most new cases 
go undiagnosed until the later stages when overt liver damage has occurred 
(WHO, 2015). 
Diagnosis 
With the use of antiviral medicines, there is a high chance of cure (up to 90%) and 
thereby reducing the risk of death due to cirrhosis and liver cancer. However, 
access to diagnosis is poor (WHO, 2015). 
HCV infection diagnosis is conducted usually by: 
1. Anti-HCV antibody screening usually identifies people with previous 
infection with the virus. 
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2. If the result of the test is positive, a PCR test for HCV RNA is required to 
confirm the diagnosis. 
About 15-45 % of infected people clear the virus spontaneously with their strong 
immune response without the need for further treatment. However, they still have 
HCV antibodies in their circulation (Wilkins et al., 2010). 
After the patient have been diagnosed with HCV, he/she should be assessed for 
the degree and type of liver damage and this can be accomplished by liver biopsy 
and liver function test. Another important thing is that the HCV genotype should 
be identified since there are six genotypes and each responds to treatment 
differently (Al Naamani et al., 2013). 
Treatment 
The treatment is based mainly on: 
1. Life style changes: these include measures to limit liver damage progress 
like stopping or lessening intake of alcohol, eating healthy balanced diet, 
stopping smoking and doing regular exercises. 
2. Taking a combination of  three medicines to stop virus replication which 
are a protease inhibitor, pegylated interferon-α and ribavirin (NHS, 
2015). 
The old treatment regimens were based on using pegylated interferon-α and 
ribavirin alone for 48 weeks which entails significant misery due to long duration 
of side effects of this combination which include: flu-like symptoms, depression, 
fatigue, anaemia, gastrointestinal symptoms and cutaneous reactions (Manns et 
al., 2006). 
Over the last decade, there has been a great progress in the understanding of 
HCV lifecycle and the viral replication mechanisms that have paved the way for 
the development of protease inhibitor drugs (Kwong et al., 2011).  
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1.10 Telaprevir (VX-950) 
 is the first anti-viral protease inhibitor that was used in the treatment of hepatitis 
C genotype 1. It was co-developed by Johnson & Johnson and Vertex 
Pharmaceuticals (Revill, 2016). It inhibits NS3-4A serine protease which is 
essential for viral replication (Jesudian et al., 2012). This enzyme is essential for 
the cleavage of posttranslational non-functional viral proteins into active 
polypeptides that are required for viral assembly (Smith et al., 2011). Another 
important role is that NS3-4A serine protease is vital for deactivating hepatic 
cellular proteins that are essential for mediating interferon cascade responsible 
for mounting antiviral response (Morikawa et al., 2011).  
Pharmacokinetics 
Absorption & bioavailability: Telaprevir is administered orally in the form of 
tablet or capsule with good absorption in small intestine. Maximal plasma 
concentration after a single dose is achieved after 4-5 hrs. 
Distribution: Telaprevir is highly bound to plasma proteins (59-76% is bound). It 
binds mainly to alpha 1–acid glycoprotein and albumin with an inverse 
concentration-dependent pattern. The mean volume of distribution is 
approximately 252 L with 72% inter-individual variation (Vertex, 2013).  
Metabolism: Telaprevir is extensively metabolized by liver through reduction, 
oxidation and hydrolysis, which leads to formation of multiple metabolites. The 
main product is VRT-127394, which is the R-stereoisomer that has 30-fold less 
potency than telaprevir. After administration of telaprevir, rapid conversion to 
VRT-127394 occurs (Figure 1.14) The relative ratio of telaprevir:VRT-127394 is 
approximately 2:1 in humans (Monitoring, 2016) 
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Other metabolites include VRT-0922061 (inactive isomer) and pyrazinoic acid 
(inactive) (FDA, 2011). Previous research has shown that CYP3A4 is the major 
isoform of cytochrome P450 family that is responsible for telaprevir metabolism 
(Vertex, 2013).  
Excretion: Following administration of 750 mg single oral dose of radio-labelled 
telaprevir, 90% of radioactivity was recovered in faeces, urine and exhaled air 
after 96 hrs. Recovery of the dose was mainly in faeces (82%), with 9% in exhaled 
air and 1% in urine.  In terms of telaprevir and its metabolite (VRT-127394), the 
unchanged recovered fraction was 31.9% & 18.8%, respectively (Vertex, 2013). 
Recommended dose:  
The recommended oral dose of telaprevir is 1125 mg (three 375 mg tabs) taken 
twice daily with food. Telaprevir should be administered in combination with 
ribavirin and interferon-α for 12 weeks (Buti et al., 2014).  
Adverse effects 
Dermatological 
1. Very common: Rash (all grades: 56% in telaprevir combination therapy as 
compared to 34% in patients receiving pegylated interferon-α and ribavirin 
  
Figure 1.14: Chemical structure of (A): telaprevir (Pubchem, 2016b) , (B) telaprevir 
metabolite (VRT-127394) (PubChem, 2016a). 
A B 
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alone), pruritus (47% in telaprevir combination therapy as compared to 
28% in patients receiving pegylated interferon-α and ribavirin alone).                                                                   
2. Common: Severe rash affecting more than 50% of body surface area with 
eczematous component and pruritus. (4.8% in telaprevir combination 
therapy as compared to 0.4% in patients receiving pegylated interferon-α 
and ribavirin alone).  
3. Uncommon (less than 1%): Serious skin reactions (including drug reaction 
with eosinophilia and systemic symptoms [DRESS], Stevens-Johnson 
syndrome [SJS]) as compared to none who are receiving pegylated 
interferon-α and ribavirin. These symptoms necessitate immediate 
stopping of treatment (Vertex, 2013).  
Telaprevir related dermatitis may occur at any time after starting treatment with a 
median of 15 days and interquartile range (4-41) days. The resolution of 
dermatological reactions is slow with a median time of 44 days and a range of (1-
504) days even for patients who have discontinued telaprevir. Moreover, it has 
been shown that there is no correlation between the severity of the skin reactions 
and the plasma level of telaprevir (Roujeau et al., 2013).  
These findings collectively denote that telaprevir related skin reactions may be 
immunological and that telaprevir is initiating an antigen-specific T-cell response 
that is responsible for (1) the increased frequency of reactions and (2) the 
appearance of severe skin reactions that are not observed in the absence of the 
drug. 
It has been reported that 7% of patients on combination therapy discontinued 
treatment because of rash and/or pruritus as compared to 1% on pegylated 
interferon-α and ribavirin alone (McHutchison et al., 2009). 
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Others 
 
Risk factors for telaprevir related skin reactions 
Telaprevir related skin reactions have shown a significantly higher incidence in 
both univariate and multivariate analyses (p≤0.03) with age above 45 yrs., body 
mass index below 30, white race and receiving treatment for the first time. 
Nevertheless, there was a modest impact of these factors on incidence (the 
incidence difference between groups was less than 20% and often below 10%) 
(Roujeau et al., 2013). 
Moreover, male sex was found to be a clinical risk factor i.e. it is associated with 
a higher incidence of more severe conditions (grade 3 dermatological reactions) 
(Suda et al., 2015).  
Role of HLA phenotype 
A study performed on 187 telaprevir treated patients measured the association 
between HLA phenotype with rash of any severity. Five alleles were significant at 
0.05 level depending on the uncorrected p values. Two alleles (B*4402 with an 
odd ratio 2.43 and DQB1*0202 with an odd ratio 2.01) were found to be risk 
markers for severe skin reactions. However, after being corrected for multiple 
comparisons none proved to be significantly associated (Roujeau et al., 2013). 
 
Table 1.7: Clinical adverse reactions to hepatitis C regimen (pegylated interferon-α and 
ribavirin)  in the presence and absence of telaprevir (Alkhouri and Zein, 2012). 
Side effect 
Telaprevir, pegylated interferon-α and 
ribavirin combination, N = 1346 (%) 
Placebo/ pegylated interferon-
α and ribavirin, N = 764 (%) 
Nausea 39 28 
Anemia 36 17 
Diarrhea 26 17 
Vomiting 13 8 
Haemorrhoids 12 3 
Anal pruritus 6 1 
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Role of TCR-Vβ 
Up to date there is no scientific literature discussing any possible association 
between TCR-Vβ expression and telaprevir reactions. 
Role of granulysin 
Suda et al (2015) have reported an association of granulysin with the severity of 
telaprevir skin reactions. Moreover, there is an early rise in serum granulysin 
levels with the onset of severe symptoms. This increase fades within 6 days. 
Thus, they concluded that granulysin could be utilized as an early predictive 
marker for telaprevir-induced skin reactions.       
Role of metabolism 
Telaprevir metabolites VRT-841125 & VRT-126032 have been shown to be 
inducers for skin sensitization in animal studies. However, the relationship of 
these metabolites to the rash incidence in humans is not clear.     
Pyrazinoic acid (PZA): is a major metabolite of telaprevir that was found in a small 
substudy phase II trial, to be at a higher plasma level in patients with severe rash 
as compared to the controls. However, the sample size was small with a high 
variation between subjects  Therefore,  further work is required to explore the 
relationship between PZA and rash (FDA, 2011).  
1.11 Aims of the thesis 
The aims of the thesis are to investigate the various chemical or immunogenic 
factors that may play a role in mediating drug hypersensitivity reactions for 
piperacillin and telaprevir. This was implemented using blood samples from 
hypersensitive patients and healthy naïve volunteers and utilising a battery of 
techniques for characterization of the antigenic determinants and testing the drug 
specific T-cells response.   
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2 Materials and Methods 
2.1 How it works 
All chemicals and biological reagents, devices, and labware that were used in this 
project are listed at the appendix (chapter 7) with additional details about the 
suppliers or the manufacturers.   
Since most of my work was on piperacillin, piperacillin is mentioned in most of the 
following protocols as the drug under investigation. However, the same protocols 
can be applied on other drugs mentioned in this thesis with relevant modifications 
that would be discussed under related headings. 
2.2 Characterisation of the response of patients T- 
lymphocytes to drugs 
2.2.1 Cell culture medium preparation 
T-cell culture medium is composed of RPMI 1640 that is supplemented with 
10% human AB serum, penicillin (1000 U/ml), streptomycin (0.1 mg/ml), and 
transferrin (25 µg/ml). HEPES (25 mM) and L-glutamine (2 mM).  
EBV-transformed B-cells (EBVs) were grown in a culture medium that is 
composed RPMI 1640 supplemented with 10% foetal bovine serum, HEPES (25 
mM), penicillin (1000 U/ml), streptomycin (0.1 mg/ml) and L-glutamine (2 mM).   
  
2.2.2 Isolation of peripheral blood mononuclear cells from 
heparinized venous blood utilising density-gradient 
centrifugation 
Requirements: 
 Venous blood from a patient.   
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 Heparinised blood-collecting tubes. 
 Blood collection set 
 Lymphoprep solution   
 50 mL sterile conical tubes. 
 HBSS solution   
 50mL syringe  
 Kwill 
Procedure: 
After collecting blood by venesection, it is layered on Lymphoprep solution in a 
(50 mL) tube (1:1, v/v) and then spun in an Eppendorf 5810 centrifuge at 2000 
rpm for 25 min with zero deceleration. After that, different layers of cells are 
visible. Tube shows different layers. The whitish layer of cells at the interface 
between the plasma and the Lymphoprep was collected, which represents the 
PBMCs (peripheral blood mononuclear cells) using a Pasteur pipette (Figure 2.1). 
The PBMCs were placed in a new tube and diluted 1:4 with HBSS and then spun 
again at 1800 rpm for 10 min. The supernatant was discarded and the cell pellet 
resuspended in HBSS. The tubes were spun at 1500 rpm for 10 min and the cells 
resuspended in a culture medium prior to counting. 
PBMCs suspension (10 µL) was added to equal volume of trypan blue (0.2 % w/v) 
and another (20 µL) of HBSS was added. Then, (10 µL) of the mixture was placed 
on a haemocytometer under a Leica DME microscope. Cell viability was assessed 
using the trypan blue, which stains the dead cells much darker than the viable 
cells. The percentage viability was estimated by the following equation: 
percentage viability=viable cells ÷ total cells × 100.  Percentage viability was 
≥95% for all the PBMCs isolations that were performed. 
After cell counting, the cells are ready for culture or to be frozen using the freezing 
mix (cryopreservation in 80% AB serum + 20% DMSO) 
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2.2.3 Detection of drug-specific PBMCs responses using the 
lymphocyte transformation test (LTT) 
Principle: 
Drug specific T-cells (memory T-cells) are present in the blood of hypersensitive 
patients. LTT is an assay that investigates the presence of these drug specific 
cells. Thus, we can delineate which patients’ samples are going to be enrolled in 
the study. Moreover, it provides valuable information about the optimal dose of 
the culprit drug for T-cell priming and subsequent testing (Pichler, 2014).  
Proliferative responses were measured by the addition of 3H-thymidine for the 
final 16h of the assay. The positive response is measured using the magnitude of 
the incorporation of 3H-thymidine into DNA during cell division. The cell nucleus 
is then trapped on paper filter mats during cell harvesting. The mats are sealed 
with wax containing scintillant and then counted in a scintillation beta counter.  
 
 
 
Figure 2.1: The procedure implemented in blood separation and PBMCs count 
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Requirements 
 PBMCs (0.15 X106)/well in a 96-well U-bottom micro titre plate. 
 Tetanus toxoid  
 Titrated concentrations of the tested drug.  
 Thymidine at concentration of 50 µCi/mL (0.5~µCi/well=10 µL). 
 Beta counter  
Procedure: 
Hypersensitive patients PBMCs (0.15X106 per well) were cultured in triplicates. 
The following reagents were added as three conditions: 
1. Serially diluted doses of the culprit drug e.g. piperacillin (62.5–2000 µM). 
2. Tetanus toxoid (5 µg/mL) as a positive control. 
3. (0=medium) as a negative control. 
The final volume is (200 µL/well) for all the conditions. The cultures were 
incubated for 6 days at 37°C and 5% CO2. Then, for the last 16 hrs (0.5 µCi) of 
3H-thymidine/well was added (Figure 2.2). Thereafter, the cells were harvested 
on paper filter mats which were read by the beta counter to measure the rate of 
3H-thymidine uptake by the cells which gives a quantitative measure of 
proliferation in counts per minute (cpm). The proliferation of the cells in 
piperacillin (+) was divided by the proliferation of the cells in medium (-) to 
calculate the stimulation index (SI). An SI ≥ 2 was accepted as a drug specific 
T-cells response.   
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2.2.4 Generation of Epstein-Barr virus transformed B-
lymphoblastoid cell lines (EBVs) 
Using established protocols (Neitzel, 1986;Naisbitt et al., 2003b), antigen 
presenting cell lines (EBVs) were generated from drug hypersensitive patients 
and drug naive controls as follows: 
Principle: 
Autologous EBVs are an essential requirement for the assays with clones T-cells 
to act as an antigen presenting cells. The marmoset cell line B9-58 acts as a 
source of the Epstein-Barr virus (EBV) which exists as circular episomal DNA 
inside these infected cells (5-800 copies/cell). The EBV virus selectively 
transforms human B-lymphocytes into an endlessly dividing, and immortalized 
lymphoblastoid cells i.e. EBVs (Neitzel, 1986).  
Requirements 
 Isolated lymphocytes total 5x 106 cells. 
 5ml of cell-free and filtered supernatant of the marmoset cell line B9-58   
 Sterile 20 mL tubes. 
 
Figure 2.2 : Lymphocyte transformation assay (LTT) scheme. 
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 24-well sterile plates. 
 Feeding medium 
 Cyclosporin-A (CSA), (1 µg/mL) in DMSO   
Procedure: 
EBVs are generated by incubating a cell pellet of PBMCs from either patients or 
normal volunteers with (5 mL) filtered supernatant from the B9-58 cell line.  
Cyclosporin-A (CSA) was added to the cells at (1µg/mL) to prevent T-cell 
proliferation and the tubes were cultured overnight (37°C, 5% CO2). After 24hrs, 
the cells were spun at 1500 rpm for 5 min and the supernatant discarded. The 
cells were resuspended in 2ml of culture medium supplemented with (1 µg/mL) 
CSA. Cells were seeded by serial dilution in a 24-well plate; keeping the total 
volume/well at (1 mL). Cells were fed twice a week with fresh medium containing 
CSA (1 µg/mL). CSA addition is stopped after 3 weeks and the cells were 
transferred to cell culture flasks when the culture medium started to turn yellow 
indicating good cell growth. 
 
2.2.5 Generation of drug-specific T-cell lines and T-cell clones 
from drug-hypersensitve patients 
 Requirements: 
 Isolated lymphocytes from the involved hypersensitive patients (2mLs of 
cells at 1x 106 cells/mL). 
 96-well U-bottom micro titre plates. 
 48-well plates. 
 T-cell growing medium. 
 PHA (1mg/mL)  
 Human r-IL-2 (100 U/mL)   
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  Drug-specific T cell enrichment "bulk culture" 
Principle: 
Piperacillin hypersensitive patients blood contains primed (reactive) T-cells 
circulating in their blood. By incubating their PBMCs with piperacillin for 14 days, 
the antigen presenting cells within the PBMCs would have the chance to present 
piperacillin (as antigen) to T-cells. Consequently, we would expect a higher yield 
in terms of the primed T-cells that can be utilized in the generation of reactive 
specific TCCs as they will be expanded over the 14-day culture period. 
Procedure: 
Patient PBMCs (2x106 cells/well) in the 48 well plates were incubated for 2 weeks 
in the presence of free piperacillin (2mM) which has been shown in previous 
research as the optimal dose for priming and testing TCCs (Monshi, 2013). The 
cells were incubated at 37 °C and 5% CO2. The cultures were fed on day 6 and 
day 9 with culture medium supplemented with IL-2 (60 U/mL). These cells 
represent the bulk cultures. 
  Serial dilution of bulk cultures 
Principle: 
The hypothesis of T cell clone generation is that each clone is generated from a 
single cell. To achieve this, the bulk cultures undergo serial dilution and are diluted 
to a degree that permits the inoculation of a single cell in each well. Proliferation 
is aided by the addition of irradiated, allogeneic PBMCs, IL-2 and PHA to induce 
the T-cells proliferation. 
Procedure: 
On day 14 of the incubation of the bulk cultures, the cells were harvested, washed 
and then counted using the trypan blue. Then the cells were serially diluted to 96-
well U-bottom plates at 3 concentrations: 0.3, 1 and 3 cells/well in culture medium   
supplemented with IL-2 (200 U/mL), PHA (10 µg/mL) and 45 Gy irradiated, 
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allogeneic PBMCs (as feeder cells). PBMCs were added at a concentration of 
50000 cell/ well in 100 μL. The serial dilution cultures were incubated for 2 weeks 
at 37 °C and 5% CO2 with feeding every 48 hrs with culture medium (25 μL/well) 
containing IL-2 (60 U/mL). 
  Restimulation and the selection of well growing cells 
Principle: 
Incubating the T-cells with irradiated allogeneic PBMCs stimulates proliferation. 
This proliferative response is augmented by the presence of IL-2 and PHA. IL-2 
is a cytokine that is well known as a T-cell stimulator (Liao et al., 2013). Likewise, 
PHA is known to induce T-cell mitosis (Movafagh et al., 2011). Using allogeneic 
PBMCs would provide HLA mismatch environment which adds to the strength of 
the stimulatory reaction in addition to their role as feeder cells.   
Procedure: 
The serial dilution plates were restimulated by using 45 Gy irradiated, allogeneic 
PBMCs at a concentration of (5x104 cell/mL), IL-2 (200 U/mL) and PHA (10 
µg/mL). The cultures were incubated at 37 °C and 5% CO2 for two weeks. They 
were fed every 2 days with culture medium (25 μL /well) supplemented with IL-2 
(60 U/mL). Plates were assessed regularly to check for the outgrowth of TCCs. 
Any well containing a large cell pellet (about 2mm) was transferred into new 96-
U bottomed plates and expanded into 2 wells and later into 4 wells. 
 
  Testing drug-specific T-cells proliferation using 
radioactive thymidine uptake assay 
Principle:  
It follows the same principle of LTT with some modifications to cope with a higher 
number of primed (memory T-cells) in the drug specific clones as compared with 
the hypersensitive patient-derived PBMCs. The proliferative response of (TCCs) 
Materials & Methods                                                                           Chapter 2  
 
 
 
97 
 
is stronger and faster than their precursor PBMCs; thus, the duration of the assay 
is limited to (48-72 hrs). Moreover, the number of cells/ well is less (5*105 /well) 
than in case of LTT and the cell incubation is conducted usually in duplicates and 
EBVS are used as APCs here.  The interpretation of data is usually in the form of 
cpm without calculating SIs because clones proliferative response is highly drug 
sensitive and specific i.e. the proliferative response of the negative control 
(background) is very low as compared to PBMCs LTT. 
Procedure: 
The TCCs 5*105 /well were incubated in duplicates in the presence (+) or absence 
of piperacillin (-) (medium was present instead of the drug) with the addition of 60 
Gy irradiated, autologous EBVs (104 cells/well) as an antigen presenting cells. 
The cultures were incubated for 48 hrs at 37°C and 5% CO2. Then, at the last 16 
hrs (0.5 µCi) of 3H-thymidine/ well was added. Thereafter, the cells were 
harvested on paper filter mats which were read by the beta counter to measure 
the rate of 3H-thymidine uptake by the cells which gives a quantitative measure of 
proliferation. The proliferation of the cells in piperacillin (+) was divided by the 
proliferation of the cells in medium (-) to calculate the stimulation index (SI). An 
SI ≥ 2 was accepted as a drug specific cell proliferation.  
 
  Quantitative assessment of the clones reactivity to 
piperacillin 
After identifying the drug specific clones, the response to piperacillin was 
assessed quantitatively. This uses the same method as above, but the T-cells 
were incubated with serially diluted doses of piperacillin.  
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  Qualitative assessment of the clones reactivity to 
piperacillin (cross reactivity test) 
Using the same protocol mentioned above, the clones that were shown to be 
reactive to piperacillin were tested for drug specificity. This entails incubating the 
lymphocytes in duplicates in the following conditions: presence (+), absence (-) of 
piperacillin and serially diluted doses of another drug which was normally nitroso-
sulfamethoxazole (SMX-NO). Then, the SI was counted for each condition. When 
the SI of piperacillin was more than 2 and the SI of the other drug (in all its 
conditions) was less than 2, then the clone was counted as drug specific. 
 
  Restimulation and expansion of drug-specific T-cell 
clones 
TCCs that have been shown to proliferate in response to piperacillin were further 
expanded in a 48 well plate in order to generate sufficient of cells to characterize 
their cytolytic activity, phenotype and their functionality in response to piperacillin. 
Expansion was performed by transfer of cells to the 48 well plates with the addition 
of 45 Gy irradiated, allogeneic 500000 PBMCs/well in 330 culture medium 
supplemented with IL-2 (200 U/mL) and PHA (10 μg/mL). Cultures were incubated 
at 37°C and 5% CO2 and fed every 2 days with 330 μL/well culture medium that 
was supplemented with IL-2 (60 U/mL).   
  T-cells proliferative response with and without APC 
fixation 
Requirements: 
1. EBVs, EBVs culture medium 
2. Glutaraldehyde, glycine powder 
3. HBSS, filter 
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Principle:  
According to the hapten hypothesis the drug (antigen) should bind to protein (e.g. 
HSA), then the formed complex (drug-HSA) would be processed and presented 
by the APCs (as a drug-peptide complex) to the TCRs on the T-cells via MHC 
molecules.  
Fixing the APCs with glutaraldehyde abolishes the intracellular processing of the 
drug (antigen) by inhibiting protease enzyme without affecting their antigen 
presentation ability (Kim et al., 1985). 
So, the aim of this assay is to identify the role of intracellular APC processing in 
mediating the T-cell response. 
Procedure: 
1. T-cells were suspended in HBSS in 2 million/mL concentration. 
2. Glutaraldehyde (1 µL/mL, 25%) was added to EBVs suspension. 
3. The mixture is incubated at room temperature for 30s. 
4. The reaction was stopped by adding glycine (0.2M) for 45s. 
5. APCs were washed 3x with 25mL medium.  
6. Another set of EBVs (unfixed) was prepared 
7. Both fixed EBVs and unfixed EBVs are irradiated and were then used in 
the usual setting of the 3H-thymidine uptake proliferation assay that is 
mentioned in the protocol 2.2.5.4. 
  APCs pulsing assay 
Principle: 
This assay explores the role of drug or protein binding with APCs in activating T-
cells. In addition, it clarifies the impact of APCs drug-protein processing on T-cells 
activation.  
The APCs are incubated with the culprit drug for variable durations 1,4,16,24 and 
48 hrs then washed three times prior to incubation with T-cells.   Repeated 
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washing will remove unbound drug and bound drug-protein adducts are the only 
antigen available for processing and presentation to T-cells.  
When T-cells show a proliferative response upon incubation with pulsed APCs, 
this is indicative of a hapten mechanism. Different drugs bind to different proteins 
with different kinetics. 
 Time dependent peptide modification  
Note: Done only with piperacillin-HSA conjugates 
Principle: 
In hapten mediated drug reactions, the free (soluble) drug (in culture medium) 
forms drug modified peptides by binding with culture medium proteins in a time 
dependent manner. Thus, APCs are incubated with free drug for specified periods 
of time. Culture supernatant can be collected and analyzed by mass spectrometry 
to measure the degree of drug-modified protein formed in cultue. APCs are 
washed several times before being irradiated to be incubated later with T-cells. T-
cells proliferative response mirrors the degree of drug-protein modification.   
Procedure: 
1. EBVs are incubated with the culprit drug (at the same concentration that 
stimulates T-cells) in 24 well plate for different durations: 1,4,16,24 and 48 
hrs (Table 2.1) 
2. To measure time dependent peptide modification, supernatant samples 
are aspirated from the culture wells (at the end of the incubation period) to 
be analyzed by mass spectrometry for the degree of protein modification.    
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3. The EBVs are harvested from the wells, washed twice and then irradiated 
with 60 Gy and then incubated at (10000 cell /well/50 µL) in 96- well test 
plate.   
4. Wells with non-pulsed irradiated with (60 Gy) EBVs are prepared. 
5. (50000/well) T-cells, are added. 
6. Culprit drug is added dissolved in medium (100 µL). 
7. Medium (100 µL) is added to control wells.  
8. The plate is incubated for 48 hrs at 37°C and 5% CO2. For the last 16 hrs 
3H-thymidine (0.5 µCi)/well was added. 
9. The plate is harvested and read using Beta counter.  
  
Table 2.1: The test plate design for the APCs pulsing assay. 
Conditions Wells 
Pulsed APCs 
for 1 hr 
50 µL T-cells+ 
50 µL pulsed EBVs (1 hr) + 
100 µL medium 
50 µL T-cells+ 
50 µL pulsed EBVs (1 hr) + 
100 µL medium 
Pulsed APCs 
for 4 hr 
50 µL T-cells+ 
50 µL pulsed EBVs (4 hrs) + 
100 µL medium 
50 µL T-cells+ 
50 µL pulsed EBVs (4 hrs) + 
100 µL medium 
Pulsed APCs 
for 16 hr 
50 µL T-cells+ 
50 µL pulsed EBVs (16 hrs) + 
100 µL medium 
50 µL T-cells+ 
50 µL pulsed EBVs (16 hrs) + 
100 µL medium 
Pulsed APCs 
for 24 hr 
50 µL T-cells+ 
50 µL pulsed EBVs (24 hrs) + 
100 µL medium 
50 µL T-cells+ 
50 µL pulsed EBVs (24 hrs) + 
100 µL medium 
Pulsed APCs 
for 48 hr 
50 µL T-cells+ 
50 µL pulsed EBVs (48 hrs) + 
100 µL medium 
50 µL T-cells+ 
50 µL pulsed EBVs (48 hrs) + 
100 µL medium 
Non pulsed APCs 
+ 
medium 
50 µL T-cells+ 
50 µL non-pulsed EBVs + 
100 µL medium 
50 µL T-cells+ 
50 µL non-pulsed EBVs + 
100 µL medium 
Non pulsed APCs 
+ 
Culprit drug 
50 µL T-cells+ 
50 µL non-pulsed EBVs + 
100 µL culprit drug 
50 µL T-cells+ 
50 µL non-pulsed EBVs + 
100 µL culprit drug 
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2.2.6 Quantitative and qualitative measurement of cytokine 
secretion by T-cell clones using ELISPOT 
Principle: 
The Enzyme-Linked ImmunoSpot (ELISPOT) assay is a very sensitive assay 
that measures the level of cytokine secretion at single cell level. This assay entails 
culturing the cells on a membrane containing plate that is coated with a specific 
capture antibody for the cytokine (Figure 2.3). When the cells secrete the specific 
cytokine it binds to the capture antibody. Then, after washing the plate, a 
biotynalated antibody is added which binds to cytokine. The binding can be 
visualized adding Streptavidin-enzyme conjugate (usually alkaline phosphatase) 
which reacts with the substrate (BCIP/NBT). Such a reaction produces a colour 
change in the form of spots (typically black) which can be counted visually with 
the aid of microscope or by the use of a spot counter. Each spot represents a 
single cytokine producing cell. The limit of detection can be as low as 1 cell in 
100,000 (Mabtech, 2014). The ELISPOTs which were carried out were performed 
according to the manufacturer’s instructions (Mabtech, Nacka Strand, Sweden)  
 
Figure 2.3: The principle of ELISPOT assay. The ELISPOT membrane is coated with a 
special coating antibody for 24 hrs. This antibody would bind the corresponding cytokine which 
would bind another (detection) biotin-bound antibody. Later, streptavidin enzyme is incubated 
in the wells for 1hr before the addition of substrate which would react in the presence of bound 
streptavidin to give the specific colour. 
Materials & Methods                                                                           Chapter 2  
 
 
 
103 
 
  ELISPOT assay for: interferon-gamma, interleukin-5, 
interleukin-13, perforin and granzyme-B 
Requirements: 
 Lymphocytes from drug hypersensitive patients or specific TCCs. 
 ELISPOT well strip plate. 
 Coating antibodies, detection antibodies (for IFN-γ, IL-5, IL-13, perforin and 
granzyme-B) are mentioned in Table 2.2. 
 Streptavidin ALP (alkaline phosphatase). 
 Detection substrate for the ELISPOT: BCIP/NBT plus. 
 Ethanol 35%, HBSS, sterile dH2O, drug of interest, PHA, PBS, FBS and    
SMX-NO. 
 ELISPOT reader. 
Procedure: 
 Coating:  on day 0: 
1. Ethanol (15 μL,35%) was added per well of the ELISPOT plate and left for 
one minute.  
2. The plate was washed 5X with (200 μL/well) sterile dH2O.  
3. Coating antibody (100 μL/well) was added and incubated overnight at 4°C.  
 Cell Incubation: On day 1: 
1. The excess antibody was washed using 5X of 200 μL HBSS.   
2. The plate was blocked by adding culture medium (200 μL/well) for more 
than 30 min.  
3. After washing the medium with 5x HBSS, 5x104 /50 μL T-lymphocytes, 60 
Gy irradiated 1x104 irradiated EBVs/50 μL, medium (-), serial dilutions of 
piperacillin (+), PHA (5µg/μL) as a positive control and SMX-NO as an 
irrelevant antigen (50 μM/mL) were added to the wells. 
4. The plate was wrapped in aluminium foil and incubated in 37 °C and 5% 
CO2 for 48 hrs.  
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 Spot Detection: On day 4: 
1. The plate was washed 5x with (200 μL) of PBS. 
2. Detection antibody (100 μL/well) was added and incubated for 2 hrs at 
room temperature.  
3. The plate was washed 5x with (200 μL) PBS. 
4. Streptavidin ALP (100 μL/well) was added and incubated 1 hr at room 
temperature. 
5. Finally, the plate was washed 5x with (200 μL) PBS and thereafter (100 
μL/well) of detection substrate (BCIP/NBT) was added.  
6. After waiting until the spots emerge (which usually takes about 13-15 min) 
the reaction was stopped by washing the plate with tap water and then the 
plate was rinsed and kept in dark until it dried. 
7. When the plate is dry it was analyzed by the ELISPOT reader to count the 
spots. 
  ELISPOT for FAS Ligand (FASL) 
Requirements: 
 Lymphocytes from drug hypersensitive patients or specific TCCs. 
 ELISPOT strip plate.   
Table 2.2: Common ELISPOT cytokines with the concentrations of their reagents 
 Coating Detection - primary Ab 
Secondary 
Ab 
Substrate 
Cytokine Name 
Stock 
conc. 
Final 
conc. 
Name 
Stock 
conc. 
Final 
conc. 
Name 
 
Name 
IFN-γ 1-D1K 1 mg/mL 
15 
μg/mL 
7-B6-1-
biotin 
1 mg/mL 1 μg/mL 
S
tr
e
p
ta
v
id
in
-A
L
P
, 
1
:1
0
0
0
 
d
ilu
te
 
B
C
IP
/N
B
T
 IL-5 TRFK5 1 mg/mL 
15 
μg/mL 
5A10-
biotin 
1 mg/mL 1 μg/mL 
IL-13 IL13-I 
0.5 
mg/mL 
10 
μg/mL 
IL13-3-
biotin 
0.5 
mg/mL 
1 μg/mL 
Perforin 
Pf-
80/164 
1 mg/mL 
30 
μg/mL 
Pf-344-
biotin 
1 mg/mL 1 μg/mL 
Granzyme-
B 
GB10 1 mg/mL 
15 
μg/mL 
GB11-
biotin 
1 mg/mL 1 μg/mL 
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 Capture antibody, streptavidin ALP (alkaline phosphatase), detection 
substrate for the ELISPOT: BCIP/NBT plus. 
 HBSS, sterile dH2O, PHA, PBS, BSA, dry skimmed milk, 70% ethanol, 
Tween 20. 
 ELISPOT reader. 
Procedure: 
 Day 0 (Coating):  
1. The PVDF plate was coated with (25 μL, 70%) ethanol for 30 second at 
room temperature. 
2. Wells were emptied. Then, plate was washed 3x with (100 μL/well) of 
HBSS. 
3. Capture antibody (100 μL) was pipetted and then added to (10 mL) of 
HBSS and mixed well. Then (100 μL) of the mixture was added per well. 
The plate was covered and incubated overnight at +4°C. 
 Day 1 (Cells Incubation): 
1. Wells were emptied and washed once with (100 μL) of HBSS. 
2. Skimmed dry milk (100 μL, 2%) in PBS was added per well. Then plate 
was covered and incubated for 2 hrs at room temperature. 
3. The plate was emptied and washed once with (100 μL /well) HBSS. Then 
tapped against paper towel. 
4. T-cells (5x104 in 50 μL medium), 60 Gy irradiated EBVs (104 in 50 μL 
medium) and (100 μL) of piperacillin were added per well. 
5. The plate was covered in AL foil and then incubated in 37 °C and 5% CO2 
for 48 hrs.  
 Day 3 (Spot Detection): 
1. Wells were emptied by flicking the plate over the sink and tapping it over a 
paper towel. 
2. PBS-0.1% Tween 20 (100 μL)/well was distributed and let sit for 10 min at 
+4°C. 
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3. Wells were washed 3x using (100 μL/well) of PBS-0.1% Tween 20. 
4. The lyophilized detection antibody was reconstituted by mixing the 
lyophilized antibody with (0.55mL) of distilled water.  
5. For one plate (100 μL) of the reconstituted detection antibody into (10 mL) 
of PBS containing 1% BSA. Then (100 μL/well) of the mixture was 
dispensed. The plate was covered and kept for 1 hr and 30 min at 37°C. 
6. Wells were emptied and washed 3x with (100 μL/well) PBS-0.1% Tween 
20. 
7. Streptavidin ALP (100 μL/well, dilution 1/1000) in each well was dispensed. 
Then the plate was sealed and incubated for 1 hr at 37°C. 
8. Wells were emptied and washed 3x with (100 μL/well) PBS-0.1% Tween 
20. 
9. Ready-to-use BCIP/NBT (100µl) was dispensed in wells. Let the reaction 
to go for about (2-10) min at room temperature. The spots formation is 
monitored visually. 
10. The plate was rinsed 3x with distilled water to stop the reaction. Then the 
plate is tapped on absorbent water. The plate was left to dry at +4°C 
overnight in the dark.  
11. Next day the plate was read by the spot reader. 
2.2.7 The quantitative and qualitative measurement of the T cell 
receptors and chemokine receptors using Fluorescence-
Activated Cell Sorting (FACS) 
Principle: 
The method of flow cytometry was first described by Wolfgang Göhde in 1968, is 
based upon the focusing of laser beams of particular wavelengths on the cells of 
interest which could be stained with extracellular or intracellular fluorescent stains. 
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This is followed by analyzing the cellular response to these beams in terms of 
distraction and fluorescence. These fluorescent stains were bound to antibodies 
which were specific to the receptors of the cells of interest. When they were 
exposed to the laser beam of certain wavelength, these stains emit light in a 
specific wavelength which can be detected by specific detectors which can 
convert the light energy to electrical signals that were measured to assess the 
degree of expression of such receptors (Figure 2.4). In some flow cytometry 
machines the technique is more advanced that it includes a system for sorting the 
cells (not used in my project) which is based on charging the cells with different 
electrical charges. Then, each type of cell can be pulled by an electrical field into 
a collecting tube depending on its charge. 
Requirements: 
 Non sterile FACS tubes 
 FACS buffer (10% FCS, 0.02% sodium azide in HBSS)  
 
Figure 2.4: The principle underlying the flow cytometry technique. Courtesy of Semrock 
(Semrock, 2015). 
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 Fluorescence labelled antibodies for CD3, CD4, CD8, CD45RO, CD45RA, 
TCR-Vβs and chemokine receptors. 
Procedure: 
The protocol mentioned below is a general protocol for all the FACS experiments 
that I have conducted, however, it was modified according to the requirements of 
each experiment in terms of the studied markers or receptors or cells. Such 
modifications will be discussed under the related headings. 
Cells labelling: 
The cells were harvested and suspended in a culture medium. Then (50ul) of the 
cells were transferred into non-sterile FACS tube. The fluorescent stains bound 
antibodies were transferred into the FACS tube in a dose that complies with the 
protocol issued by the manufacturer as shown in Table 2.3, Table 2.4 and Table 
2.5. Then the FACS tubes were incubated for (20 min) at 4°C (except for those of 
the TCR-Vβ which should be left at room temperature) in the dark. After the 
incubation, (500 μL) of FACS buffer is added per tube. This is followed by 
centrifugation at 1500 rpm for (5 min). The supernatant is discarded and the cells 
were resuspended in (200 μL) FACS buffer if they were to be tested by the flow 
cytometer on the same day. Otherwise, they should be fixed in (4%, 200 μL) 
paraformaldehyde and kept in the fridge. 
Compensation Preparation: 
If the experiment includes multicolour staining, then compensation should be 
prepared. The pupose of compensation is to optimise the flow cytometry machine 
readings of various lasers by wiping out the interference of the fluorescent dyes 
signals.  Compensation kit comes as 2 droppers which contain beads that can be 
stained with the fluorochromes antibodies used in the FACS.  
FACS buffer (400 μL) was added to one non-sterile FACS tube. Then, one drop 
of each compensation beads droppers were added to the tube. After shaking, 
(100 μL) of the mixture was transferred to non-sterile FACS tubes and the number 
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of the tubes equals the number of the colours of the fluorescent antibodies used 
in the experiment +1 (as a control). For example, an experiment was conducted 
using CD3-APC, CD4-FITC and CD8-PE. Then, (3 μL) of the fluorescent stain 
labelled antibody that were used in labelling the cells were transferred to each 
tube. i.e. (3 μL) of CD3-APC to 1st tube, (3 μL) CD4-FITC to the 2nd tube and (3 
μL) CD8-PE to the 3rd tube while the 4th tube was left without stain as a control. 
The tubes were incubated at 4ºC. 
When the cells or the (compensation beads) were analyzed on the flow cytometer, 
they appear as dots (dot plot) on the screen. Such dots need to be gated using 
forward scattering and side scattering into populations. Then these populations 
are gated again according to the fluorochrome stain which the marker of interest 
is attached to.    In this way we can separate the cells into groups of certain criteria 
e.g. memory cells, CD4 or CD8 cells. The data were represented in the form of 
percentages (or in the case of chemokines, the cells appear as histogram and the 
results are expressed in terms of mean fluorescence index).  
  Characterisation of the phenotypic profile of T-cell 
clones of hypersensitive patients 
The clones were characterized using the same protocol mentioned above under 
heading 2.2.7 but with implementation of the scheme highlighting the doses of 
the reagents outlined in the Table 2.3. The cell clones were T-cells if they bind 
CD3 antibody and they were CD4 or CD8 depending on the type of the receptor 
antibody binding whether they bind to CD4 antibody or CD8 antibody, 
respectively. T-cells are naïve if they are CD45RO–ve while they are memory T-
cells if they are CD45RO+ve. 
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  Characterisation of The TCR-Vβ of T-cell clones of          
hypersensitive patients  
After characterising the clones phenotypically in terms of their CD3, CD4, CD8, 
CD45RA and CD45RO surface markers, TCCs were characterized in terms of 
their TCR-Vβ expression using the flow cytometry. The clones were labelled using 
the TCR-Vβ kit reagents mixture. Each vial contained a mixture of three 
fluorochrome labelled monoclonal antibodies. Using the same protocol mentioned 
in heading 2.2.7, T-cells were labelled with TCR-Vβ reagents as mentioned in the 
scheme shown in Table 2.4. 
 
 
 
 
 
 
 
 
 
 
Table 2.3: Protocol scheme for labelling of the T-cells to characterize their phenotypic 
profile. 
Tubes labelling Compensation Incubation 
Tube 1=None 
FITC, PE, APC, 
and PerCP-Cy5.5 
20 min on ice (4°C), 
in the dark. 
Tube 2=CD3-APC, CD4- FITC, CD8-PE (3 μL 
of each antibody) 
Tube 3=CD45RO-PerCP-Cy5.5, 
CD45RA-FITC (3 μL of each antibody). 
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Table 2.4. scheme of labelling tubes for TCR-Vβ of TCCs (Beckman Coulter, 2015). 
Tube number 
Reagent 
vial to be 
added   
TCR-Vβ 
to be 
tested   
Fluorochromes 
attached  
Compensation  
used 
Incubation  
1 A (5μL) 
Vβ 5.3     PE   
FITC, PE 
20 min in room 
temperature, in 
the dark 
Vβ 7.1  PE+FITC 
Vβ 3  FITC   
2 B (5μL) 
Vβ 9   PE   
Vβ 17   PE+FITC 
Vβ 16    FITC   
3 C (5μL) 
Vβ 18  PE   
Vβ 5.1    PE+FITC 
Vβ 20    FITC   
4 D (5μL) 
Vβ 13.1    PE   
Vβ 13.6                                     PE+FITC 
Vβ 8                     FITC   
5 E (5μL) 
Vβ 5.2                        PE  
Vβ 2               PE+FITC 
Vβ 12   FITC 
6 F (5μL) 
Vβ 23  PE   
Vβ 1  PE+FITC 
Vβ 21.3  FITC   
7 G (5μL) 
Vβ 11 PE   
Vβ 22  PE+FITC 
Vβ 14  FITC   
8 H (5μL) 
Vβ 13.2 PE   
Vβ 4  PE+FITC 
Vβ 7.2  FITC   
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  Characterization of chemokine receptors expression of 
T-cells clones of hypersensitive patients 
Using the same protocol for labelling the T-cells mentioned under the heading 
2.2.7, TCCs were characterized in terms of chemokine receptors expression 
according to the scheme shown in Table 2.5. 
 
2.3 Characterisation of the response of naive volunteer 
T-lymphocytes to drugs 
In this part of the project, we tried to characterize the response of T-cells primed 
to piperacillin that were collected from normal (naive) volunteers. Blood was taken 
from three healthy volunteers (not allergic to piperacillin). 
PBMCs were separated from the blood according to the protocol mentioned under 
the heading 2.2.2 
Note: In this part of the study which focuses upon the responses of naive volunteer 
derived T-cells, I use the terms free piperacillin primed T-cells and SMX-NO 
primed T-cells to denote T-cells which have been subjected to the priming 
technique of free piperacillin and SMX-NO respectively. These cells are not 
Table 2.5: The labelling of TCCs by the fluorescence labelled antibodies for various 
chemokines. 
Tubes APC FITC PE Compensation 
Incubation 
type 
1 None None None 
APC, FITC, 
PE 
20 min on 
ice (4°C), 
in the 
dark 
2 CXCR3(3μL) CCR5 (3μL) CCR1 (3μL) 
3 CCR2 (3μL) CCR3 (3μL) CCR4 (3μL) 
4 CCR9 (3μL) CCR8 (3μL) CCR10 (3μL) 
5 CCR6 (3μL) CLA (3μL) CXCR6 (3μL) 
6 None CD69 (3μL) E-cad (3μL) 
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necessarily expected to be primed when analyzed by their responses by the 
battery of assays mentioned below (i.e. they could be primed or not) but the 
nomenclature is used to differentiate between them and the naïve T-cells. 
Eventually, the assays mentioned below will confirm their priming status in terms 
of specificity and the magnitude of the response. 
 
Ds-T-cells priming assay: 
Requirements: 
 108 mL blood taken by venesection   
 CD14, CD3, CD45RA, CD45RO microbeads  
 Pan T Isolation kit    
 LS columns    
 MACS buffer: 50mls HBSS, 2mL (0.5M) EDTA, 2.5g BSA (mix and then 
filter 0.2µm). Then dilute with HBSS 10:1     
 T-cell culture medium         
 Human GM-CSF, 
 Human IL-4     
 Human TNFα    
 LPS        
Principles:  
T-cell-DC priming: This assay is based upon the ability of the antigen presenting 
cells (in this assay DCs) to prime the naïve (CD45RO-ve) T-cells to become 
reactive (primed i.e. CD45RO+ve) to the drug under investigation. Successful 
priming can be achieved when DCs are incubated with the naïve cells at a ratio 
of 1:31 and the drug with a specific dose of the drug for 8 days. T-cells priming 
was performed according to the protocol described in (Faulkner et al., 2012). 
Magnetic separation of cells: Magnetic bead labelled antibodies are prepared 
according to the type of cells that are required to be separated. These antibodies 
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will bind to specific receptor e.g. CD14 leaving the non-CD14 cells unlabelled. 
Then, the cells are poured in a column that contains magnetic ferrospheres and 
is surrounded by a strong mobile magnet. These ferrospheres amplify the 
magnetic field 10000 times and so creating a strong magnetic gradient to hold the 
labelled cells while allowing the flow of unlabelled cells (Figure 2.5). The spheres 
lie at 30 µM distance from each other which allows the separation of most kinds 
of cells. The labelled cells are not attached to the column matrix but they are rather 
held in suspension inside the column. After that, the magnet is taken off and the 
labelled cells are pushed out by plunging the column with MACS buffer (Biotec, 
2015). 
Procedure: 
108 mL of blood was taken by the process of venesection from a naive volunteer 
and the blood cells were separated according to the protocol of the heading 2.2.2. 
All cell separations using the beads isolations mentioned below were carried out 
according to the protocols designed by manufacturer (Miltenyi Biotech Ltd). 
    
Figure 2.5:The principle of the magnetic separation. The cells are labelled with magnetic 
beads attached to specific antibodies. Next, the cells are passed through a column that contains 
magnetic ferrospheres and surrounded by a magnet. The bead labelled cells are held inside 
the column while unlabelled flow through. Finally, the magnet is removed and the column is 
plunged firmly to get the labelled cells out (Biotec, 2015). 
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2.3.1 Positive selection of CD14 cells (Day 0)  
1. The cells, microbeads and MACS buffer should be all kept on ice 4ºC. 
2. The cells which were in AB medium were spun down. Then, (800 
μL)MACS buffer per 108 cells + (200 l) CD14 microbeads per 108 cells 
were added to the cells. After mixing, the mixture was incubated for 15 min 
in the fridge at 4°C. 
3. MACS buffer (15 mL) per 108 cells were added to the mixture and then 
spun at 1500rpm for 10 min at 4°C. 
4. The supernatant was pipetted and the cells were resuspended at 108 cells 
per (750 μL) MACS buffer. 
5. The LS column was placed on the magnet and washed with (3 mL) MACS 
buffer. 
6. The cell suspension was added to the column. The tube was rinsed twice 
with (500 μL) MACS buffer. 
7. The column was washed 3 times with (3 mL) MACS buffer. 
8. The flow through was collected as containing the CD14 –ve cells. 
9. The column was removed from the magnet and placed over a collection 
tube. MACS buffer (5mL) was added to the column and the cells were 
harvested by applying the plunger firmly to the column. The collected cells 
are CD14 +ve cells. 
10. By adding the MACS buffer (10 mL), the positive cells were made and 
counted by 1:2 dilutions, while the negative cells were made to (15 mL) 
and counted to 1:4 dilution. 
11. The CD14 cells were resuspended at 12-16x106 cells/mL in 10% AB 
medium.  
12. 0.5 mL of the cell suspension was used to establish the CD14 culture for 
the DCs, while the remaining CD14 cells were resuspended at 5-10x106 
cells/cryovial, then 20% DMSO, 80% AB serum was added dropwise in an 
equal volume while the cryovials were still on ice 4ºC. The cryovials were 
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stored overnight in Mr Frosty tubs at -80°C and then transferred to -150°C 
for storage. 
13. The non-CD14 cells were used for T-cell separation. 
2.3.2 Negative selection of CD3 T-cells (Day 0) 
1. Non-CD14 were spun down and the supernatant was discarded. Then, 
(40μL) MACS buffer and (10μL) antibody cocktail per 107 cells were added 
to the cells. The cells were mixed well and incubated at 4°C for 10 min. 
2. MACS buffer (30 mL) and (20 μL) anti-biotin microbeads per 107 cells were 
added to the cells. Following mixing, the cells were incubated at 4°C) for 
15 min. 
3. MACS buffer (1.5 mL) per 107 cells was added and spun at 1500 rpm for 
10 min at 4°C. The supernatant was pipetted completely and resuspended 
at 108 cells in (500 μL) MACS buffer. Next, the cells were added to LS 
column. This was followed by twice rinsing of the tube with (500 μL) MACS 
buffer. 
4. The LS column was washed with (3 mL) MACS buffer 3x. 
5. The flow through was the CD3+ve cells. Their volume was made up to (15 
mL). 
6. The CD3-ve cells were recovered from the column and the volume was 
made up to (10 mL), then cells were counted. 
7. CD3-ve cells were either frozen down or utilized in the preparation of EBVs 
according to the protocol discussed under the heading 2.2.4. 
2.3.3 Positive selection of CD25 and CD45RO T-cells (Day 0) 
1. The CD3 +ve cells were spun down and (70 μL) MACS buffer per 107 cells, 
(10 μL) CD25 and (20l) CD45RO microbeads per 107 cells were added. 
After mixing, the ells were incubated for 15 min in the fridge at 4°C. 
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2. MACS buffer (1.5 mL) per 107 cells were added to the mixture. After 
centrifugation at 1500 rpm for 10 min at 4°C. The supernatant was removed    
completely and cells were resuspended at 108 cells per (500 μL) MACS 
buffer. 
3. The cells were added to the LS column, and then the tube was rinsed twice 
with (500 μL) MACS buffer. 
4. The LS column was washed with (3 mL) MACS buffer 3x.  
5. The flow through cells (CD45RO–ve) were made up to (15 mL) by adding 
MACS buffer and counted at a 1:4 dilution. The harvested cells from the 
column by pressure (CD45RO +ve) were made up to (5 mL) and counted 
at 1:2 dilution.  
6. The cells were cryopreserved.   
2.3.4 DCs maturation from CD14 cells (Days 0, 2, 4, 6) 
Principle: CD14 cells (monocytes) have the ability to differentiate into dendritic 
cells (DCs) in the presence IL-4, GM-CSF, LPS and TNFα (Han et al., 2009). 
CD14 cells can differentiate into DCs or macrophages.   The presence of IL-4 and 
GM-CSF favours the DC pathway and prevents the formation of macrophages, 
while TNFα and LPS promote the maturation of DCs (Hiasa et al., 2009).  
1. (6 mL) of 1-2x106 CD14 cells/mL were suspended in medium containing 
(800 U/mL) GM-CSF and IL-4. Then, (3mL/well) were aliquoted to a 6 well 
plate. 
2. On day 2, (3 mL/well) medium with (800 U/mL) GM-CSF and IL-4 were   
added. 
3. On Day 4, (3 mL) of the medium supernatant/well were withdrawn and 
discarded. Then, 3 mL of the medium containing (800 U/mL) GM-CSF and 
IL-4 were added. 
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4. On day 6, (3mL) of the supernatant/well were withdrawn and discarded. 
Then, 3mL/well medium containing (800 U/mL) GM-CSF and IL-4, (1 
µg/mL) LPS and (25 ng/mL) TNFα were added. Figure 2.6 shows the 
stages of dendritic cells maturation from day 0 to day 7  
2.3.5 DCs stimulation of T-cells (coculture) (Day 7): 
1. Frozen CD45RO-ve T-cells were thawed quickly and resuspended in 
medium. After washing, they were resuspended in medium and the count 
made up to 2.5x106 cells/mL in medium. Then, using 24 well plate, cells 
were added as (1mL/well). 
2. DCs were harvested from the bottom of the plate using the scraper to wipe 
the bottom (3 times vertical and 3 times horizontal). Next, the cells were 
aspirated using a Pasteur pipette. Then, cells were spun down and 
resuspended in 10% AB medium at 1.6x105 cells/mL. (0.5 mL/well) was 
added to the wells of the 24 well plate containing T-cells. 
3. The drug (piperacillin) was prepared in culture medium in a concentration 
that is 4 times the required concentration. (0.5 mL) of the prepared drug 
was added to the wells of the T-cell-DCs coculture. A control drug (SMX-
 
Figure 2.6: The stages of dendritic cells maturation from day 0 till day 7. The CD-14 cells 
on day 0 are round with no projections (dendrites). Day after day the number of the dendrites 
increases gradually and by day 7 the cells have long dendrites denoting that they are mature 
DCs. 
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NO) was also prepared in the same way as piperacillin and added to one 
of the wells of the T-cell-DCs coculture. 
4. The T-cell-DC coculture plate is then incubated at 37°C and 5% CO2 for 8 
days. 
2.3.6 DCs culture from CD14 cells (Days 7, 9, 11, 14) 
DCs were prepared using the same protocol mentioned under the heading 2.3.4. 
 
2.3.7 TCR-Vβ analysis on day 7 
Principle:   
In order to measure the skewing of TCR-Vβ before and after the priming 
procedure, we analysed of the TCR-Vβ on day 7 (before the priming) and on day 
18 (after the priming). The protocol for staining is mentioned below which entails 
in addition to the usual antibodies for the TCR-Vβ other antibodies for CD3 
(general receptor for T-cells), CD4, CD8 (both for the phenotype of the T-cells), 
CD45RA and CD45RO (both to measure the magnitude of priming).    
 
Procedure:  
 Flow cytometric analysis:  
1. (600 μL) of naïve T-cells at 2x106 cells/ mL were set aside for the  
TCR-Vβ analysis. 
2. (50 μL) of cells were added to 12 non-sterile FACS tubes. 
3. The antibodies CD3-APC, CD4-FITC, CD8-PE, CD45RO-PerCP-Cy5.5, 
CD45RA-FITC and TCR-Vβ antibodies A–H were added according to 
Table 2.6.  
4. The tubes 1,2,11 and 12 were incubated on ice (at 4°C) while the tubes A-
H were incubated at room temperature. All the tubes were kept in dark for 
20 min. 
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5. (500 μL) of FACS buffer was added to each tube. This was followed by 
centrifugation at 1500 rpm. 
6. After discarding the supernatant, (200 μL) FACS buffer was added to each 
tube. 
 
7. The compensation was prepared according to the protocol mentioned 
under the heading 2.2.7 using the antibodies for CD3-APC, CD4-FITC, 
CD8-PE and CD45RO-PERCP-CY5.5  
8. The cells were analyzed using FACS Canto II. At least 50000 cells per tube 
were acquired. Cells percentages were analyzed later by Cyflogic 
software. 
 
2.3.8 T-cells reactivity and specificity assays (Day 15) 
Principle:  
The aim of these assays is to check the efficiency of the priming in terms of 
sensitivity and specificity. This can be accomplished by implementing several 
Table 2.6: Fluorochrome antibodies that are used to stain the cells for FACS analysis. 
Tubes Antibodies TCR Vβ kit 
1 None None 
2 CD3-APC (3µL), CD45RO (3µL) None 
3 CD3-APC (3µL), CD45RO (3µL) A (5µL) 
4 CD3-APC (3µL), CD45RO (3µL) B (5µL) 
5 CD3-APC (3µL), CD45RO (3µL) C (5µL) 
6 CD3-APC (3µL), CD45RO (3µL) D (5µL) 
7 CD3-APC (3µL), CD45RO (3µL) E (5µL) 
8 CD3-APC (3µL), CD45RO (3µL) F (5µL) 
9 CD3-APC (3µL), CD45RO (3µL) G (5µL) 
10 CD3-APC (3µL), CD45RO (3µL) H (5µL) 
11 CD3-APC(3µL), CD4-FITC (3µL), CD8-PE(3µL) CD45RO(3µL) None 
12 CD3-APC (3µL), CD45RA(10µL), CD45RO (3µL), None 
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useful assays which include: ELISPOT, 3H-thymidine uptake proliferation assay, 
CFSE uptake analysis and chemokine receptor analysis. 
3H-thymidine uptake proliferation assay involves culturing primed T-cells and DCs 
with the culprit drug for 48-72 hrs. 
From previous research on priming naïve T-cells from naïve healthy volunteers, it 
was found that the DC-T-cell coculture post priming does not contain many primed 
T-cells as what is found in TCCs. Therefore, it was decided to make the duration 
of 3H-thymidine uptake proliferation assay 72 hrs instead of 48 hrs to allow more 
time for the activation of drug specific T-cells to achieve higher counts to be 
detected by beta counter. 
Procedure: 
DCs and the T-cells were harvested according to the protocol mentioned under 
the heading 2.3.5. The T-cells which were in two groups: one primed for 
piperacillin and the other is primed for SMX-NO. Both were made up to 2x106 
cells/mL. (50 μL/well) was added into U-bottom 96 well plate. The DCs were made 
up to 1.6x105 cells/mL and (25 μL/well) was added. 
  ELISPOT 
1. The plate for ELISPOT was coated the day before with coating antibodies 
for IFN-γ, IL-5 and IL-13 according to the protocol mentioned under the 
heading 2.2.6. T-cells and the DCs and the drugs were added according 
to the conditions and doses mentioned in Table 2.7. The drugs were added 
in (50 μL). Then, all the wells were made up to 200 μL by adding medium. 
2. The processing of the ELISPOT plate was conducted on day 17 of the T-
cell priming assay according to the protocol mentioned under the heading 
2.2.6. 
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  3H-thymidine uptake proliferation assay:  
1. The cells were added to the plate using the same counts and volumes 
mentioned in the heading 2.3.8.1 with the exception that they were 
arranged in triplicates as shown in Table 2.8. In addition to that, there are 
wells for T-cells only, DCs only and T-cells+DCs+ (5 µg/mL) PHA as   
control conditions. 
2. 3H-thymidine was added on day 18 of the T-cell priming assay (i.e. after 72 
hrs of the preparation of the test plate). After 16 hrs of incubation, the plate 
was harvested according to the protocol mentioned under the heading 
2.2.5.4. 
Table 2.7: The design of the ELISPOT plate in terms of cells and the doses of the drugs 
used. 
Piperacillin 
primed cells 
IFN-γ  
Piperacillin 
primed cells 
IL-5  
Piperacillin 
primed cells 
IL-13  
SMX-NO primed 
cells  
IFN-γ  
SMX-NO primed 
cells   
IL-5  
SMX-NO primed 
cells   
IL-13  
0 0 0 0 0 0 0 0 0 0 0 0 
0.5mM 
pip 
0.5mM 
pip 
0.5mM 
pip 
0.5mM 
pip 
0.5mM 
pip 
0.5mM 
pip 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
1 mM 
pip 
1 mM 
pip 
1 mM 
pip 
1 mM 
pip 
1 mM 
pip 
1 mM 
pip 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
      
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
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  Proliferation assay by CFSE (Carboxyfluorescein 
succinimidyl ester) uptake: 
Principle: CFSE is an intracellular fluorescent stain with a fluorochrome 
wavelength in the range of the FITC stain. It binds to intracellular molecules 
especially lysine residues by forming covalent bonds with the privilege to be 
retained in cell for very long time (Parish, 1999).  CFSE has been used extensively 
to measure cellular proliferation by flow cytometry. CFSE-labelled cells 
proliferation will lead to spread of the CFSE stain on to a greater number of cells 
(daughter cells) (Lyons et al., 2013) which appear on the histogram of the FACS 
Canto II as a shift of the curve to the left with diminished peak (Figure 2.7). This 
technique if combined with the labelling of the cells with specific fluorochrome 
antibodies (e.g. CD4-APC, CD8-PE) has the advantage over thymidine uptake 
proliferation assay that it can measure specific cell subset proliferation rates 
(Hilchey and Bernstein, 2007).  
Table 2.8: design of the 3H-thymidine uptake proliferation assay plate in terms of 
conditions and cells. 
Piperacillin primed cells Piperacillin primed cells  SMX-NO primed cells 
0 0 0 
DCs 
(only) 
DCs 
(only) 
DCs 
(only) 
 0 0 0 
0.5 mM 
pip 
0.5 mM 
pip 
0.5 mM 
pip 
T-cells 
(only)  
T-cells 
(only) 
T-cells 
(only) 
 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
1 mM 
pip 
1 mM 
pip 
1 mM 
pip 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
5 
μg/mL 
PHA 
 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
       
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
50 μM 
SMX-
NO 
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Procedure: 
 CFSE staining: 
1. The cells were transferred to sterile FACS tubes (one tube for the cells 
primed to piperacillin and the other for cells primed with SMX-NO). 
2. The cells were spun down at 1500 rpm for 5 min and the supernatant was 
discarded. Then, the cells were resuspended in (1 mL) 5% AB/HBSS. 
3. The wash process was repeated as above. 
4. CFSE (2 μL) was added to Eppendorf vial that contained (100 μL) HBSS  
5. CFSE mixture (50 μL) was added to each tube of cells. The tubes were 
protected from light and incubated at room temperature for 5 min. 
6. (1 mL) 5% AB/HBSS was added per tube and then the tubes were spun at 
1500 rpm for 5 min and the supernatant was discarded. The cells were 
then resuspended in 1 mL 5% AB/HBSS. 
 
 
Figure 2.7: CFSE analysis using FACS. The blue line represents the cells CFSE signal at 
the start of incubation as a single sharp high signal. If the cells proliferate, there will be a shift 
in CFSE signal to the left with multiple and lower peaks (brown curve).  
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7. The wash process was repeated as above. 
8. Medium was added to the cells which were resuspended at (2×106 
cells/mL). 
9. Using the same counts and volumes mentioned in the heading 2.3.8.1. 
The T-cells, DCs and drugs were added to the wells of the plate shown in 
the Table 2.9. 
 CFSE analysis (Day 19): 
1. (90 μL) of the wells supernatant were removed from each well of the CFSE 
plate and duplicate wells were combined. 
2. (3 μL) of antibodies CD4-APC, CD8-PE were added to each well with the 
exception of the CFSE only labelled and the unlabelled cell conditions.  
3. Compensation controls were prepared using beads which were labelled 
with the CD4-APC, CD8-PE and CD3-FITC antibodies. 
4. The cells were incubated on ice for 20 min. 
5. (200 μL) of FACS buffer was added to each well and then the cells were 
spun for 3 min at 2200 rpm at 4°C. The supernatant was discarded. 
6. The cells were resuspended in (200 μL) FACS buffer in preparation for the 
FACS analysis and transferred to tubes. At least 50000 cells/tube were 
acquired by the FACS Canto II, then, the results were analyzed by the aid 
of Cyflogic software. The cells were first gated on FSC (forward scattering) 
and SSC (side scattering) to identify the lymphocyte population. Then, the 
lymphocyte population was gated for CD4 or CD8 population. The amount 
of CFSE was plotted as a histogram. 
Materials & Methods                                                                           Chapter 2  
 
 
 
126 
 
 
  Chemokine receptor analysis: 
Principle:  The assay focuses on the chemokine receptor expression of the 
primed cells. This is achieved by labelling the cells with CD45RO and the 
chemokine receptor antibodies. Then, the gating is based upon the CD45RO and 
the chemokine receptor expression by which the CD45RO positive and negative 
cells are compared and analyzed with the aid of FACS Canto II (Faulkner et al., 
2012). 
Procedure: 
The plate was prepared (on day 15) using the same counts and volumes 
mentioned under the heading 2.3.8.1.  
1. The wells supernatant (90 μL) were removed from each well of the plate 
(Table 2.10) and duplicate wells were combined (so instead of 14 wells 
we have 7 wells, each one of them would be stained as one of the 7 tubes 
used in the assay). 
Table 2.9. Design of the CFSE assay plate in terms of conditions and cells. 
Piperacillin primed cells Piperacillin primed cells SMX-NO primed cells 
0 0 
Unlabelled 
cells 
Unlabelled 
cells 
0 0 
0.25mM pip 0.25mM pip 
Labelled 
cells 
Labelled 
cells 
25 μM SMX-
NO 
25 μM SMX-
NO 
0.5mM pip 0.5mM pip   
50 μM SMX-
NO 
50 μM SMX-
NO 
1 mM pip 1 mM pip   5 μg/mL PHA 5 μg/mL PHA 
2 mM pip 2 mM pip   2 mM pip 2 mM pip 
5 μg/mL PHA 
5 μg/mL 
PHA 
    
50 μM SMX-
NO 
50 μM SMX-
NO 
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2. (3 μL/well) of antibodies was added according to the Table 2.11. The cells 
were incubated on ice for 20 min. 
3. Compensation controls were prepared using beads which were labelled 
with the CD45RO-Cy5 (2μL), APC (3μL), PE (3μL), FITC (3μL) 
4. (200 μL/well) FACS buffer was added and the plate was spun for 3 min at 
2200 rpm at 4°C. The supernatant was discarded. 
5. (100 μL/well) FACS buffer was added. Then, the contents were transferred 
to non-sterile FACS tubes. 
6. The cells were analyzed by flow cytometric analysis. At least 50000 cells 
per tube were acquired. Mean fluorescence index of the cells was 
analyzed by Cyflogic software.  
Table 2.10: Design of the chemokine receptor expression assay plate in terms of 
conditions and cells. 
Piperacillin primed cells 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
2 mM 
pip 
          
Table 2.11 Staining of chemokine receptor expression tubes 
Tube Cy5.5 APC FITC PE 
1 none none none none 
2 CD45RO 2μL none none none 
3 CD45RO 2μL CXCR3 3μL CCR5 3μL CCR1 3μL 
4 CD45RO 2μL CCR2 3μL CCR3 3μL CCR4 3μL 
5 CD45RO 2μL CCR9 3μL CCR8 3μL CCR10 3μL 
6 CD45RO 2μL CCR6 3μL CLA 3μL CXCR6 3μL 
7 CD45RO 2μL  CD69 3μL E-cad 3μL 
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2.4 Identifying optimal dose of the drugs for T-cells 
priming (toxicity assay) 
Requirements:  
 Volunteers PBMCs  
 Medium  
 PHA  
 Culprit drug 
Principle: 
Each drug has an optimal dose for which T-cells are the most reactive in terms of 
the priming assay. Higher doses than optimal would lead to toxicity and T-cells 
death. While lower doses than optimal wouldn’t yield positive results even though 
the T-cells are sensitive.  
The toxicity assay involves incubating PBMCs from a volunteer with serially 
diluted doses of the drug in the presence and absence of (5µg/mL) PHA. 
The optimal dose is selected when the PHA stimulated proliferation curve starts 
to decrease (in terms of cpm proliferation). Only culprit drug doses that do not 
inhibit the T-cells proliferation by more than 15% can be utilized in priming assays 
(Pichler and Tilch, 2004).  
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Rarely, the culprit drug could be stimulatory for PBMCs proliferation, a situation 
which denotes that optimal dose would be identified from (PHA -ve) conditions. 
This was not seen during this piece of work. 
Procedure: 
Volunteers PBMCs were incubated at 100000/well in triplicates in 96-well U 
bottomed plate in two conditions: in the presence and absence of (5 µg/mL) PHA 
(Table 2.12). Serially diluted doses of the drug are added to the wells making the 
total volume of the well (200 µL). The cells were incubated for 24 hrs at 37°C and 
5% CO2. Then, for the final 16 hrs (0.5 µCi) of 3H-thymidine/well was added that 
is followed by harvesting and reading the plate using beta counter. 
 
2.5 PBMCs priming 
Principle: 
PBMCs typically contain APCs which could be macrophages, B-cells, DCs in 
addition to the presence of naïve and memory T-cells. Hence, incubating the 
PBMCs with culprit drugs would provide the chance to generate primed T-cells to 
the culprit drug via priming naïve T-cells. 
Table 2.12: Design of the plate for the toxicity assay in terms of drugs, conditions and 
doses. 100000 PBMCs are incubated in each well (in triplicates) in addition to serially diluted 
doses of the culprit drug with and without 5µg/ml PHA. 
Culprit drug + 5µg/ml PHA Culprit drug 
64x 64x 
32x 32x 
16x 16x 
8x 8x 
4x 4x 
2x 2x 
1x 1x 
0 0 
Materials & Methods                                                                           Chapter 2  
 
 
 
130 
 
Another possibility, PBMCs may already contain some drug specific memory T-
cells. Thus, by incubating PBMCs with this drug, the APCs would have the chance 
to provide stimulatory signals to trigger the proliferation of these cells boosting 
their numbers.  Repeating this incubation process several times should boost the 
numbers of the primed T-cells to a level that may yield positive results in terms of 
reactivity to culprit drug in in vitro T-cells assays. 
Procedure: 
1. PBMCs are collected from a donor and counted to make up (4-6x106 
cells/mL) in medium. Then, the cells were aliquoted into 24-well plate as 
(1mL/well). 
2. Culprit drug was prepared at 2x final concentration then; it was added to 
the test plate as (1mL/well). 
3. SMX-NO wells are prepared as an irrelevant drug antigen control. 
4. The plate was cultured at 37°C and 5% CO2 for 5 days. 
5. From day 5, the wells were fed by withdrawing (600µL) and adding (660µL) 
of medium containing (2µL/mL) IL-2 every 2-3 days. 
6. Every two weeks (day 14, 28) the PBMCs cultures were restimulated with 
1mL irradiated autologous PBMCs (1.5x106 cells/mL) with drugs 2x + (200 
U/mL) IL-2. 
7. Autologous EBVs were generated for each donor. 
8. T-cells assays responses were carried out on days 14/28/35 which include 
3H- thymidine proliferation assay & IFN-γ ELISPOT.  
9. Clones were generated from the PBMCs using serial dilution technique. 
2.6 Liquid chromatography/Tandem mass spectrometry 
Principle: 
Over the last two decades there was a revolutionary progress in inventing and 
developing the technique of mass spectrometry (MS) which paved the way for 
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more detailed and sophisticated analytic studies especially in the field of 
proteomics. 
MS instruments that are utilising electrospray ionization (ESI) or matrix assisted 
laser desorption ionization (MALDI) are combined with other mass analysers 
(time-of-flight (TOF), quadrupole or ion trap) to create a highly sensitive and 
specific tool for protein identification (Ahmed, 2008;Koomen et al., 2005;Patterson 
SD, 2001). 
The first stage in processing the sample involves protein(s) cleavage using 
different reduction and alkylation steps in which the disulphide bonds cross linking 
the protein are broken and capped to prevent their reestablishment. 
This process involves unfolding the protein to allow the enzyme (trypsin) get 
access to the polypeptide backbone. This process results in a series of peptides.   
In liquid chromatography electrospray ionisation tandem mass 
spectrometry (LC-ESI-MS/MS), the peptides are prefractionated using inline 
reversed phase chromatography, thus the MS machine will analyse few species 
at a time. 
Every multiple charged peptide ion will be bombarded by with nitrogen leading to 
a reasonable fragmentation at the peptide bond between the amino acid residues. 
In this way the LC-MS/MS can yield precise data about the sequence and the 
chemical, post-translational modifications of the proteins. 
This highly sensitive technique analyses molecules depending on their weight 
(mass, m) and the charge (z).  In general, the mass spectrometer is composed of 
three components which are the ion source, mass analyser and the ion 
detector (Figure 2.8).  
The sample in our study is composed of a complex mixture of peptides. Initially, 
the sample will undergo vaporization and ionization process which is followed by 
accelerating the ions. The ions are selected according to their mass to charge 
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ratio (m/z) and then undergo further fragmentation. This is followed by the second 
round of MS in which the m/z of the fragments is determined. 
Multiple Reaction Monitoring MS (MRM-MS) is another highly sensitive and 
specific method for detecting and quantifying peptides in complex mixtures 
(Kitteringham et al., 2009). Here a triple quadrupole instrument is essential since 
it is able to select ions of specific m/z ratio in the first Q1 and the third quadrupole 
Q3 by modifying the voltage settings. Quadrupole 2 (Q2) functions as a collision 
chamber for the peptides to be fragmented into smaller ions to reveal the peptide 
sequences.  
Consequently, the ions are selected in Q1 and fragmented in Q2 and then 
preferentially selected in Q3 (Unwin et al., 2009).  
The transition (combination of parent ion mass and fragment ion mass) is 
designed to be as diagnostic for the peptide of interest as possible, but it also 
 
Figure 2.8: Analysis of the conjugates. Involves the use of liquid chromatography followed by 
mass spectrometry. In liquid chromatography the proteins are fragmented into small peptides 
and sent to mass spectrometry to be converted into ions which are accelerated through three 
quadruples which act to separate ions according to their mass/charge (m/z) ratio. Finally, these 
ions are detected by several detectors which generate electrical signals to be plotted. 
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should be detected with good sensitivity. This means that the selection of the 
MRM transitions is critical for highly sensitive and specific peptide quantification.  
Procedure: 
HSA-drug conjugates were reduced by the addition of 10mM dithiothreitol (DTT) 
followed by incubation room temperature for 15 minutes. The cysteine residues 
were capped by the addition of 55mM iodoacetamide and incubation for a further 
15 minutes at room temperature. The protein solution was diluted to (3.2mg/mL) 
in phosphate buffer and to each 50L (160g) aliquot was added 5g sequencing-
grade modified trypsin. The samples were incubated overnight at 37oC. Then, 
they were desalted by reversed phase chromatography using C18 ZipTips and 
dried in a centrifugal concentrator. 
Samples were reconstituted in 2% acetonitrile (ACN)/0.1% formic acid (v/v), and 
aliquots of (2.4 – 5 pmol) were delivered into a QTRAP 5500 hybrid quadrupole-
linear ion trap mass spectrometer by automated in-line LC (U3000 HPLC System, 
5 mm C18 nano-precolumn and 75 μm × 15 cm C18 PepMap column) via a 10-μm 
inner diameter PicoTip. A gradient from 2% ACN/0.1% formic acid (v/v) to 50% 
ACN/0.1% formic acid (v/v) in 70 min was applied at a flow rate of 300 nl/min. The 
ionspray potential was set to 2200–3500 V, the nebulizer gas to 18, and the 
interface heater to 150°C. Multiple reaction monitoring (MRM) transitions specific 
for drug-modified peptides were selected as follows: the mass/charge ratio (m/z) 
values were calculated for all possible peptides with a missed cleavage at a lysine 
residue; to these were added the mass of the appropriate hapten (cyclized 
Piperacillin, 517 atomic mass units [amu]; hydrolyzed Piperacillin, 535 amu; 
Amoxicillin, 365 amu; Amoxicillin with loss of NH2, 349 amu; Benzyl Penicillin, 334 
amu; Flucloxacillin, 453 amu; Penicillin V, 350 amu ); the parent ion masses were 
then paired with a fragment mass of 160 ([M+H]+ of cleaved thiazolidine ring 
present in all of the haptens) and/or a fragment mass of 106 ([M+H]+ of cleaved 
benzylamine group of hydrolyzed Piperacillin haptens). MRM transitions were 
acquired at unit resolution in both the Q1 and Q3 quadrupoles in order to 
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maximize specificity, they were optimized for collision energy and collision cell exit 
potential, and the dwell time was 50 ms. MRM survey scans were used to trigger 
enhanced product ion MS/MS scans of drug-modified peptides, with Q1 set to unit 
resolution, dynamic fill selected, and dynamic exclusion for 20 s. Total ion counts 
were determined from a second aliquot of each sample as analyzed by 
conventional LC tandem MS and were used to normalize sample loading on 
column. MRM peak areas were determined by MultiQuant 1.2 software (Sciex). 
Epitope profiles were constructed by comparing the relative intensity of MRM 
peaks for each of the modified lysine residues within a sample and normalization 
of those signals across samples.  
The analysis of piperacillin-HSA conjugates was performed by exploiting a very 
characteristic fragment ion from the drug hapten. The thiazolidine ring of the drug 
was readily cleaved leading to an intense ion in the MS/MS spectrum at m/z 160 
(Jenkins et al., 2009). The presence of the drug also hindered access by trypsin 
to the peptide backbone of the protein, leading to a missed cleavage at every 
modified lysine residue. The masses selected in Q1 were therefore the theoretical 
masses of every peptide in a particular protein with a missed cleavage at lysine 
plus the mass of the drug (+517 for the cyclized, +535 for the hydrolyzed, +489 
for the desethyl cyclized and +507 for the desethyl hydrolyzed hapten). The 
fragment ion selected in Q3 was 160. Using these “transitions” highly sensitive 
and selective identification of modified peptides could be achieved. 
2.7 HSA conjugate western blots 
Aliquots of 1 µg protein conjugate were prepared in Laemmli sample buffer and 
electrophoresed on 10% SDS-PAGE minigels. The proteins were transferred to a 
nitrocellulose membrane and blocked with 2% non-fat dry milk block in 
Tris/saline/Tween (150mM NaCl; 10mM Tris-HCl, pH 8.0; 0.1% Tween-20) 
overnight at 4oC. Tris/saline/Tween was used to perform all washes. Anti-penicillin 
primary antibody was diluted 1:20000 in 2% skimmed milk/TST and incubated for 
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1h at room temperature with shaking. The blots were washed for 3 X 5mins in 
TST before incubation with secondary goat anti-mouse HRP conjugated antibody, 
1:2000 in 2% skimmed milk/TST for 1h at room temperature. Bands were detected 
by incubation with Western Lightning Chemiluminescence reagent for 1min. This 
was followed by exposure to ECL sensitive film and imaging on a GS-800 
densitometer. 
2.8 Synthesis of drug-modified albumin conjugates 
Synthetic drug HSA conjugates were generated for functional studies by 
incubating drugs (piperacillin, penicillin G, and amoxicillin) with HSA at molar ratio 
of 100:1-250:1 for 24hr in phosphate buffer. The conjugates were purified by 
ultracentrifuge with a 3,000 MW cut off centrifugal filter according to the 
manufactory’s protocol. Briefly, 600 µL conjugates were added to the filter device 
followed by addition of 14 mL phosphate buffer (10mM, pH 7.4). The device was 
centrifuged at 5000Xg for 20 min and the filtrate was discarded. The process of 
washing was repeated for 6 times until the concentration of the free drug has been 
sufficiently reduced. The concentration of free drug in the filtrate from the last 
wash was determined by LC-MS and was found to be below 2.5nM. 
2.9  Isolation of HSA from plasma 
HSA was isolated by affinity chromatography, A POROS anti-HSA affinity 
cartridge attached to a Vision Workstation was used to affinity capture HSA which 
was then eluted with 12 mM hydrochloric acid. Fractions containing protein were 
identified by means of UV detection at 280 nm, and were methanol precipitated 
and processed for MS analysis, as described previously. 
2.10  Ethics approval 
The piperacillin hypersensitive patients with cystic fibrosis enrolled in the study on 
the piperacillin from the Regional Adult Cystic Fibrosis Unit, St James's University 
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Hospital, and Leeds, UK. The parameters of diagnosing CF were simply typical 
clinical profile in addition to positive sweat test and/or mutations involving both 
alleles of the cystic fibrosis transmembrane conductance regulator gene.  
Piperacillin hypersensitive patients were defined as a patient who developed 
hypersensitivity reaction after 48 hrs or more of I.V. piperacillin administration 
The naive group were healthy volunteers who have not been administered the 
tested antibiotic/drug. 
Written informed consent was obtained from all the patients and the volunteers. 
Moreover, the study was granted approval by the Leeds East Ethics Committee. 
For healthy volunteers in the telaprevir chapter the approval was obtained from 
the Liverpool Local Research Ethics Committee. Informed written consent was 
obtained from each volunteer.  
2.11 Statistical Analysis 
Statistical analysis was carried out by implementing the Kruskal-Wallis test in case 
of many conditions (three or more) and using Dunn’s test for multiple 
comparisons. When there were two conditions per experiment, the statistical 
analysis was performed utilising Mann–Whitney test. 
The implemented level of statistical significance for both tests is p< 0.05. The 
levels of significance are denoted as *, ** and *** where they were positive which 
signifies 0.05, 0.01 and 0.001 respectively. The error bars wherever found in 
figures represents standard deviation.  
The graphs were drawn using Graph Pad Prism 5 software apart from pie charts 
and the graphs of mass spectrometry which were conducted using Excel.
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3 Characterization of the specificity and functionality of 
drug-specific T-cells isolated from piperacillin  
hypersensitive patients with cystic fibrosis  
 
3.1 Introduction 
Over the last decade, there has been great focus on the field of personalized 
medicine trying to tailor medical services (in terms of decision, clinical practice, 
diagnostic tests and therapies) to suit each patient individually. This was the result 
of and at the same time the cause for the development of revolutionary diagnostic 
techniques capable of delineating the patients into categories that are defined by 
specific criteria which eventually qualify them to personalized therapeutic 
modalities.  
Specific HLA alleles are now known to be associated with increased susceptibility 
to different forms of drug hypersensitivity. However, this is not the case for 
piperacillin. The high frequency of reactions excludes the involvement of a single 
allele. 
One alternative aspect of this rapidly growing field is the importance placed on T-
cell phenotype. Several researchers have recently focused on the possible 
involvement of T-cells expressing a specific TCR-Vβ phenotype. In fact, it has 
been suggested that TCR-Vβ analysis may be used for both the screening of 
susceptible individuals and the treatment of patients with drug hypersensitivity 
reactions (Ko et al., 2011). 
Thus, we have conducted research in this area trying to identify a possible 
pathognomonic TCR-Vβ profile for susceptible candidates for developing 
piperacillin hypersensitivity. 
Consequently, we have addressed the following questions: 
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1. Is it possible to generate TCCs to free piperacillin from patients PBMCs?  
2. Is there a predominant pattern for TCR-Vβ expression in piperacillin-
specific TCCs? 
3. Is it possible to prime healthy volunteer T-cells to free piperacillin? If so, 
what is the TCR-Vβ profile after priming and is it similar to that of the 
patients’ TCCs? 
4. Is it possible to generate clones to free piperacillin from the primed T-cells 
of healthy volunteers?  What is their TCR-Vβ expression profile? Is it 
similar to that of the patients’ TCCs or the primed T-cells from the T-cells 
priming assays? 
5. What is the sensitivity, specificity, and cytokine secretion profile and 
chemokines receptor pattern on piperacillin-specific clones? 
3.2 Aim of the study 
In accordance with the questions above, we have formulated the main aim of this 
chapter to be: 
 To explore T-cell antigenic determinants in hypersensitive patients and 
healthy volunteers and the nature of the induced response focussing on TCR 
Vβ usage and cytokine release. 
3.3 Materials & methods 
The methods implemented in this chapter are described in detail in the relevant 
sections in materials and methods chapter and they are shown in Figure 3.1, 
Figure 3.12 and Figure 3.22. 
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3.4 Results: 
Notes:  
 The term selected clone means selecting a well growing clone from serial 
dilution plates.  
 The term reactive clone implies a clone that achieves an SI≥2 unless 
mentioned otherwise. I.e. it is synonymous with sensitive clone. 
 The term Bulks implies T-cells or PBMCs post priming either by (DC-T-cell 
priming technique or by incubating PBMCs with culprit drug respectively). 
 Statistical significance is mentioned whenever it is confirmed.  
 The term free piperacillin is piperacillin that comes commercially in a 
powder form and dissolved in medium to be added to culture plates 
instantaneously without any intermediate processing as opposed to 
conjugated piperacillin which requires processing to be generated. 
 
3.4.1 Piperacillin reactive clones from piperacillin 
hypersensitive patients 
  Generation of piperacillin reactive clones from 
piperacillin hypersensitive patients 
Free piperacillin specific and sensitive clones were generated and tested for 
phenotype, TCR-Vβ, chemokine receptor expression and cytokine secretion 
according to the scheme shown in Figure 3.1.  
PBMCs were collected from six CF piperacillin hypersensitive patients who have 
previously shown to be +ve for piperacillin hypersensitivity in LTTs with historical 
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delayed-onset maculopapular exanthema (Whitaker et al., 2011). In every case, 
the treatment had to be discontinued, and patients received anti-histamines 
and/or oral steroids, when clinically indicated. Blood samples were collected after 
4 weeks.  The demographics of those patients are illustrated in Table 3.1.  
 
 
 
 
 
 
 
Figure 3.1: The sequential steps and the methods implemented in the PBMCs culture, 
serial dilution, T-cell restimulation and clones testing. 
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 Table 3.1: Demographic data of the piperacillin hypersensitive CF patients. 
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P1 27 
M 
Cystic Fibrosis 
Chronic Pseudomonas infection 
FEV1 1.1lites (28% predicted) 
BMI 17 
Osteoporosis 
96 days intravenous antibiotics 
over past 12 months 
Ceftazidime 
Piperacillin 
MPE 
MPE/ 
fever 
5 
2 
4 
0.5 
-ve 
-ve 
-ve 
+ve at 48 
hours 
P2 26 
M 
Cystic Fibrosis 
Chronic Pseudomonas infection 
FEV1 1.82 lites (48% predicted) 
BMI 32 
CF related diabetes 
48 days of intravenous antibiotics 
over past 12 months 
Ceftazidime 
Piperacillin 
Fevers 
MPE 
2 
5 
4 
2 
-ve 
-ve 
-ve 
+ve at 48 
hours 
P3 21 
F 
Cystic Fibrosis 
Chronic Pseudomonas infection 
FEV1 0.63 lites (19% predicted) 
BMI 17 
Osteoporosis 
84 days of intravenous antibiotics 
over past 12 months 
Piperacillin 
Ceftazidime 
Arthralgia
/fevers 
MPE 
12 
6 
1 
5 
Not done 
Not done 
 
Not done 
Not done 
 
P4 26 
M 
Cystic Fibrosis 
Chronic Pseudomonas infection 
FEV1 2.87 litres (68% predicted) 
BMI 23 
CF related diabetes 
5 days of intravenous antibiotics 
over last 12 months 
Piperacillin 
Aztreonam 
Ceftazidime 
 
Meropenem 
MPE/ 
Fevers 
MPE 
Delayed 
Angio-
edema 
MPE 
9 
4 
3 
 
5 
7 
5 
5 
 
5 
-ve 
-ve 
-ve 
 
-ve 
-ve 
-ve 
-ve 
 
-ve 
P5 
 
35 
F 
Cystic Fibrosis 
Chronic Pseudomonas infection 
FEV1 1.91 lites (62% predicted) 
BMI 25 
35 days of intravenous antibiotics 
over past 12 months 
Ceftazidime 
Piperacillin 
MPE 
Fevers/ 
arthralgia 
8 
9 
4 
6 
-ve 
-ve 
-ve 
-ve 
P6 28 
M 
Cystic Fibrosis 
Chronic Pseudomonas infection 
FEV1 0.61lites (15% predicted) 
BMI 16 
Osteoporosis 
197 days of intravenous antibiotics 
over past 12 months 
Piperacillin MPE 11 4 -ve +ve at 24 
hours 
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Clones were generated by serial dilution and tested using a lymphocyte 
proliferation assay. If clones were responsive to free piperacillin at (2mM) (i.e. SI≥ 
2 to indicate a reactive clone), they were expanded by mitogen stimulation and 
characterized in greater detail. In total, six patients yielded 360 piperacillin 
reactive clones (out of 1642) (Figure 3.2). The number of piperacillin reactive 
clones generated from each patient was highly variable. Five patients yielded 
many reactive clones while one patient did not yield any (Table 3.2).   
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Figure 3.2 Sensitivity test of all clones. Piperacillin reactive clones were generated from the 
PBMCs of 6 piperacillin hypersensitive patients after incubation with (2mM) free piperacillin for 
2 weeks. Then serial dilution was performed to select well growing clones. Later the clones 
were tested for their reactivity with free piperacillin (2mM). 360 out of 1642 clones were 
sensitive towards piperacillin (all clones are shown in the graph i.e. the sensitive and the non-
sensitive ones). The dotted line represents the SI level=2 above which clones are counted 
sensitive.   
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 Quantitative assessment of the piperacillin clones 
reactivity to piperacillin 
195 piperacillin reactive clones from 5 patients were challenged with serially 
diluted doses of piperacillin starting with (2mM) in addition to the medium as a 
negative control.   
Clones displayed a dose-dependent response to piperacillin with the maximal 
response observed with (2mM) free piperacillin with high statistical significance at 
p<0.001 (as analyzed by Kruskal-Wallis test as shown in) (Figure 3.3). 
Figure 3.4 shows the different dose dependent proliferative responses observed 
with selected piperacillin-responsive clones. For all clones, the strongest 
response was observed with 2mM piperacillin. 
 
Table 3.2: Free piperacillin clones generated from six piperacillin 
hypersensitive CF patients. PBMCs were separated from their blood and 
bulks were prepared followed by serial dilution. The clones were tested at 
(2mM) free piperacillin. SI≥2 was the cut-off point to identify sensitive clones. 
Patient I.D 
number 
Number of 
reactive clones 
Total clones 
number 
Percentage of 
reactive clones 
P 1 193 533 36.2% 
P 2 92 262 35.1% 
P 3 53 208 25.5% 
P 4 10 69 14.5% 
P 5 12 517 2.3% 
P 6 0 53 0.0% 
Total 360 1642 21.9% 
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Figure 3.3: (A) 3H-thymidine uptake assay for 195 selected piperacillin clones from 5 patients 
(P1-P5). (B,C,D,E and F) show the T-cells clones proliferative response for each patient 
separately. T-cells were incubated with free piperacillin and autologous irradiated APCs for 48 hrs. 
At last 16 hrs radioactive thymidine was added and followed by harvesting.  Proliferation was 
determined by 3H-thymidine incorporation. The clones show a dose-dependent response curve.. 
Statistical analysis using Kruskal-Wallis test reveal high statistical significance ***:p<0.001. Error 
bars represent standard deviation. (cpm) represents the count per minute (i.e. radiation unit). 
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 Reactivity of piperacillin-responsive clones with an 
unrelated drug antigen nitroso sulfamethoxazole 
61 piperacillin-reactive clones from 5 patients were assessed for cross reactivity 
between free piperacillin and the unrelated drug metabolite antigen SMX-NO 
using 3[H]thymidine-uptake to measure proliferation, T-cells were challenged with  
piperacillin (2mM) and 3 concentrations of SMX-NO (50, 25 and 12.5 µM; shown 
previously to be optimal for the activation of SMX-NO-responsive clones) 
(Castrejon et al., 2010) in addition to the medium (-ve control).  
The maximal response was for piperacillin with high statistical significance 
p<0.001. Comparatively, significant proliferative responses were not observed 
with SMX-NO (Figure 3.5).  
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Figure 3.4: Selected clones to free piperacillin showing different dose-dependent 
proliferative responses. T-cells were incubated with free piperacillin at the indicated 
concentrations and autologous irradiated EBVs for 48 hrs. Radioactive thymidine was 
added for the last 16h of the experiment to measure proliferative responses. 
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 Measurement of cytokine secretion from the piperacillin-
responsive T-cell clones  
The reactivity of the clones which are sensitive and specific where assessed in 
terms of their cytokine expression using ELISPOT. 
3.4.1.4.1  IFN-γ secretion  
44 selected clones from patients 1, 3, 4 & 5 were analyzed for piperacillin 
mediated IFN-γ expression using serially diluted doses of free piperacillin starting 
with (2mM). PHA (5µg/mL) was used as a +ve control and medium (0) as a -ve 
control. Figure 3.6 (A) shows the piperacillin dose-dependent release of IFN- 
from the clones.  The maximal response was observed with 2mM free piperacillin 
with high statistical significance at p<0.001. In total, 86% of clones (n=38) were 
positive for IFN-γ secretion with an SI≥2. Images of representative clones with a 
dose-dependent proliferative response pattern are shown in Figure 3.6 (B). 
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Figure 3.5: Cross reactivity test using 3H-thymidine uptake proliferation assay for 61 
selected piperacillin sensitive clones using (2mM) free piperacillin, serially diluted 
doses of SMX-NO (as an irrelevant antigen) and medium (0 as a –ve control).  The clones 
show a high responsiveness to piperacillin and no response to SMX-NO. Statistical analysis 
using Kruskal-Wallis test reveal high statistical significance ***:p<0.001. Error bars represent 
standard deviation. (cpm) represents the count per minute (i.e. radiation unit). 
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3.4.1.4.2 Interleukin-5, interleukin-13, perforin, granzyme-B and 
Fas ligand secretion 
The profile of cytokines secreted from 44 piperacillin-responsive clones (the same 
clones selected for IFN-γ secretion) is shown in Figure 3.7 (A). Twenty-two (50%) 
of piperacillin-reactive clones secreted IL-5, 17 (38.6%) secreted IL-13, 22 (50%) 
secreted perforin, 12 (27%) secreted granzyme-B and 23 (52%) secreted Fas 
ligand (SI ≥ 2). In terms of statistical significance there was a high statistical 
significance at *:p<0.05 ,*:p<0.01 and *** p<0.001 according to the Mann-Whitney 
test. Images for the wells of ELISPOT for IL-5, IL-13, perforin, granzyme-B and 
Fas ligand secretion for four selected clones from the patients are shown in 
Figure 3.7 (B). 
In terms of the statistical significance of difference between the control and the 
free piperacillin the results were as follows in descending order: For Fas ligand 
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Figure 3.6: (A) IFN-γ ELISPOT for 44 representative piperacillin specific T-clones from patients 
(1, 4, 5 & 6) showing a dose dependent response for serially diluted doses of free piperacillin with 
high statistical significance. Data were analyzed with Kruskal-Wallis test. (B) Images of IFN-γ 
ELISPOT wells of 4 selected clones showing a clear dose dependent response that is maximal 
at (2 mM) in terms of the spots count. (5µg/mL) PHA was used as a +ve control.  Statistical analysis 
using Kruskal-Wallis test reveal high statistical significance ***:p<0.001. Error bars represent 
standard deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
A 
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(p<0.0001), for IL-5 (p=0.0095), less with perforin (p=0.014) and granzyme-B 
(p=0.027), and non-statistically significant for IL-13 (p= 0.63) as analyzed by 
Mann –Whitney test.  
  Measurement of the T-cell receptors and chemokine 
receptors expressed on piperacillin-responsive clones 
3.4.1.5.1 CD4/CD8 receptor expression: 
79 reactive clones from the patients (1-5) were analyzed by flow cytometry. This 
has revealed that the majority of clones are CD4+ (n=73, 92%), while CD8+ 
clones account for only 5% (n=4). Finally, only 2 double positive CD4+CD8+ 
clones were observed.  All of the clones displayed a memory T-cells phenotype 
(n=97, 100%) expressing high levels of CD45RO.  A detailed description of the 
phenotype of the clones is listed in Table 3.3.  
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Figure 3.7: (A) Cytokine profile of 44 piperacillin-responsive clones. The expression of 
IL-5, IL-13, perforin, granzyme-B and Fas ligand in the presence and absence of 2 mM free 
piperacillin were measured by ELISPOT. Statistical analysis was performed using the Mann-
Whitney test. (B)  Images for the wells of ELISPOT for IL-5, IL-13, perforin, granzyme-B 
and Fas ligand secretion for four selected clones from the patients 1, 2, 4 and 5 
respectively.  Statistical analysis using Mann-Whitney test reveal high statistical significance 
*, **, and **** where they were positive which signifies 0.05, 0.01, and 0.0001 significance 
levels respectively. Error bars represent standard deviation. (SFU) represents spot forming 
unit i.e cytokine secreting cell. 
B 
**** 
A 
Free Piperacillin  Chapter 3  
 
 
 
151 
 
Images for the selected piperacillin clones showing gating and the individual 
populations are shown in . The T-cell population was gated according  
Table 3.3: The number of piperacillin-specific clones analyzed from each patient and their 
phenotypic subdivisions. 
Patient 
ID 
number 
Number of 
reactive 
specific 
clones 
Number of 
CD4+ 
clones 
Percentage 
of CD4+ 
clones 
Number 
of CD8+ 
clones  
Percentage 
of CD8+ 
clones 
Number of 
CD4+CD8+  
Percentage of 
CD4+CD8+ clones 
P 1 42 37 88.10% 3 7.14% 0 0.00% 
P 2 7 6 85.71% 0 0.00% 1 14.29% 
P 3 28 26 92.86% 1 3.57% 1 3.57% 
P 4 2 2 100.00% 0 0.00% 0 0.00% 
P 5 2 2 100.00% 0 0.00% 0 0.00% 
Total 81 73 90.12% 4 4.94% 2 2.47% 
C
D
4
+
 
   
 CD8+ 
 Patient 1: clone 46 CD4+ Patient 2: clone 288 CD4+ Patient 3: Clone 69 CD4+ 
C
D
4
+
 
   
 CD8+ 
 Patient 3: Clone 70           
CD8+ 
Patient 4: Clone 91 CD4+  Patient 5: Clone 15  
CD4+CD8+            
Figure 3.8: Images of the flow cytometry data gating on the FACS machine showing the 
phenotype of selected piperacillin specific clones in terms of CD4/CD8 expression. Cells 
are plotted on a dot plot and gated according to the staining of the fluorochrome labelled 
antibodies (CD4+ for FITC and CD8+ for PE) into four quadrants. So, when a clone shows 
a dots signal at the FITC quadrant only (upper left) this denoted that it is CD4+ clone, 
while if the signal at PE quadrant alone (lower right), this denotes that it is a CD8+. If dots 
are present in upper right quadrant, it denotes that the clones is CD4+CD8+ (double 
positive). 
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to the labelling with CD4+ for FITC and CD8+ for PE. When a clone displayed a 
signal in the FITC quadrant only (upper left) (clones 46, 288, 69 and 91) this 
denoted that they are CD4+ clones, while if the signal was in the PE quadrant 
alone (lower right), this denotes that it is a CD8+ (clone 70). If a signal is present 
in upper right quadrant it denotes that the clone is CD4+CD8+ (double positive) 
(clone 15).  
3.4.1.5.2 Characterisation of TCR-Vβ expression on the T-cell 
clones from hypersensitive patients 
After characterizing the clones in terms of their CD4/CD8 expression, we carried 
out analysis of TCR-Vβ receptors. 64 clones from the patients (1-5) were analyzed 
by flow cytometry. 24 clones were found to express high levels of a single TCR-
Vβ 13.1 (30%). However, an array of TCR-Vβs were expressed on the other 
clones. As shown in Figure 3.10 15 TCR-Vβs were detected on the piperacillin-
responsive clones with variable expression. 
 
 
 
Figure 3.9: The phenotype of 79 selected free piperacillin specific clones from 5 patients 
in terms of CD4, CD8 expression as analyzed by the flow cytometry technique.  
73, 92%
4, 5%
2, 3%
CD4+ CD8+ CD4+CD8+
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  Characterization of chemokine receptors and CD69 
expression on piperacillin-responsive T-cell clones from 
hypersensitive patients 
The chemokine receptors and CD69 expression on 23 clones from patients 1, 2 
and 4 were analyzed by flow cytometry. Figure 3.11 shows that clones expressed 
for CD69 (5.80±3.21; mean fluorescence index), CCR4 (5.07±3.13), CCR9 
(5.31±1.93), CXCR3 (4.04±2.48), CCR10 (2.95±1.28), CCR2 (2.59±1.18) and 
CCR8 (2.75±0.96). 
 
 
Figure 3.10: Flow cytometric analysis of 64 free piperacillin specific clones from 5 
patients for the TCR-Vβ expression. 
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Figure 3.11:(A) Chemokine receptors and CD69 expression for 23 piperacillin-specific 
clones (from patients 1, 4 & 5). 13 chemokine receptors were analyzed by the flow 
cytometry. The bars represent the mean fluorescence index of chemokines receptors. Bars 
that have SI≥2 are highlighted in red denoting a high expression while blue ones are for low 
expression. (B):  CD69 & chemokine receptor expression MFIs for the clones in a 
descending order showing the highly expressed chemokines receptors in yellow. Error bars 
represent standard deviation. 
A B 
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3.4.2 Healthy naive volunteer T-cell priming to piperacillin  
Naïve T-cells from healthy piperacillin-naïve volunteers were primed and tested 
for sensitivity, specificity, phenotype and cytokines secretion as shown in Figure 
3.12. 
Three healthy piperacillin naive volunteers were selected for T-cell priming 
experiments. Blood samples were collected and the PBMCs were separated. 
Then, DC-T-cell priming was performed to activate the naïve T-cells to free 
piperacillin. Thus, drug-responsive T-cell lines were generated. Table 3.4 shows 
the basic characteristics of the donors. 
 
 
 
Figure 3.12: The sequential steps and the methods implemented in healthy naive 
volunteer T-cells priming to piperacillin. 
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  T-cell reactivity and specificity assays 
3.4.2.1.1 3H-thymidine uptake proliferation assay 
On day 15 of the T-cell priming assay, T-cells were harvested from the co-culture 
plates and then incubated with autologous DCs and the test compounds (serially 
diluted doses of free piperacillin, 5 µg/mL PHA (positive control) and 50 µM SMX-
NO (irrelevant drug antigen).  
A dose-dependent increase in T-cell proliferation was observed when the primed 
T-cells were restimulated with piperacillin (Figure 3.13 A). In contrast, the T-cells 
were not activated with SMX-NO. The results of individual experiments on each 
volunteer are illustrated in Figure 3.13 B, C and D showing reactivity to free 
piperacillin.  
In similar experiments, naïve T-cells were primed to SMX-NO.  An increase in 
proliferation was observed when the primed T-cells were restimulated with SMX-
NO, but not piperacillin Figure 3.13 E.  
 
Table 3.4: The demographics of the three normal healthy volunteers enrolled in this 
study. 
Donor ID Age Sex History of allergies Medical history 
HVN-051 40 Male Nil Not relevant 
HVN-066 36 Male Nil Not relevant 
HVN-089 37 Male Nil Not relevant 
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3.4.2.1.2 ELISPOTS 
On day 15 of the T-cell priming assay, the primed T-cells were tested for cytokine 
release to serially diluted doses of free piperacillin, PHA (5 µg/mL; as a +ve 
control) and SMX-NO (50 µM; as an irrelevant drug antigen). 
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Figure 3.13: 3H-thymidine uptake proliferation assay for (A) free piperacillin for all 
volunteers combined (B), (C) and (D) for each volunteer experiment individually (E) SMX-
NO primed T-cells for all volunteers combined. Primed T-cells were incubated with 
autologous DCs and the drugs for 72 hrs then radioactive thymidine was added for the last 16 
hrs. Proliferation was determined by 3H-thymidine incorporation. Statistical analysis using 
Kruskal-Wallis test did not reveal statistical significance at p<0.05 significance level. Error bars 
represent standard deviation. (SI) represents the stimulation index. 
B C 
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 IFN-γ ELISPOT  
Figure 3.14 A: shows that the piperacillin primed T-cells secreted IFN- in a 
concentration-dependent fashion when restimulated with the drug. Similar to the 
patients cells, maximal responses were observed with 2mM piperacillin (372±60.9 
SFU). The piperacillin-primed T-cells were not activated with SMX-NO 
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Figure 3.14: IFN-γ ELISPOT assay. (A) Free piperacillin for all volunteers combined (B), 
(C) and (D) for each volunteer experiment individually (E) SMX-NO primed T-cells for all 
volunteers combined. Primed T-cells were harvested from the co-culture plate and incubated 
with autologous DCs and serially diluted concentrations of free piperacillin or SMX-NO on a 
coated plate with coating antibody for IFN-γ. Cells were incubated for 48 hrs and then 
developed and read by the ELISPOT counter.  Statistical analysis using Kruskal-Wallis test did 
not reveal statistical significance at p<0.05 significance level. Error bars represent standard 
deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
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(170.2±37.58 SFU). Results of individual experiments for each volunteer cells are 
illustrated in Figure 3.14 B, C and D. 
 
Similar experiments were conducted with SMX-NO-primed T-cells. T-cells 
secreted IFN- in the presence of SMX-NO, but not piperacillin (Figure 3.14 E). 
Table 3.5 shows images of the IFN-γ ELISPOT were it can be clearly seen that 
piperacillin-primed T-cells were activated with piperacillin, but not SMX-NO, 
whereas the SMX-NO primed cells were activated with SMX-NO, but not 
piperacillin.  
Table 3.5: IFN-γ ELISPOT for free piperacillin and SMX-NO. Primed T-cells were harvested 
from the coculture plate and incubated with autologous DCs and serially diluted doses of free 
piperacillin and SMX-NO on a coated plate with the coating antibodies for IFN-γ and incubated 
for 48 hrs and then developed and read by the ELISPOT counter. The table below shows 
images of wells of the ELISPOT plate. 
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 IL-5 ELISPOT 
Piperacillin primed T-cells secreted low levels of IL-5. (2mM free piperacillin; 
8.5±32.74 SFU) with no cross reactivity to SMX-NO (46±8.54 SFU) (Figure 3.15  
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Figure 3.15: IL-5 ELISPOT assay. (A) Free piperacillin for all volunteers combined (B), (C) 
and (D) for each volunteer experiment individually (E) SMX-NO primed T-cells for all 
volunteers combined.  Primed T-cells were harvested from the coculture plate and incubated 
with autologous DCs and serially diluted doses of piperacillin and SMX-NO on a coated plate 
with the coating antibodies for IL-5 and incubated for 48 hrs and then developed and read by 
the ELISPOT counter. Statistical analysis using Kruskal-Wallis test did not reveal statistical 
significance at p<0.05 significance level. Error bars represent standard deviation. (SFU) 
represents spot forming unit i.e cytokine secreting cell. 
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A). In contrast, SMX-NO primed T-cells secreted significantly higher levels of IL-
5 (50 µM SMX-NO; 215.5±104.4 SFU), but again no cross reactivity with 
piperacillin was observed (Figure 3.15 B). Images of the ELISPOT are shown in 
Table 3.6. 
 
 
 IL-13 ELISPOT 
The free piperacillin primed T-cells secreted of IL-13 in a dose-dependent manner 
when restimulated with piperacillin. SMX-NO primed T–cells secreted IL-13 
response to SMX-NO, but not piperacillin (Figure 3.18; Table 3.6).  
Table 3.6.  IL-5 ELISPOT images for free piperacillin and SMX-NO conditions. Primed T-
cells were harvested form the coculture plate and incubated with autologous DCs and serially 
diluted doses of piperacillin and SMX-NO on a coated plate with the coating antibodies for IL-
5 and incubated for 48 hrs and then developed and read by the ELISPOT counter. 
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Moreover, these results for IL-13 ELSIPOT proves that there is no cross reactivity 
between free piperacillin and SMX-NO. 
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Figure 3.16:  IL-13 ELISPOT. (A) Free piperacillin for all volunteers combined (B), (C) and 
(D) for each volunteer experiment individually (E) SMX-NO primed T-cells for all volunteers 
combined.  Primed T-cells were harvested from the coculture plate and incubated with 
autologous DCs and serially diluted doses of piperacillin and SMX-NO on a coated plate with the 
coating antibodies for IL-13 and incubated for 48 hrs and then developed and read by the 
ELISPOT counter. Statistical analysis using Kruskal-Wallis test did not reveal statistical 
significance at p<0.05 significance level. Error bars represent standard deviation. (SFU) 
represents spot forming unit i.e cytokine secreting cell. 
A 
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 Flow cytometric analysis of T-cell phenotype and TCR-Vβ 
expression pre- and post-priming 
Naïve T-cells were analyzed using flow cytometry (on day 7; just prior to priming) 
and then the analysis was repeated after priming (on day 18). The results were 
compared to determine the ratio of CD4 & CD8 receptor expression, priming  
 
Table 3.7: IL-13 ELISPOT images for the free piperacillin and the SMX-NO primed T-cells. 
Primed T-cells were harvested from the coculture plate and incubated with autologous DCs 
and serially diluted doses of piperacillin and SMX-NO on a coated plate with the coating 
antibodies for IL-13 and incubated for 48 hrs and then developed and read by the ELISPOT 
counter. 
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Table 3.8: The average percentages of the T–cell phenotypes in prepriming (day 0) and 
post priming (day 18) flow cytometry analysis.  
Cells phenotype 
Pre-priming average 
percentage 
Post-priming 
average percentage 
Change 
ratio 
CD4+ cells 50.03% 40.66% 0.81 
CD8+ cells 46.43% 35.11% 0.75 
CD4+CD8+ cells 0.84% 7.91% 9.41 
CD4-CD8-  cells 2.69% 16.29% 6.04 
Table 3.9. Percentages of the T-cells pre and post priming in terms of their CD4, CD8 
receptors expression as analyzed by the flow cytometry technique. The analysis was 
conducted on day 7 for the naïve T-cells (prepriming) and on day 18 for the primed T-cells (post 
priming).  
 HVN-051 HVN-066 HVN-089 
 Pre-
priming 
Post-
priming 
Pre-
priming 
Post-
priming 
Pre-
priming 
Post-
priming 
CD4+ cells 41.9% 63.5% 43.3% 29.7% 64.9% 28.8% 
CD8+ cells 55.7% 29.2% 51.4% 47.0% 32.2% 29.2% 
CD4+CD8+ cells 0.7% 3.7% 1.4% 16.8% 0.4% 3.2% 
CD4-CD8- cells 1.7% 3.6% 3.9% 6.5% 2.5% 38.8% 
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Figure 3.17: Percentages of the T-cells pre and post priming in terms of their CD45RO 
receptor expression as analyzed by the flow cytometry technique. The analysis was 
conducted on day 7 for the naïve T-cells (prepriming) and on day 18 for the primed T-cells (post 
priming). 
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magnitude (in terms of CD45RO expression) and the skewing of TCR-Vβ 
expression. 
The ratio of CD4+ and CD8+ T-cells did not significantly change pre- and post-
priming of the naive-primed T-cells. In contrast, an increase in the number of 
double positive (DP) CD4+CD8+ T-cells was seen (from 0.84% pre-priming to 
7.91% post-priming). Moreover, the double negative (DN) CD4-CD8- cell number 
increased (from 2.69% pre-priming to 16.29% post-priming) (Table 3.8). 
An increased expression of CD45RO was observed with the primed cells. 
CD45RO expression ranged from 1-13% on the pre-primed T-cells. In contrast, 
this increased to 60-97% on the T-cells post priming (Figure 3.17). 
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A heterogeneous change in TCR-Vβ expression was observed post-priming with 
piperacillin (Figure 3.18). Vβ9 (5.71±3.42; ratio of postpriming/prepriming 
 
 
 
Figure 3.18: TCR-Vβ analysis by flow cytometry of the naïve (on day 7) and primed 
(on day 18) T-cells of three naïve healthy volunteers.  
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expression), Vβ13.2 (2.04±0.51), Vβ 18 (4.81±2.13) and Vβ4 (2.01±1.77) showed 
a marked increase in Vβ expression in the post priming stage (i.e., 
postpriming/prepriming ≥ 2). 
  CFSE analysis 
On day 15, free piperacillin and SMX-NO primed T-cells were labelled with CFSE, 
restimulated and then analyzed on day 19 by flow cytometry.   
CD8+ T-cells from piperacillin-primed cultures showed a strong dose-dependent 
proliferative response when restimulated with piperacillin. In comparison, the 
CD4+ T-cells proliferated to a much lesser extent (Figure 3.20 A). The SMX-NO 
primed CD4+ and CD8+ T cells show a dose-dependent response when 
restimulated with SMX-NO (Figure 3.20 B). 
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Figure 3.19: Postpriming/prepriming (SI) ratio for TCR-Vβ expression for naïve and 
primed T-cells for three volunteers. There is high expression of the TCR-Vβ 9, 13.2, 18 and 
4 (SI) ≥2 (highlighted in red). Error bars represent standard deviation. 
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 Chemokine receptor analysis 
On day 15, free piperacillin primed T-cells were incubated with DCs and free 
piperacillin (2mM). Seven days later T-cells were harvested, labelled with a panel 
of chemokine receptor antibodies and then analyzed by flow cytometry. 
An increased expression of CCR4 (5.84± 3.39), CXCR3 (3.74±1.35), CCR2 
(2.51±0.89) and CCR9 (2.5±1.01) was observed on T-cells when pre- and post-
piperacillin restimulation cells were compared (Figure 3.21). 
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Figure 3.20: CFSE study of the (A) free piperacillin and (B) SMX-NO primed T-cells 
showing the proliferative response of CD8+ T-cells and CD4+ T-cells. T-cells were labelled 
with CFSE on day 15 and incubated with the DCs and the drugs. On day 19 the cells were 
labelled with antibodies for CD4 and CD8 and proliferative responses were measured using 
flow cytometry depending on the percentage of CFSE labelling. Statistical analysis using 
Kruskal-Wallis test did not reveal statistical significance at p<0.05 significance level. Error bars 
represent standard deviation.  
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Figure 3.21: Chemokine receptor and CD69 expression. Free piperacillin primed T-cells 
were incubated with DCs and 2mM free piperacillin on day 15 of the priming assay. Then on 
day 21 the T-cells were harvested from the plate and labelled with the fluorochrome stained 
antibodies for the above mentioned chemokines receptors. Receptor expression was analyzed 
by the flow cytometry. (A): Chemokines receptors and CD69 expression with highly 
expressed ones (MFI≥2) highlighted in red. (B):  CD69 & Chemokines receptors MFIs 
results in table with the highest ones (MFI≥2) highlighted in yellow. Error bars represent 
standard deviation. 
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3.4.3 Generation of clones from piperacillin-primed T-cells from 
naïve healthy volunteers  
After the completion of the ELISPOT and 3H-thymidine uptake assays that 
confirmed priming to free piperacillin was successful, clones were generated 
using serial dilution. In addition, autologous EBVs were generated according to 
the scheme shown in Figure 3.22 and used as a source of autologous antigen 
presenting cells.  
Well-growing clones were tested for piperacillin reactivity using a lymphocyte 
proliferation assay and if responsive (SI≥ 2), they were expanded via mitogen 
stimulation for more detailed phenotypic and functional analysis. 
In total, 40 piperacillin-responsive clones (out of 812) were detected (Table 3.10). 
 
Figure 3.22: The sequential steps and the methods implemented in the generation and 
testing of piperacillin specific TCCs from healthy naïve volunteers. 
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  Quantitative assessment of clones reactivity to 
piperacillin using 3H- thymidine uptake assay 
14 clones showing initial responses to free piperacillin were selected and tested 
using 3H-thymidine-uptake to explore dose-dependent proliferative responses. All 
clones proliferated in a dose-dependent manner, with the strongest response 
detected with 2mM piperacillin. Since several clones proliferated only weakly 
following piperacillin treatment, a SI threshold of 1.5 was accepted from this assay 
and onwards as a drug-specific effect (Figure 3.23). Statistical significance was 
observed with all clones when medium control was compared with 2 or 1 mM free 
piperacillin at **:<0.01, *=<0.05 respectively as analyzed by Kruskal-Wallis test. 
Figure 3.25 (B), (C) and (D) show selected clones from each volunteer with their 
dose response curve. 
 
Table 3.10:  Clones generated from piperacillin-primed T-cells from three healthy 
volunteers. 812 clones were generated by the technique of serial dilution. Autologous EBVs 
were generated and used as antigen presenting cells. The clones were tested with vehicle 
control and 2 mM free piperacillin. If SI ≥2 the clone was regarded as sensitive.   (A): Figure 
shows SI of all clones generated. (B) Table shows the numbers and percentages of 
sensitive clones from each volunteer. 
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051 11 407 2.7% 
066 14 176 7.9% 
089 15 229 6.5% 
Total 40 812 4.9% 
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  Reactivity of the piperacillin clones against nitroso 
sulfamethoxazole using 3H-thymidine uptake assay 
Five clones were selected to test for reactivity against the irrelevant drug antigen 
SMX-NO. A strong proliferative response to free piperacillin (24597.4±22768.9 
cpm; 2 mM) was observed. In contrast, clones were not activated with SMX-NO. 
Figure 3.24 (A). Figure 3.24 (B), (C) and (D) show proliferative responses of 
representative clones. 
3.4.4 Quantitative and Qualitative measurement of cytokine 
secretion profile of the T-cell clones by ELISPOT 
14 piperacillin-specific clones were tested for the cytokines they secrete after drug 
stimulation (IFN-γ, IL-5, IL-13, perforin, granzyme-B and Fas ligand) using 
ELISPOT. 
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Figure 3.23: (A) 3H-thymidine-uptake assay showing the dose-dependent 
proliferation of 14 clones from three healthy volunteers responsive to free 
piperacillin. T-cells were incubated in the presence of EBVs and serially diluted doses of 
free piperacillin for 48 hrs. Radioactive thymidine was added for the last 16 hrs. Cells were 
then harvested and counted using a beta counter.  The clones show a dose-dependent 
response curve. Statistical analysis using Kruskal-Wallis test reveal high statistical 
significance *, ** and *** signifying p<0.05, p<0.01 and p<0.001 respectively. Error bars 
represent standard deviation. (cpm) represents the count per minute (i.e. radiation unit). 
(B), (C) and (D) show selected clones from each volunteer.     
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 IFN-γ secretion  
A dose-dependent increase in IFN-γ secretion was observed when clones were 
activated with piperacillin. The maximal response was seen with 2mM free 
piperacillin (117.7±113.6 cpm) with a statistical significance at *:p<0.05 as 
analyzed by the Kruskal-Wallis test. Figure 3.25 (A). Figure 3.25 (C), (D) and (E) 
show piperacillin-specific IFN- secretion from selected clones. 
 IL-5, IL-13, perforin, granzyme-B and Fas ligand  
The clones showed a marked increase in the secretion of IL-5 (17.8±20.2 SFU), 
IL-13 (53.5±64 SFU), perforin (69.4±80.2 SFU), granzyme-B (71.4±49.1 SFU) 
and Fas ligand (119.3±136.6 SFU) following treatment with piperacillin (Figure 
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Figure 3.24 (A): Cross reactivity test using 3H-thymidine uptake assay for 5 selected TCCs 
primed to free piperacillin-cells were incubated with autologous irradiated EBVs and (2 mM) free 
piperacillin and serially diluted doses of SMX-NO for T-cells for 48 hrs. Radioactive thymidine 
was added in the last 16 hrs. Then, harvested and read by beta counter. Statistical analysis using 
Kruskal-Wallis test reveal no statistical significance at p<0.05. Error bars represent standard 
deviation. (cpm) represents the count per minute (i.e. radiation unit).  (B), (C) and (D) show 
selected clones. 
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3.26 A).  When all clones were analyzed together, a statistical significance was 
observed for the secretion of IL-13, perforin and Fas ligand as analyzed by Mann- 
 
Whitney test. Statistical significance was not achieved with the other cytokines as 
they were secreted by only a portion of the clones.  
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Figure 3.25: (A) IFN-γ ELISPOT for 14 piperacillin-specific clones generated by DCs-T-
cell priming from 3 volunteers. TCCs were incubated with irradiated autologous EBV-
transformed B-cells and the drug for 48 hrs in IFN-γ antibody coated plates. After 48 hrs plates 
were developed and spots were counted using the ELISPOT counter.  Statistical analysis using 
Kruskal-Wallis test reveal statistical significance at p<0.05. Error bars represent standard 
deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. (B) Images for 
selected clones (C), (D) and (E). 
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 Measurement of the T cell receptors and chemokine 
receptors expressed on piperacillin-specific clones 
3.4.4.1.1 CD4/CD8 receptors expression 
14 piperacillin-specific clones were selected and analyzed. CD4 was expressed 
on 9 clones (64%) and 5 clones expressed CD8 (36%) ( A).   
 
3.4.4.1.2 TCR-Vβ expression 
14 selected clones were labelled and analyzed for TCR-Vβ expression. The 
clones showed a diverse pattern of TCR-Vβ expression ( B).  
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Figure 3.26: (A) ELISPOT analysis for IL-5, IL-13, perforin, granzyme B and Fas ligand 
expression. Primed T-cells were incubated with irradiated autologous EBV-transformed B-
cells and the (0) medium and 2mM free piperacillin on a coated ELISPOT plate with the 
antibodies for the aforementioned cytokines for 48 hrs. then the plate was developed and read 
by the ELISPOT counter. The statistical significance was analyzed by Mann-Whitney test which 
revealed statistical significance *,** and *** signifying p<0.05, 0.01 and 0.001 significance levels 
respectively. (SFU) represents spot forming unit i.e cytokine secreting cell. (B) Images of the 
wells of selected clones as analyzed by the ELISPOT counter. 
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3.4.4.1.3  Chemokine receptors and CD69 analysis 
 14 selected clones were analyzed for chemokine receptor and CD69 expression 
by flow cytometry.  There was a high expression ≥2 mean fluorescence index 
(MFI) for the following chemokines receptors (Figure 3.28): CCR4 (8.15±5.21 
MFI), CXCR3 (2.66±1.32 MFI), CCR2 (2.67±1.38 MFI), CCR9 (3.72±1.3 MFI), 
CCR10 (3.15±2.16 MFI), CXCR6 (2.47±1.11 MFI) CD69 the expression was 
(1.95±0.88). 
 
 
   
Figure 3.27:(A) Phenotypic analysis of 14 free piperacillin primed TCCs as analyzed by 
flow cytometry (B) TCR-Vβ expression of TCCs from three volunteers as analyzed by 
flow cytometry.   
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Figure 3.28: Chemokine receptor and CD69 expression on 14 piperacillin-specific clones as 
analyzed by flow cytometry. T-cells were labelled with the fluorochrome stained 
antibodies for the above-mentioned chemokine receptors and CD69. Then, the cells 
were analyzed by the flow cytometry. (A): Chemokine receptors and CD69 expression 
with highly expressed receptors (MFI≥2) highlighted in red. (B): Chemokine receptor and 
CD69 MFI results in table with the highest ones (MFI≥2) highlighted in yellow. Error bars 
represent standard deviation. 
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3.5 Discussion 
Idiosyncratic drug reactions are a major concern for the health authorities. 
Furthermore, treatment of patients with reactions represents a significant financial 
burden. Regarding β-lactam-induced idiosyncratic drug reactions and particularly 
piperacillin, T-cells are known to be the main effector cells. Previous research on 
piperacillin has shown that piperacillin-specific T-cells could be isolated from 
blood of piperacillin hypersensitive patients (Whitaker et al., 2011).  
3.5.1 Activation of T-cells isolated from blood of piperacillin 
hypersensitive patients with CF  
This chapter initially focused on the isolation and characterization of piperacillin-
specific TCCs from blood of hypersensitive patients. Six patients in total were 
analyzed. They varied in terms of the number of piperacillin-specific TCCs 
generated. For example, almost 200 clones generated from one patient were 
activated with piperacillin, whereas with others the number of drug-specific clones 
was 10-fold lower. Finally, we failed to generate clones from one patient classified 
clinically as piperacillin hypersensitive. This might be due the low number of 
clones that were expanded from the initial seeding plates (i.e. only 59 clones were 
tested for reactivity). Thus, we can assume that the yield of clones from each 
patient PBMCs is patient specific and may be related to the actual number of 
piperacillin-specific cells in blood of each patient which could be variable between 
different patients depending on many drug related or patient related factors 
(discussed in detail in thesis introduction). 
Drug related factors: include dose, frequency and duration of treatment. 
Higher dose or more frequent or longer duration would increase the chance of 
developing hypersensitivity reaction and consequently the number of piperacillin 
specific T-cells in blood or skin (Thong and Vervloet, 2014).  
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Patient related: include age: the frequency of hypersensitivity increases with 
increased age due to cumulative exposure over many years. 
Sex: drug hypersensitivity reactions are more common in females. 
Concurrent medical illness: asthma or presence of other infections like EBV or 
HIV (Sullivan and Shear, 2001) increases the chance of hypersensitivity 
development.   
Presence of multiple drug allergy syndrome: increases the chance of 
hypersensitivity development (Thong and Vervloet, 2014). 
HLA association: For some drugs there is an association between the drug 
hypersensitivity reactions and the HLA phenotype of the patient e.g. Abacavir 
reactions association with HLA-B*5701 (odds ratio 960) (Mallal et al., 2008), 
carbamazepine association with HLA-B*1502 in Han Chinese (odds ratio 2504) 
(Chung et al., 2004). The high frequency of hypersensitivity means it is unlikely 
that susceptibility is linked to a specific HLA allele. In fact, unpublished data from 
our laboratory screening HLA alleles expressed on 250 patients with CF revealed 
no obvious HLA expressed by the hypersensitive patient cohort. It is still possible 
that piperacillin-derived antigens are preferentially presented to T-cells on a range 
of HLA alleles; however, these would be difficult to identify in genetic studies.  
Pharmacokinetic and pharmacodynamic state of the patient: Although each 
patient in this study received the same drug treatment regimen, it is likely that they 
are exposed to different concentrations of free drug and bound protein adduct. 
This is due to the inter-individual variation in the pharmacokinetic and 
pharmacodynamic state that would result in diverse plethora of reactions to the 
same drug.  
 
As stated in most published papers investigating T-cell responses to drugs, it was 
decided to choose ≥2 stimulation index (SI) as a positive response to piperacillin 
(Pichler, 2014). The isolation of drug-specific clones from 5/6 patients is very close 
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to previous research that detected piperacillin specific lymphocyte proliferative 
responses in about 75 % of patients (Whitaker et al., 2011).  
The results shown in (Figure 3.3) show the optimal dose for activating T-cells with 
free piperacillin was 2mM. Clinically, the normal peak serum concentration for 
piperacillin is 389-484 µg/mL with a 4 g I.V. dose of piperacillin (ARUP, 2016). 
Thus, the dose that we give in vitro is 2-2.6 times above the clinical dose. It is 
common in in vitro cultures to use higher doses than found in vivo due to the 
different environment drug exposure and antigen presentation in vitro: culture 
media constituents and the absence of concomitant infections which make cells 
in vitro less sensitive to drugs (Huntjens et al., 2006;Sande and Zak, 1999). 
SMX-NO, an oxidative metabolite of SMX was used as a structurally irrelevant 
antigen to test the specificity of the piperacillin-specific clones. SMX causes a high 
incidence of cutaneous hypersensitivity reactions and SMX-NO-responsive T-
cells have been identified in all hypersensitive patients that have been studied to 
date (Elsheikh et al., 2010;Elsheikh et al., 2011). The piperacillin-responsive 
clones were not activated to proliferate in the presence of titrated concentrations 
of SMX-NO.  
Flow cytometry data has shown that the majority of clones were CD4+ (n=79, 
92%) while a few displayed either a CD8+ (n=4, 5%) or CD4+CD8+ (n=2, 3%) 
phenotype. The piperacillin-specific clones also secreted high amounts of IFN-γ 
and Th2 cytokines in response to serially diluted doses of free piperacillin. The 
mixed Th1 and Th2 cytokine profile suggested that molecules released from these 
clones will support the recruitment and activation of other immune cells that 
participate in the hypersensitivity reaction. To investigate whether the piperacillin-
specific T-cells might cause tissue injury directly, the secretion of cytolytic 
molecules was also measured using ELISPOT. The activated clones were found 
to secrete granzyme-B and perforin, which are able to induce apoptosis in target 
cells. High expression of perforin and granzyme-B has been reported previously 
with T-cells from patients with drug-induced skin reactions (Yawalkar et al., 2001) 
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especially, non-immediate allergic reactions to drugs (Torres et al., 2009). The 
presence of cytolytic CD4+ T cells suggests a need to revise the classical Th1/Th2 
T-cells model to cover wider and more conventional roles played by the T-cells. 
This would pave the way for a better understanding of the T-cell immune response 
in drug hypersensitivity reactions.  
For CD4+ TCCs, the TCRs interact with piperacillin presented on MHC class II 
molecules whereas for CD8+ TCCs the TCRs interact with piperacillin presented 
on MHC class I molecules. This was demonstrated previously using blocking 
antibodies for the different MHC molecules (El-Ghaiesh et al., 2012). Double 
positive T-cells are present normally in human blood and are known to respond 
to MHC I or II restricted antigens which culminate the Th1/Tc profile (Nascimbeni 
et al., 2004). It is unknown if there is a role for cross presentation in their activation. 
Extensive research on delayed hypersensitivity reactions to drugs has shown a 
compartmental distribution of T-cell subtypes. CD4 cells are predominantly in the 
dermis and blood while the CD8 cells predominantly are in the inflamed epidermis 
(Friedmann et al., 1994). This suggests that CD8+ T-cells might be the major 
mediators of certain drug hypersensitivity reactions. However, several studies 
have shown an increased number of CD4+ T-cells in blood and skin of 
hypersensitive patients especially in cases of maculopapular exanthema (MPE), 
which is the predominant clinical presentation in piperacillin hypersensitivity. 
Thus, it is possible that CD4+ T-cells are the mediators of milder forms of 
cutaneous hypersensitivity, while CD8+ T-cells are involved in bullous exanthema 
like SJS and TEN (Hari et al., 2001). 
The cells that we used to generate the free piperacillin-responsive clones are 
PBMCs (i.e. blood derived). Thus, by linking these studies with the T-cells isolated 
from skin (an on-going project in the CDSS), it will be possible to obtain a detailed 
assessment of the drug-specific skin-resident and migrating T-cells that are 
generated in hypersensitive patients.  
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Apart from the cytolytic actions of T-cells (i.e., secretion of perforin, granzyme-B 
and Fas ligand), T-cells play a pivotal role in mediating the hypersensitivity 
reactions by secreting cytokines that act as chemo-attractants and inducers for 
other inflammatory cells and keratinocytes. Moreover, T-cells express 
chemokines receptors which determine the tissue they will migrate towards. First 
of all, IFN-γ exerts a series of actions including activation of macrophages with 
the resultant eczema (type IVa response according to the revised Gell and 
Coombs classification) (Torres et al., 2009). IFN-γ secretion with TNFα and T-bet 
expression (Th1 cytokines) has been shown to be associated with more severe 
reactions (as in SJS/TEN) (Cornejo-Garcia et al., 2007). Th2 cytokines i.e.IL-5, 
IL-13, play an important role in triggering B-cells to produce antibodies especially 
IgE and IgG. Moreover, Th2 cytokines have a stimulatory effect on mast cells and 
eosinophils (Torres et al., 2009). Th2 cytokines have previously been shown to 
participate in MPE, DRESS and bullous exanthema and airway hyper-
responsiveness in the form of asthma or rhinitis (Torres et al., 2009;Pichler, 2007). 
Collectively, the immunological mechanisms and the clinical features implicated 
above are classified under type IVb drug hypersensitivity according to the revised 
Gell and Coombs classification (Pichler, 2007). 
Flow cytometry revealed that TCR-Vβ expression in the piperacillin-specific 
clones was diverse. No dominant expression by one TCR-Vβ was observed. 
Several studies have previously explored the involvement of specific TCR-Vβs in 
drug hypersensitivity reactions. Notably, carbamazepine induced SJS/TEN has 
been found to be associated with TCR-Vβ 11 in 84% of hypersensitive patients 
but none of the tolerant volunteers.  T-cells expressing TCR-Vβ-11 could be 
detected in the blister fluid of the SJS/TEN and the blood of carbamazepine 
hypersensitive patients. Moreover, utilising anti Vβ-11 prevented the activation of 
T-cells (Ko et al., 2011). On the other hand, abacavir hypersensitivity shows a 
diverse pattern of TCR-Vβ expression (Illing et al., 2012). 
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The piperacillin reactive clones expressed high levels of the following chemokines 
receptors: CCR4, CCR9, CXCR3, CCR10, CCR2 and CCR8. CCR4 ,CXCR3 and 
CCR10 are receptors involved in the homing of immune cells towards skin (Restifo 
et al., 2013). This provides an explanation for why the skin is targeted in 
piperacillin hypersensitive patients. CXCR3 and CCR2 are expressed by Th1 T-
cells while CCR3, CCR4 and CCR8 are expressed mainly by Th2 T-cells (Kim et 
al., 2001), which aligns with the secretion of Th1 and Th2 cytokines by the clones. 
CCR9 is a marker on gut-homing T-cells (Agace, 2008). It has a role in the 
development of small and large intestinal inflammation. Moreover, CCR9 
antagonists have been found effective in ulcerative colitis treatment (Bekker et al., 
2015). Intestinal involvement in case of piperacillin hypersensitivity is relatively 
common (0.9%) which manifests in the form of diarrhoea, nausea, vomiting and 
abdominal pain (Rxlist.com, 2015).  However, its mechanism involves disruption 
of the intestinal flora (Barbut and Meynard, 2002). Thus, the role of CCR9 in 
piperacillin hypersensitivity is not clear. It is possible that the receptor expression 
might be involved in the migration of T-cells to organs other than the skin, but this 
topic requires further investigation. Another important role for CCR9 is that it 
promotes the migration of T-cells to the liver and it has been shown to be highly 
expressed in cases of primary sclerosing cholangitis (Eksteen et al., 2004). Liver 
involvement in piperacillin hypersensitivity has been rarely reported.  
CD69 is a commonly used marker to measure the activation status of T-cells. This 
marker has been shown to increase robustly in response to TCR triggering 
(Porebski et al., 2011).  Expression of CD69 by CD4+ memory T-cells is critical 
for their migration and persistence in bone marrow environment (Schoenberger, 
2012). Bone marrow is an important secondary lymphoid organ that acts as 
reservoir for the memory T-cells (CD4+ and CD8+) in addition to other types of 
cells including naïve T-cells, DCs and B-cells which interact together to mount 
long-term immune responses (Di Rosa and Pabst, 2005). 
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3.5.2 Priming of piperacillin-specific T-cell responses from 
healthy drug-naive volunteers 
Methods have recently been developed to study the drug-specific priming of naïve 
T-cells from healthy volunteers. The assay relies on the initial co-culture of highly 
purified naive T-cells with autologous dendritic cells and drug for around 8 days. 
The primed T-cells are then restimulated with a second batch of dendritic cells 
and drug and antigen-specific responses can be assessed through measurement 
of proliferation and/or cytokine release (Faulkner et al., 2012;Richter et al., 2013).    
Importantly, this assay (DC-T-cell priming) was established with the drug 
metabolite antigen SMX-NO and the priming of naïve T-cells to β-lactam 
antibiotics has not been investigated. T-cells primed to free piperacillin showed a 
dose-dependent proliferative response following restimulation. Moreover, the 
primed cells do not react with SMX-NO denoting that these cells are sensitive and 
specific to free piperacillin. The concentration of piperacillin required to activate 
newly primed T-cells and T-cells from hypersensitive patients was the same. 
For ELISPOT assays, IFN-γ cytokine was chosen since it reflects the Th1 T-cell 
response while the IL-5 and IL-13 reflects the Th-2 T-cell response. Free 
piperacillin primed T-cells were found to secrete IFN- when they were activated 
with piperacillin, but not SMX-NO. Once successful priming had been established, 
the secretion of other cytokines was assessed. IL-5 and IL-13 secretion by the 
primed T-cells to free piperacillin was low. However, the detection of Th1 and Th2 
cytokine from piperacillin-specific T-cells from healthy volunteers coincides with 
that of the clones generated from the hypersensitive patients. 
In general, the phenotypic profile of pre-priming and post-priming T-cells shows 
mild predominance of CD4+ over CD8+ T-cells. However, the percentages of both 
the CD4+ and the CD8+ T-cells decreased post-priming due to the marked 
increase in double positive (CD4+CD8+) and double negative (CD4-CD8-) T-cells 
post-priming. The rise in the percentage of double positive and double negative 
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CD4+ CD8+ may be regarded as a consequence of the priming process that leads 
to disruption of the T-cell receptors leading to their hyper or hypo expression. The 
double positive CD4+CD8+ T-cells constitute 1-3% of the T-cells in the peripheral 
blood of healthy individuals (Blue et al., 1985). The priming technique entails 
interaction with the antigen presenting cells (DCs) which exert a stimulatory effect 
on the T-cells. Such an interaction has been found to be responsible for: 
1. The expression of CD4 receptors on CD8 T-cells (Yang et al., 1998). 
Interestingly, the presence of CD4+ T-cells by itself is an important 
triggering factor promoting the expression of CD4+ on CD8+T-cells. It has 
been suggested that these cells are a distinct population of cells and not 
an artefact from the classical CD4+ cells (Sullivan et al., 2001). 
 
2. The expression of CD8+ receptors on CD4+ T-cells.  
Antigenic stimulation plays an important role on the development of these 
cells as shown by the sharp rise of CD4+CD8+ after bacterial or viral 
infection (Hernández et al., 1998). This CD8 receptor is distinct from the 
classical CD8 receptor in that the CD8 receptor on the double positive cell 
is composed of CD8αα chains (Moebius et al., 1991) while that of the 
classical CD8 receptor is composed of CDαβ chains (Norment and Littman, 
1988). They do not express CD1 receptor so that they are not immature 
cells that have escaped the thymus (Zuckermann, 1999). CD4+CD8+ T-
cells can be cloned from peripheral blood CD4+ cells and they secrete IL-
2 and IFN-γ and provide help for B–cell differentiation (Patel et al., 1989). 
Moreover, they express αβTCR (Moebius et al., 1991). They also express 
high levels of CD29 which a marker for memory T-cells (Horgan et al., 
1992). These cells have been found to increase in number with increasing 
age signifying the role of longer antigenic stimulation for their development 
(Zuckermann, 1999).  
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Theoretically, the CD4 and CD8 co-expression can enhance the reactivity of the 
T-cell by increasing the avidity of the TCR at the target. This would promote the 
activation of memory CD4/CD8 double positive cells either by low levels of the 
antigen or by the presence of antigen presenting cell with MHC class II at the 
surface at an insufficient level to activate a memory T-cell. The latter situation is 
likely to happen outside the secondary lymphoid tissues (Zuckermann, 1999). 
Double negative T-cells are assumed to originate from thymus and then escape 
the negative selection and migrate to the periphery which is followed by expansion 
after antigenic stimulation (Priatel et al., 2001). They constitute 1-5% of T-cells in 
the peripheral blood and the lymphoid organs in humans (Juvet and Zhang, 2012). 
A plethora of studies have highlighted the role of double negative T-cells in the 
development autoimmune diseases e.g. myasthenia gravis, systemic lupus 
erythematosus (Reinhardt and Melms, 2000). However, to date there is no 
specific marker to identify this subset of cells and further work is needed to explore 
their ontogenesis and profile (Juvet and Zhang, 2012). Another possible 
explanation for the increase in the double negative T-cells is the activation of the 
γδ T-cells (which lack both CD4 and CD8 expression). These cells are normally 
present in the blood of healthy individuals in a low proportion 1-10% (Pinheiro et 
al., 2012). 
The marked increase of double positive and double negative cells represents an 
interesting finding that requires further work to investigate its precise nature and 
the role of these T-cells in disease pathogenesis.  
The possible number of TCR-Vβ combinations in human is 2x107 (Laydon et al., 
2015). For the sake of simplicity the these TCR-Vβs were classified by merging 
them into 24 families based upon sequence similarity (Wei et al., 1994). This 
would allow us to detect 70-75% of the total TCR-Vβ repertoire (van den Beemd 
et al., 2000). To date, there are two methods for studying and analysing the TCR-
Vβ: (1) flow cytometry and (2) PCR techniques. In comparison to PCR, the flow 
cytometry is much quicker and cheaper with the privilege of allowing the 
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researcher to analyse the Vβ repertoire within the T-cell subsets in a highly 
precise manner. Moreover, it can be utilized as a screening tool for detecting large 
T-cell expansion with a single TCR-Vβ. Flow cytometry permits the selection of 
different T-cells subsets by combining TCR-Vβ mAbs with other markers (van den 
Beemd et al., 2000).  
Based on this discussion, flow cytometry was chosen to study the TCR-Vβ 
expression on piperacillin-primed T-cells. There was a high variation (skewing) in 
the TCR-Vβ expression from prepriming to post priming with some TCR-Vβs 
increasing and others decreasing. However, when data from the individual donors 
were compared, variation of the mean change ratio (post priming/prepriming) for 
some TCR-Vβ was observed. The following TCR-Vβ showed a marked increase: 
Vβ-9, Vβ-13.2, Vβ-18 and Vβ-4. By comparing this result with the levels of TCR-
Vβ in healthy controls from another study (van den Beemd et al., 2000), we can 
notice that there is a marked increase from the average TCR-Vβ of healthy naïve 
volunteers as shown in Table 3.11: 
This profile shows some similarity to that obtained with piperacillin specific clones 
from hypersensitive patients in that there is expression of Vβ-9 Vβ-13.2. It is also 
important to emphasize that the piperacillin hypersensitive patients suffered from 
CF. In contrast, the T-cell priming experiments were conducted on healthy 
volunteers. If the priming experiments were performed on patients with CF, a more 
Table 3.11: Comparison of selected high TCR-Vβ post priming (in out study) with their 
expression in healthy volunteers as shown in (van den Beemd et al., 2000) 
 Postpriming Healthy controls  
  Mean  
Standard 
deviation 
Mean  
Standard 
deviation 
change percentage 
Vb 9 3.1 1.7 2 3.5 155.33% 
Vb 18 1.9 0.4 2 3.5 94.33% 
Vb 13.2 10.4 1.6 4 7 260.58% 
Vb 4 2.9 1.0 1.5 2 191.11% 
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similar profile of Vβ receptors might have been detected on the drug-specific 
clones.  
The profile of chemokine receptors expressed following priming was similar to the 
chemokine receptors expressed by piperacillin-specific clones isolated from 
hypersensitive patients. The patient clones expressed CCR4, CCR9, CXCR3, 
CCR10, CCR2 and CCR8. In general, the phenotypic profile of the free 
piperacillin-primed T-cells (in terms of proliferation, cytokines, chemokines 
receptors, and flow cytometric data) show great deal of similarity to that of the 
patients-derived clones. This would imply that DC-T-cell priming to free 
piperacillin could be implemented as a simulation to in vivo priming that occurs in 
the hypersensitive patients. 
3.5.3 Piperacillin-specific T-cell clones generated from PBMCs 
of healthy naive volunteers 
The average percentage of reactive clones that were generated from the naive 
volunteers after priming was 4.9% (n=40 out of 812 clones). Compared to that of 
the clones from hypersensitive patients which is 21.9% (n=360 out of 1642 clones) 
it is clear that it is easier to isolate clones from hypersensitive patients. Thirty 
piperacillin-reactive clones were selected for phenotyping and functional analysis. 
Similar to clones from hypersensitive patients, clones generated from volunteers 
following priming, proliferated in a dose-dependent manner with a maximal 
response observed at 2mM free piperacillin. The proliferative response of the 
piperacillin-specific clones was significantly weaker than that of clones from 
hypersensitive patients. Thus, hypersensitive-patients T-cells seem to have a 
higher affinity to the specific drug antigen. This may be due to repeated drug 
exposure for long durations in vivo which would mediate affinity maturation for the 
specific antigen (Rees et al., 1999). Due to short incubation time with piperacillin 
in DC-T-cell priming, we do not expect a strong affinity maturation to occur. 
Practically, we can perceive this in the lower SIs of clones from naïve volunteers 
as compared with those of hypersensitive patients.  
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Clones were not activated with the irrelevant antigen SMX-NO. Fourteen clones 
secreted IFN- following piperacillin treatment. A number of these clones secreted 
Th2 cytokines alongside cytolytic molecules. These cytokine data are similar to 
that of the clones generated from the piperacillin hypersensitive patients and also 
similar to the cytokines results of the DC-primed T-cells in that it shows a mixed 
picture of Th1 and Th2 cytokines. Higher numbers of CD4+ clones were isolated 
from hypersensitive patients compared with the DC-T-cell priming. All of the 
clones expressed a CD45RO+ve memory phenotype. Fourteen clones analyzed 
for their TCR-Vβ expression using the flow cytometry showed that TCR-Vβ 
expression profile was diverse, similar to that expressed by the patients clones.  
In conclusion, the data described in this chapter describe the isolation and 
characterization of piperacillin-specific TCCs from the blood of hypersensitive 
patients. Clones expressed a mixed Th1 and Th2 phenotype and secreted 
cytolytic molecules that might cause tissue injury in patients. Furthermore, it was 
possible to prime naïve T-cells to piperacillin using a recently established DCs-T-
cell co-culture system. Cloning revealed that the functionality of the drug-primed 
T-cells was similar to the T-cells isolated from hypersensitive patients.   
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4 Characterization of the T-cell response to piperacillin 
HSA adducts 
4.1 Introduction 
β-lactam antibiotics have a common structure that is composed of β-lactam core 
ring which mediates the inhibitory effect on the bacterial cell wall and side chains. 
In addition to these, there is a five membered thiazolidine ring in the penicillin 
group of antibiotics (Figure 4.1). β-lactams form adducts with protein through an 
irreversible covalent bond and as such represent an ideal drug class to investigate 
the relationship between hapten protein binding and induction of an immune 
response. 
 
Figure 4.1: The common structure of penicillin group of β-lactams. 
For adduct formation, the β-lactam ring is targeted by reactive amino acid 
residues in protein. The initial nucleophilic attack leads to opening of the β-lactam 
ring and binding of the penicilloyl group. Drug-protein adducts also derive from 
spontaneous conversion the parent drug into penicilloic acid and penicilloate 
(Levine and Ovary, 1961).  
Through evolution of bioanalytical technologies, mainly protein mass 
spectrometry, it has been possible to probe the nature of the drug protein 
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interaction in greater detail. β-lactam antibiotics bind to extracellular protein with 
a degree of selectivity (Ariza et al., 2014;Ariza et al., 2012). 
Furthermore, when cellular and serum protein is separated by an intact plasma 
membrane, β-lactam antibiotics bind to serum proteins, in particular human serum 
albumin (HSA) (Jenkins et al., 2013;El-Ghaiesh et al., 2012;Whitaker et al., 
2011;Meng et al., 2011).  Mass spectrometric analysis of relative peak intensity 
suggests that adduct formation on albumin is time and concentration-dependent 
and under physiological conditions. Modifications are detected at fewer than 10% 
of available nucleophilic sites (Whitaker et al., 2011). Lysine residues in HSA are 
the only amino acid residues modified by β-lactam antibiotics. The selective 
binding interaction does not only relate to pKa and therefore reactivity of the side-
chain amino group as most adducts form at or around Sudlow sites, which are 
hydrophobic pockets involved in the non-covalent binding of drugs and 
endogenous molecules (Sudlow et al., 1975). A recent study exploring the 
ceftriaxone/albumin interaction found that the drug reacts spontaneously via van 
der Waals forces and hydrogen bonds and alters the proteins secondary structure 
(Pan et al., 2012). Collectively, these data suggest that non-covalent binding of β-
lactam antibiotics with albumin partly determines the site selective covalent 
binding interaction and adduct formation. 
T-cells from patients with hypersensitivity are activated with β-lactam-HSA 
adducts (Brander et al., 1995). Furthermore, synthetic designer peptides modified 
with penicillin haptens stimulate T-cell proliferative responses (Padovan et al., 
1996) indicating that protein processing likely generates haptenic antigenic 
determinants. It is well-known that antigen dose plays a crucial role in the severity 
of the hypersensitive phenotype (Aguilar-Pimentel et al., 2010;Long et al., 2011)  
and in determining the characteristics of the responding T-cell repertoire (Oling et 
al., 2010). The use of liquid chromatography coupled with mass 
spectrometry (LC-MS) together with suitable internal standards is now one of 
the most widely used techniques for quantification purposes. Therefore, this study 
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aimed to utilize mass spectrometric methods to quantify the level of β-lactam 
protein binding in patients and to define the association between the adduct 
exposure and the drug-specific T cell response. The study focuses on piperacillin, 
an intravenous β-lactam antibiotic often administered to patients with cystic 
fibrosis for the treatment of recurrent respiratory infections. Previous research has 
shown the presence of piperacillin hapten-specific CD4+ T-cells in approximately 
75% of hypersensitive patients (El-Ghaiesh et al., 2012;Whitaker et al., 2011). 
Furthermore, studies described in chapter 3 characterized the cellular phenotype 
and functionality of TCCs responsive to free piperacillin. Thus, piperacillin 
represents the ideal candidate to investigate the quantitative relationship between 
adduct formation and drug immunogenicity.  
HSA was implemented as a model protein to quantify piperacillin binding in 
patients and to study the level of modification needed for the activation of specific 
T-cells.   
4.2 Aims of the study 
Great progress has been made over the last decade in defining the role of drug-
protein binding in hypersensitivity reactions. However, our knowledge is still far 
from complete. There are questions that remain unanswered; some of these are 
detailed below: 
1. How to characterise and compare the levels of piperacillin-HSA adducts 
formed in vivo and in vitro?  
2. Is it possible to generate clones reactive against synthetic piperacillin-HSA 
adducts from PBMCs of hypersensitive patients and/or healthy volunteers? 
3. What is the role of APCs in mediating the T-cell response to piperacillin protein 
adducts? 
4. What are the characteristics of the clones in terms of sensitivity, antigen 
specificity and cytokine secretion?  
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5. Does the concentration of piperacillin-HSA adduct required to trigger T-cell 
activation correlate with the levels of adduct formed in plasma of 
hypersensitive patients? 
6. What is the phenotype of clones?  
7. Are clones responsive against free piperacillin activated with synthetic 
piperacillin-HSA adducts? 
In accordance with the aforementioned questions, the aim of this study is detailed 
below: 
• To explore the role of drug conjugation in the activation of T-cells 
from hypersensitive patients and compare the level of adduct needed 
to activate T-cells with that formed in patients. To address this aim, 
we have 
1. Characterized piperacillin-albumin binding sites by mass spectrometry. 
2. Generated synthetic piperacillin HSA adducts. 
3. Generated T-cells responsive against piperacillin-HSA adducts and 
explored the nature of the induced response focussing on mechanisms of 
T-cell activation, TCR Vβ usage and cytokine release. 
Note: The term free piperacillin mentioned in this chapter refers to soluble 
piperacillin available in the medium during T-cells assays. During this time (2-3 
days) piperacillin-HSA adducts will form and these have been characterized. 
 
 
 
 
Conjugated Piperacillin Chapter 4  
 
 
 
195 
 
4.3 Methods 
The methods used in this chapter are discussed in detail in chapter 2.  In 
summary, the methods implemented in generation and testing of piperacillin-HSA 
sensitive clones are mentioned in Figure 4.2. 
 
 
 
 
 
 
 
Figure 4.2: Methods implemented in the preparation, characterization and testing of 
piperacillin-HSA sensitive TCCs. 
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4.4 Results 
The modified peptide synthesis, piperacillin-HSA synthesis and mass 
spectrometric analysis was conducted by Drs Xiaoli Meng and Rozalind Jenkins 
(MRC Centre of Drug Safety Science, University of Liverpool). 
4.4.1 Synthesis of piperacillin-modified albumin peptide 
Our previous studies have shown the formation of piperacillin-modified lysine 
residue (Lys541) at low concentrations of piperacillin. While at higher 
concentrations, there are up to 13 lysine residues found to be modified by 
piperacillin. Some of these residues are detected in patients plasma like (Lys190, 
195, 432 and 541). Thus, we proceeded in developing a technique to synthesize 
the peptide (ATK(piperacillin)EQLK) which is an amino acid sequence peptide 
with the modified piperacillin-lysine (Lys541) of HSA. This synthetic peptide is 
essential to allow us to generate a standard curve enabling us to quantify 
piperacillin hapten binding at this site in both, the tolerant CF patients plasma 
samples and the in vitro culture assays.  
To quantify drug hapten albumin binding, methods were developed to synthesize 
a piperacillin-modified HSA peptide incorporating the amino acid sequence 
around Lys541 (ATK[Pip]EQLK) as described in Figure 4.3 B. The synthesis of 
peptide was performed manually in solution phase using Fmoc strategy 
employing orthogonal protection strategy. Piperacillin benzyl ester was selectively 
conjugated to ε-amino group of lysine in mild reaction conditions, and the resulting 
piperacillin-modified lysine was incorporated with relevant amino acid residues, 
followed by deprotection by using catalytic hydrogenolysis to generate peptide 
ATK(Pip)EQLK. LC-MS/MS analysis revealed formation of desired peptide. The 
presence of a doubly charged ion at m/z 676.8, corresponding to the peptide 
ATKEQLK with an additional mass of 535 amu, demonstrated that a hydrolyzed 
piperacillin-modified peptide was formed. The peptide sequence was confirmed 
by a product ion spectrum that generated partial singly charged y and b series 
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ions. The modification was defined by b3* (peak at m/z 517) and b5*(peak at m/z 
774.4), with a mass addition of 216 amu, providing evidence that piperacillin is 
attached to K541 as shown in Figure 4.3 C. Purification of crude peptide products 
by HPLC afforded peptide ATK(piperacillin)EQLK in 90% purity.  
Patients details 
Plasma samples were isolated from blood of ten piperacillin tolerant patients with 
cystic fibrosis prior to piperacillin exposure and immediately after a standard 14-
day treatment course (4.5g qds).  Plasma was aliquoted and stored at -80oC 
immediately after isolation for characterization and quantification of piperacillin 
hapten HSA adducts.  
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Figure 4.3: Piperacillin hapten structures and the synthesis of a piperacillin-modified 
peptide incorporating Lys541. (A) The two forms of piperacillin-HSA adduct.  The first is 
cyclized in which the dioxypiperazine ring is closed. The second is the hydrolyzed form in which 
the ring is open (Whitaker et al., 2011). The scheme showing the 2 potential piperacillin haptens 
bound covalently to protein. (B) Scheme showing the synthetic pathway for piperacillin 
modified K541 peptide ATK(Pip)EQLK. (C) MS/MS spectra of synthetic peptide 
ATK(Pip)EQLK with characteristic fragment ions from piperacillin circled. The presence 
of a doubly charged ion at m/z 676.8, corresponding to the peptide ATKEQLK with an additional 
mass of 535 amu, demonstrated that a hydrolyzed piperacillin-modified peptide was formed. 
The peptide sequence was confirmed by a product ion spectrum that generated partial singly 
charged y and b series ions. The modification was defined by b3* (peak at m/z 517) and 
b5*(peak at m/z 774.4), with a mass addition of 216 amu, providing evidence that piperacillin 
is attached to K541. 
C 
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4.4.2 Quantitative analysis of piperacillin-modified albumin in 
patients 
Up to 13 lysine residues were modified with cyclized and hydrolyzed forms of 
piperacillin hapten at different drug to protein ratios in vitro (Figure 4.4 A). Using 
relative quantification based on ionization efficiency, Lys541 was the most 
frequently modified residue. Lys541 and Lys190 peptides were present at similar 
level in patients (results not shown). A peptide containing piperacillin-modified 
Lys541 was therefore used to quantify piperacillin-modified albumin in patients.  
Albumin was isolated from patients plasma samples (n=10) after a 14-day 
treatment course by means of affinity column. Following processing the samples 
were analyzed directly by LC-MS/MS. In contrast to the two hapten structures 
detected on piperacillin albumin adducts generated in vitro (cyclized and 
 
Figure 4.4: Relative quantification of 
piperacillin hapten albumin binding in 
vitro. (A) Relative mass spectrometric 
quantification of piperacillin haptens 
(cyclized and hydrolyzed forms) 
formed at different lysine residues in 
vitro when the drug was incubated at 
different drug:protein ratios.(B) Model 
of HSA showing piperacillin lysine 
binding sites.  
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hydrolyzed (Figure 4.3 A).   The hydrolyzed form was the only hapten detected 
on albumin Lys residues in patients (results not shown), with tryptic peptides 
incorporating Lys541 and Lys190 being the dominant sites of modification. A total 
of four lysine residues, namely Lys190, Lys432, Lys 525, and Lys541, were 
detected in all patients.  
A calibration curve was constructed using the synthetic piperacillin-Lys541 
peptide to quantify piperacillin albumin binding in patients (Figure 4.5 A); the 
analyses were conducted on three separate occasions). The level of modification 
of Lys541 in total HSA ranged from 2.7-4.7% (mean 3.86%), with 6 patients 
displaying modification levels of 4% or more (Figure 4.5 B). Interestingly, the 
levels of piperacillin-modified Lys541 in some patients were above that formed in 
vitro after a 24 hrs incubation (3.6% for drug-protein molar ratio 10:1 as shown in 
Figure 4.6 C).   
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Figure 4.5:   Absolute quantification of piperacillin hapten albumin binding in patient 
plasma. (A) Standard curve constructed using synthetic piperacillin-modified K541 
peptide with concentrations ranging from 0.05µM to 1.5µM. (B) The mean level of 
piperacillin-modified K541 peptide (= 3.86% shown as a red line) detected in plasma from 
10 patients exposed to a 14-day treatment course. Error bars represent standard 
deviation. 
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4.4.3 Generation and characterization of piperacillin-HSA 
adducts  
Synthetic piperacillin-HSA adducts were characterized by mass spectrometry and 
western blot. Epitope profiling showed that both cyclized and hydrolyzed hapten 
were formed; notwithstanding the disparity in the ionisation efficiency of the 
peptides, piperacillin-modified K541 was the major binding site (Figure 4.6 A and 
B).  The levels of hydrolyzed piperacillin-modified K541 elevated with increased 
concentrations of piperacillin, ranging from 3.6% at the lowest T-cell stimulatory 
molar ratio 10:1 (discussed later under heading 4.4.5.2) to 23.5% at a 
drug:protein ratio of 250:1 (Figure 4.6 C.). The concentration-dependent binding 
of piperacillin was also mirrored using western blotting (Figure 4.6 D.). 
 
 
  
Figure 4.6: Relative quantification of (A) cyclized and (B) hydrolyzed forms of piperacillin 
hapten generated at different lysine residues on piperacillin albumin adduct 
(drug:protein ratios of 10:1-250:1). (C) The absolute level of piperacillin-modified K541 
peptide detected on piperacillin albumin adduct generated at drug:protein ratios of 10:1-
250:1. (D) Western blot analysis of piperacillin albumin adducts.  Error bars represent 
standard deviation. 
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4.4.4 Characterization of the epitope profile of piperacillin- HSA 
adducts 
After being digested with trypsin and analyzed using mass spectrometry, 13 
peptides containing piperacillin were detected out of 59 lysine residues for both 
forms of piperacillin: the cyclized and the hydrolyzed (Table 4.1).  
 
4.4.5 Characterisation of the response of patient T- 
lymphocytes to piperacillin adducts 
  Generation of drug-specific T-cell lines and T-cell clones 
from piperacillin-hypersensitive patients 
Three piperacillin hypersensitive patients were chosen (the first three patients 
illustrated in Table 3.1) who have previously been shown to be positive for 
piperacillin in LTTs (Whitaker et al., 2011) with historical delayed-onset 
maculopapular exanthema. In every case, the treatment had to be discontinued, 
Table 4.1: Lysine residues containing piperacillin after tryptic digestion of piperacillin-
HSA and analysis of the resultant peptides using mass spectrometry. *=piperacillin  
Lysine residue Peptide 
Hydrolyzed 
hapten 
Cyclized 
hapten 
4 DAHK*SEVAHR     
12 FK*DLGEENFK     
137 K*YLYEIAR     
162 YK*AAFTECCQAADK     
190 LDELRDEGK*ASSAK     
195 ASSAK*QR     
199 LK*CASLQK     
212 AFK*AWAVAR     
351 LAK*TYETTLEK     
432 NLGK*VGSK     
525 K*QTALVELVK     
541 ATK*EQLK     
545 EQLK*AVMDDFAAFVEK     
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and patients received anti-histamines and/or oral steroids, when clinically 
indicated. Blood samples were collected after 4 weeks of drug discontinuation and 
PBMCs were separated. T-cell lines were prepared by incubating the PBMCs in 
culture with (2mg/mL) of piperacillin-HSA (250:1 molar ratio) for 14 days. 
Subsequently, clones were generated using the method of serial dilution.  
Following mitogen-driven expansion, clones were tested using 3H-thymidine 
proliferation assay with irradiated EBV-transformed B-cells as antigen presenting 
cells. 2mg/mL unmodified HSA was used as a comparator against 2mg/mL 
piperacillin-modified HSA generated with a 250:1 molar ratio. SI ≥2 was used as 
a cut-off point to identify the reactive clones.  
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Figure 4.7:(A) Proliferation assay here showing SIs for all the clones generated for 
piperacillin-HSA adducts. T-cells are incubated with irradiated autologous EBVs and 
(2mg/mL) HSA and (2mg/mL) piperacillin-HSA for 48 hrs. In the last 16 hrs radioactive 
thymidine was added which was followed by harvesting and reading the plate with a beta 
counter. The dotted line represents SI=2 which is the threshold for selecting reactive clones. 
(B) The clones for the piperacillin HSA adducts generated for each piperacillin 
hypersensitive CF patient showing percentages of reactive clones as assessed by the 
3H-thymidine uptake assay. 
Patient ID 
Number
Number of 
reactive clones
Total clones 
number
Percentage of 
reactive clones
P1 60 677 8.8%
P2 0 257 0%
P3 0 264 0%
A 
B 
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60 clones (out of 1198) were found to proliferate actively in the presence of 
piperacillin HSA conjugate (Figure 4.7).   
  Measurement of the reactivity of piperacillin-HSA primed 
clones to various molar ratios of piperacillin-HSA adduct 
using 3H-thymidine uptake proliferation assay 
Ten clones were assessed for their reactivity in terms of proliferation to piperacillin 
HSA adducts (2mg/mL) generated at different molar ratios of drug:protein. Cell 
culture medium (0) and unmodified HSA (2mg/mL) exposed to the same 
extraction method as the protein adduct were used as negative controls. 
Furthermore, clones were cultured with piperacillin at (2 mM) to assess cross 
reactivity between piperacillin-HSA adducts and the free drug. Clones were all 
0
2 
m
M
 H
.S
.A
2:
1 
pi
p-
H
.S
.A
10
:1
 p
ip
-H
.S
.A
50
:1
 p
ip
-H
.S
.A
25
0:
1 
pi
p-
H
.S
.A
2 
m
M
 fr
ee
 p
ip
0
10000
20000
30000
40000
***
**
*
10 Clones
P
ro
li
fe
ra
ti
o
n
 (
c
p
m
)
 
0
2 
m
g/
m
L 
H
.S
.A
25
0:
1 
2 
m
g/
m
L 
pi
p 
H
.S
.A
 
2 
m
M
 p
ip
0
10000
20000
30000
40000
50000 ****
37 clones
P
ro
li
fe
ra
ti
o
n
 (
c
p
m
)
 
Figure 4.8: 3H-thymidine proliferation assay for the (A) piperacillin-HSA, (B) free 
piperacillin primed clones using (2mg/mL) piperacillin-HSA in various molar ratios, 
(2mg/mL) HSA and (2mM) free piperacillin. T-cells were incubated with irradiated autologous 
EBVs and (2mg/mL) HSA and (2mg/mL) piperacillin-HSA for 48 hrs. In the last 16 hrs 
radioactive thymidine was added which was followed by harvesting and reading plate with beta 
counter. The clones show a dose-dependent response curve. Statistical analysis using Kruskal-
Wallis test reveal high statistical significance *, ** and *** signifying p<0.05, p<0.01 and p<0.001 
respectively. Error bars represent standard deviation. (cpm) represents the count per minute 
(i.e. radiation unit). 
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activated to proliferate with piperacillin-HSA adduct, with the strongest response 
observed at a 250:1 piperacillin-HSA molar ratio as shown in Figure 4.8 A. 
Statistical significance was observed at a molar ratio of 10:1,50:1 and 250:1 
piperacillin-HSA as analyzed by Kruskal-Wallis test.  
Interestingly, some clones displaying reactivity to piperacillin-HSA adducts were 
activated with free piperacillin, while others were not (Figure 4.9). This is despite 
the fact that piperacillin-HSA adducts are generated spontaneously in the cell 
culture medium containing free drug. 
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Figure 4.9: Certain piperacillin-HSA responsive clones are activated with free 
piperacillin. Two groups of clones were detected: A. Two representative clones which 
do not cross react with free piperacillin i.e., they only respond to piperacillin-HSA adducts.  
B. Two representative clones which are reactive to both piperacillin-HSA adducts and 
free piperacillin (based upon their SIs which were higher than 2 for both piperacillin-HSA and 
free piperacillin). In each case the response to free piperacillin was significantly lower.  
Proliferation was determined by radioactive thymidine incorporation. (SI) represents the 
stimulation index. 
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Cross Reactive 
clones 
Not cross 
reactive clones 
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  3H-thymidine uptake proliferative response of free 
piperacillin clones to piperacillin-HSA adducts  
Thirty-seven clones reactive to free piperacillin, generated from 5 piperacillin 
hypersensitive CF patients, (see chapter 3) were selected and tested for their 
cross reactive proliferative response to piperacillin-HSA adducts using 3H-
thymidine uptake proliferation assay.  
The results in Figure 4.8 B show that these clones have very high reactivity to 
free piperacillin (2mM) (****: p<0.0001) as analyzed by Kruskal-Wallis test. The 
clones in general did not show reactivity for piperacillin adducts. Three clones 
were found to show reactivity for both the free piperacillin and the adducts (Figure 
4.10).  
In total, (50%) of piperacillin-HSA conjugates primed TCCs are cross reactive to 
free piperacillin while few of the free piperacillin primed TCCs (8.1%) are cross 
reactive with piperacillin-HSA conjugates as shown in Table 4.2. 
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Figure 4.10: Proliferative response of clones primed to free piperacillin (selected from 
the previously tested clones in Figure 4.8 B), shows the variation in proliferative 
response when clones were challenged with piperacillin-HSA conjugates. A. Two 
representative clones which do not cross react (i.e., they only respond to free 
piperacillin).  B. Two representative clones which are reactive to both piperacillin-HSA 
adducts and free piperacillin. T-cells were incubated with irradiated autologous EBVs and 
(2mg/mL) HSA, (2mg/mL) piperacillin-HSA and (2mM) free piperacillin for 48 hrs. In the last 16 
hrs radioactive thymidine was added which was followed by harvesting and reading plate with 
beta counter. Proliferation was determined by radioactive thymidine incorporation. (SI) 
represents the stimulation index.  
Table 4.2: Cross reactivity of piperacillin and piperacillin-HSA clones tested in Figure 
4.8  
 
10 Clones primed to 
piperacillin-HSA 
conjugates  
37 Clones primed to 
free piperacillin 
Clones reactive to 
piperacillin-HSA adducts 
10 
(100%) 
3  
(8.1%) 
Clones reactive to free 
piperacillin  
5  
(50%) 
37 
 (100%) 
Cross Reactive 
clones 
Not cross 
reactive clones 
A B 
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  Measurement of the dose-dependent proliferative 
response of piperacillin-HSA responsive clones  
Thirteen clones were tested for their sensitivity to serially diluted doses of a 
piperacillin-HSA adduct generated with a 250:1 molar ratio of piperacillin-HSA 
using the 3H-thymidine uptake proliferation assay. 
A clear proliferative response to serially diluted doses of the HSA adduct was 
observed (Figure 4.11). Statistical significance was observed for all the selected 
doses ranging between (0.25-2 mg/mL) as analyzed by Kruskal-Wallis test.        
 
  Proliferative response of T-cell clones with and without 
APC fixation 
To confirm that the clones responsive against piperacillin-HSA were activated via 
a hapten mechanism involving protein processing, antigen presenting cells were 
fixed with glutaraldehyde. Fixation blocks the ability of the APC to process and 
present antigen (including drug-protein adducts), but not free drugs that bind 
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Figure 4.11: 3H-thymidine uptake proliferation assay for piperacillin-HSA responsive 
clones to serially diluted doses of piperacillin-HSA adduct generated at a 250:1 molar 
ratio of drug:protein. T-cells were incubated with autologous irradiated EBVs and piperacillin-
HSA for 48 hrs. In the last 16 hrs radioactive thymidine was added which was followed by 
harvesting and reading the plate with beta counter.  Proliferation was determined by radioactive 
thymidine incorporation. Statistical analysis using Kruskal-Wallis test reveal high statistical 
significance * and ** signifying p<0.05 and p<0.01 respectively. Error bars represent standard 
deviation. (cpm) represents the count per minute (i.e. radiation unit). 
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directly to MHC molecules expressed on antigen presenting cells (Yaseen et al., 
2015;Zanni et al., 1999;Monshi, 2013). Fixation of antigen presenting cells 
prevented the activation of all clones with free piperacillin (El-Ghaiesh et al., 
2012). 
Ten clones were tested for their proliferative responses when challenged with 
piperacillin-HSA adducts, HSA and medium. These clones were incubated with 
irradiated autologous APCs and fixed irradiated autologous APCs.  
With irradiated APCs, the clones were activated with piperacillin-modified, but not 
unmodified HSA (Figure 4.12). Fixation of APCs completely inhibited the 
proliferative response to the protein adduct.  
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Figure 4.12: APCs fixation inhibits the proliferative responses of TCCs to piperacillin-
HSA adduct. 
T-cells were incubated with non-fixed autologous EBVs and glutaraldehyde fixed EBVs. Both 
sets of APCs were incubated with (2mg/mL) HSA and (2mg/mL) piperacillin-HSA for 48 hrs. In 
the last 16 hrs radioactive thymidine was added which was followed by harvesting and reading 
the plate with beta counter. Statistical significance at p<0.05 was analyzed by Kruskal-Wallis 
test. Error bars represent standard deviation. (cpm) represents the count per minute (i.e. 
radiation unit). 
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  Quantification of the threshold level of piperacillin 
modified albumin required to trigger a T-cell response 
Piperacillin modification of lysine residues at the lowest concentration of 
conjugate that activated T-cells (i.e. 0.25 mg/mL) (Figure 4.11) was calculated to 
be (2.9%) which was in a similar range to the level of modification detected in 
patients plasma (4%) (Figure 4.5 B).  
In chapter 3, clones cultured with antigen presenting cells and titrated 
concentrations of piperacillin (0.125–2mM) were shown to be activated at the 
lowest concentration studied; thus, piperacillin concentration was reduced to 
establish a threshold for T-cell stimulation. A piperacillin-specific T-cell 
proliferative response was detected with 5 out of 9 clones at a concentration of 
0.01mM. However, statistical significance was only reached with concentrations 
of 0.1mM and above (Figure 4.13 A).  Coinciding with the T-cell response, 
piperacillin-modified K541 was detectable after 48h with 0.1mM piperacillin 
(approx. 1%). Increasing the concentration of piperacillin resulted in higher level 
of piperacillin hapten-modified Lys 541, with 4.7% modification detected at 2mM 
piperacillin. Moreover, hapten albumin binding was detected at earlier time-points 
(4-24h) with piperacillin concentrations ranging from 0.5-4mM (Figure 4.13 B).  
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  Proliferative response of T-cells clones with APCs 
pulsed with free piperacillin   
The level of piperacillin hapten adduct required for triggering T-cells was 
determined by pulsing antigen presenting cells with free piperacillin (2mM) for 1, 
4, 24, and 48h prior to washing and exposure of the antigen presenting cells to 
free piperacillin responsive TCCs. Antigen-presenting cells pulsed with free 
piperacillin for 1 and 4 h did not stimulate a proliferative response and only low 
level of piperacillin-modified Lys541 were detected in the culture supernatants 
(Figure 4.14). In contrast, 24 and 48h pulsed antigen presenting cells stimulated 
all clones to proliferate and the strength of the induced response was equivalent 
to or stronger than that seen with the free drug.  From this data, it can be estimated 
that HSA adducts with 2.8% of Lys541 modified by piperacillin act as antigens to 
activate T-cell proliferative responses. 
 
 
 
 
Figure 4.13: Activation of piperacillin-responsive CD4+ clones from hypersensitive 
patients and quantification of piperacillin albumin binding. TCCs were cultured with 
irradiated antigen presenting cells and (A) piperacillin 0.01µM-2mM and proliferative 
responses were measured by 3H-thymidine uptake. (B) The absolute level of time-
dependent piperacillin-modified K541 peptide detected in culture supernatant.  Statistical 
analysis using Kruskal-Wallis test reveal high statistical significance at p<0.05. Error bars 
represent standard deviation. (cpm) represents the count per minute (i.e. radiation unit). 
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  Cross reactivity between piperacillin-HSA adducts and 
HSA modified with other β-lactam antibiotics 
Penicillin G, amoxicillin, piperacillin and flucloxacillin HSA adducts were 
generated by culturing the drugs with HSA at 100:1 and 250:1 ratios for 24hr 
(except for flucloxacillin which was prepared at only 100:1 molar ratio since the 
higher concentration damaged the tertiary structure of albumin). Epitope profiles 
showed that similar subsets of lysine residues were targeted by all four drugs; 
however, the relative level of binding differed at the individual sites of modification.  
Modification by penicillin G at Lys4, Lys137, Lys195, Lys199 and Lys432 resulted 
in strong MRM signals (Figure 4.15 A and B); however, Lys190 and Lys541 were 
primary targets for modification with amoxicillin (C and D), and Lys190, Lys212, 
Lys432, Lys525, and Lys541 were preferentially targeted by piperacillin (E and 
 
 
Figure 4.14: Time-dependent activation of CD4+ clones with free piperacillin-pulsed 
antigen presenting cells and quantification of piperacillin albumin binding. (A) TCCs 
(n=8) were cultured with antigen presenting cells pulsed with free piperacillin (2mM; 1-48h) and 
proliferative responses were measured by 3H-thymidine uptake. Antigen presenting cells were 
subjected to repeated washing with drug-free medium prior to exposure to clones. (B) The 
absolute level of time-dependent free piperacillin-modified K541 peptide detected in antigen 
presenting cell culture supernatant. Error bars represent standard deviation. (cpm) represents 
the count per minute (i.e. radiation unit). 
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F). For 100:1 flucloxacillin Lys4, Lys137, Lys195, Lys212 and Lys432 Lys525, and 
Lys541 were preferentially targeted (G). 
 
  
  
  
 
Figure 4.15: Epitope profile for selected β-
lactam antibiotics as analyzed by mass 
spectrometry. 
Relative mass spectrometric quantification of 
benzyl penicillin, amoxicillin, piperacillin and 
flucloxacillin haptens formed at different lysine 
residues in vitro when the drug was incubated at 
drug: protein molar ratios of (A, C, E and G) 
100:1 and (B, D and F) 250:1 for 24 hr. 
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The proliferative response of piperacillin-HSA adduct responsive clones was 
tested with the other β-lactam adducts at a dose of 2mg/mL (Figure 4.16). Clones 
were stimulated to proliferate in the presence of the piperacillin-HSA adduct 
(slightly higher for the 250:1 in comparison to the 100:1 molar ratio), but not with 
HSA modified with the other β-lactams structures. 
  Quantitative and qualitative measurement of IFN-γ 
secretion profile of the T-cell clones by ELISPOT 
Three clones were tested for secretion of IFN-γ using the ELISPOT technique 
when challenged with various molar ratios of the piperacillin-HSA adduct at the 
dose of (2mg/mL). 
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Figure 4.16: 3H- thymidine uptake proliferation assay showing the lack of cross reactivity 
between piperacillin-HSA adducts and several other β-lactam adducts. T-cells were 
incubated with autologous irridiated APCs and (2mg/mL) HSA and (2mg/mL) of piperacillin, 
flucloxacillin, amoxicillin and penicillin-G HSA adducts (100:1 and 250:1 ratio of drug:protein) 
for 48 hrs. In the last 16 hrs radioactive thymidine was added which was followed by harvesting 
and reading the plate with a beta counter. Statistical significance was analyzed by Kruskal-
Wallis test revealed no statistical significance. Error bars represent standard deviation.  
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Clones were found to secrete IFN-γ in response to piperacillin-HSA adducts in a 
dose dependent manner with the highest response observed at a 250:1 molar 
ratio of drug:protein (Figure 4.17). Clones were stimulated to secrete only low 
levels of IFN- with free piperacillin.  
 Measurement of T cell receptors using the 
fluorescence-activated cell sorting (FACS): 
 CD4/CD8 phenotype, CD45RO expression (memory phenotype) 
23 TCCs were analyzed using flow cytometry for expression of CD4, CD8, 
CD45RO and TCR-Vβ expression 
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Figure 4.17: IFN-γ secretion by three representative clones as measured by the 
ELISPOT.T-cells were incubated with autologous irradiated EBVs and (2mg/mL) HSA, 
(2mg/mL) piperacillin-HSA, (2mM) free piperacillin on a coated 96-well ELISPOT plate for 48 
hrs. The incubation period is followed by development and reading with a spot counter. 
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Figure 4.18 shows that there is a predominance of the CD4 memory phenotype 
(95%, n=22) while only 1 clone expressed a CD8 memory phenotype constitutes 
(5%). 
 TCR-Vβ expression 
23 representative clones were analyzed for TCR-Vβ expression using flow 
cytometry. Clones expressed a restricted pattern of TCR-Vβs. TCR-Vβ 9 was 
observed on 15 clones (68%), while other clones expressed the following TCR-
Vβs: TCR-Vβ 17 (n=2, 9%), 2 (n=2, 9%) and 20 (n=1, 5%). No TCR-Vβ expression 
was observed on 2 clones (9%) (Figure 4.19).  
 
Figure 4.18:CD4/CD8 phenotype of 23 TCCs as measured by the FACS. T-cells were 
stained with relevant fluorescent-labelled antibodies. Tubes were then incubated on ice for 20 
min prior to analysis using flow cytometry. 
CD 4+  memory, 
21, 95%
CD 8+  memory, 
1, 5%
CD4/CD8 phenotype expression of the 23 T-cells 
clones
CD 4+  memory
CD 8+  memory
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 Characterization of chemokine receptors and CD69 expression on 
piperacillin-HSA responsive T-cell clones 
13 TCCs were stained with fluorochrome labelled antibodies for chemokine 
receptors and then analyzed by flow cytometry. High expression of the following 
chemokine receptors was observed (mean fluorescence index greater than 2): 
CXCR3, CCR4, CCR2, CCR10, CCR9 and CCR8 in addition to the activation 
marker CD69 (Figure 4.20). 
 
Figure 4.19: TCR-Vβ expression on piperacillin-HSA responsive TCCs show a 
predominance of TCR-Vβ 9 (68% n=15). T-cells were stained with relevant fluorescent-
labelled antibodies. Tubes were then incubated in room temperature for 20 min prior to analysis 
using flow cytometry. 
Vβ 9, 15, 68%
Vβ 17, 2, 9%
Vβ 2, 2, 9%
Vβ 20, 1, 5%
Nil, 2, 9%
TCR-Vβ for 23 piperacillin-HSA conjugate responsive 
clones
Conjugated Piperacillin Chapter 4  
 
 
 
218 
 
 
4.4.6 Characterisation of T-lymphocytes response from naive 
healthy volunteer to piperacillin-HSA adducts 
In this part of the project, we tried to characterize the response of T-cells from the 
PBMCs of healthy normal (drug naive) donors primed to piperacillin HSA adducts.  
Blood was taken from three healthy volunteers (Table 4.3). Peripheral blood 
mononuclear cells (PBMCs) were separated from the blood. Naive T cells were 
C
LA
C
C
R
6
C
C
R
3
C
C
R
5
E
 C
A
D
C
X
C
R
6
C
C
R
1
C
C
R
8
C
C
R
9
C
C
R
10
C
C
R
2
C
C
R
4
C
X
C
R
3
C
D
69
0
1
2
3
4
5
6
7
8 13 clones
M
e
a
n
 f
lu
o
r
e
s
c
e
n
c
e
 i
n
d
e
x
 (
M
F
I)
  
Figure 4.20: (A). Chemokine receptors and CD69 expression on 13 piperacillin-HSA 
responsive clones as analyzed by FACS. T-cells were stained with relevant fluorescent-
labelled antibodies. Tubes were then incubated on ice for 20 min prior to analysis using flow 
cytometry. (B). CD69 & chemokines receptors expression MFIs for the clones in a 
descending order showing the highly expressed chemokines receptors in yellow. Error bars 
represent standard deviation.  
Table 4.3: The volunteers’ demographics. Three normal healthy volunteers were 
enrolled in this study. 
Donor ID Age Sex 
History of 
allergies 
Medical history 
HVN-051 40 Male Nil Not relevant 
HVN-066 36 Male Nil Not relevant 
HVN-131 35 female Nil Not relevant 
A B 
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separated from the PBMCs. Dendritic cell-T-cell priming to piperacillin-HSA 
adducts (250:1 molar ratio) was conducted at the dose of (2mg/mL) in addition to 
another priming experiment using SMX-NO at (50µM) (to be used as an irrelevant 
drug antigen in the assays). T-cells were then harvested from the co-culture plates 
and tested for their specificity in proliferation and IFN-γ secretion assays. 
  3H-thymidine uptake proliferation assay 
 T-cells primed to piperacillin-HSA adducts did not proliferate when restimulated 
with a second batch of dendritic cells and either piperacillin HSA adduct (0.5-
2mg/mL, 250:1 molar ratio) or SMX-NO. T-cells did proliferate vigorously in the 
presence of the positive control PHA (Figure 4.21 A).  
In contrast, the SMX-NO primed T-cells (Figure 4.21 B) proliferated weakly in a 
dose-dependent manner with SMX-NO. The SMX-NO-responsive T-cells were 
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Figure 4.21: 3H-thymidine uptake proliferation assay :(A) T-cells primed to piperacillin-
HSA. (B) T-cells primed to SMX-NO. T-cells were incubated with autologous DCs and 
piperacillin-HSA (250:1 molar ratio), HSA (2mg/mL), PHA (5 µg/mL), SMX-NO (50 µM) or free 
piperacillin (2 mM) for 72 hrs. In the last 16 hrs radioactive thymidine was added which was 
followed by harvesting and reading the plate with a beta counter. Statistical significance was 
analyzed by Kruskal-Wallis which revealed statistical significance for PHA at * and ** signifying 
p<0.05 and p<0.01 significance levels respectively, significance level. Error bars represent 
standard deviation. (SI) represents the stimulation index. 
A B 
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not stimulated to proliferate with piperacillin-modified HSA (2mg/mL).   Similar 
data was obtained when IFN- ELISPOT was used as a readout for the drug 
antigen-specific T-cell response (Figure 4.22 A and B).   
Clones were generated from the piperacillin-HSA primed cultures. However, 
following restimulation, none were found to be responsive to piperacillin-HSA 
(results not shown).  
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Figure 4.22: ELISPOT for IFN-γ primed T-cells for (A) piperacillin-HSA adducts (B) SMX-
NO primed T-cells.  T-cells are incubated with autologous DCs and, serially diluted doses of 
piperacillin (250:1) molar ratio, (2mg/mL) HSA, (5 µg/mL) PHA, (50 µM, 25 µM) SMX-NO and (2 
mM) free piperacillin on an antibody coated for 48 hrs. Then, the plate was developed and 
counted. Statistical significance was analyzed by Kruskal-Wallis which revealed no statistical 
significance at p<0.05 significance level. Error bars represent standard deviation. (SFU) 
represents spot forming unit (cytokine secreting cell). 
 
 
 
 
 
A
 
B
 
Conjugated Piperacillin Chapter 4  
 
 
 
221 
 
4.5 Discussion 
Drug hypersensitivity reactions represent a significant clinical problem and an 
impediment to drug development. It is currently impossible to develop drugs with 
no immunological liability; furthermore, it is very difficult to predict which 
individuals will develop hypersensitivity when exposed to a therapeutic treatment 
regimen. This is because susceptibility is a function of the chemistry of the drug, 
the genetic background of the patient and environmental factors such as 
patient demographics, disease and concomitant medications. One of the 
predominant problems is the complexity of processes that deliver drug-derived 
antigens to the T-cell receptor. To activate CD4+ and/or CD8+ T-cells, the T-cell 
receptor must receive signals from an MHC-peptide-drug complex. In vitro 
analyses have revealed that certain drugs bind directly to the MHC peptide 
binding cleft and/or pre-bound peptides to activate T-cells (Yun et al., 2014;Adam 
et al., 2014;Illing et al., 2012;Ko et al., 2011;Ostrov et al., 2012;Chung et al., 
2015). 
However, the dominant pathway for drugs such as the β-lactam antibiotics 
(Monshi, 2013;Brander et al., 1995;Padovan et al., 1997;Yaseen et al., 2015) and 
sulphonamides (Elsheikh et al., 2011;Castrejon et al., 2010;Schnyder et al., 2000) 
involves the formation of a protein adduct with the drug hapten bound irreversibly 
to specific amino acid residues on non-MHC associated protein. The protein 
adduct is processed by antigen presenting cells liberating peptides that associate 
with MHC molecules to activate T-cells.  The evolution of quantitative mass 
spectrometry methodology has allowed us to relate the level of drug hapten 
protein binding in patients to the activation of T-cells. In this study, analysis of 
hapten binding in patient’s plasma and in vitro revealed that piperacillin binds to 
HSA at comparable levels. Thus, antigenic determinants with the potential to 
activate T-cells and cause tissue injury are formed in most patients exposed to 
the drug.  
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Our previous studies have demonstrated that piperacillin covalently modifies Lys 
residues at drug binding “Sudlow sites” on HSA in plasma (Whitaker et al., 2011). 
Meover, piperacillin HSA adducts formed in vitro stimulate hypersensitive patient 
T-cells to proliferate and secrete cytokines (El-Ghaiesh et al., 2012). These data 
lead us to investigate whether the level of piperacillin HSA modification differs in 
individuals exposed to the same treatment regimen. Quantification of drug protein 
adducts has been always difficult. Mass spectrometric techniques have made it 
feasible to achieve relative quantification based on ion intensity of tryptic peptides. 
However, absolute quantification is only possible when mass spectrometric 
analysis is performed with a synthetic drug hapten peptide standard incorporating 
amino acid residues found in the native protein (Lange et al., 2008;Gallien et al., 
2011). 
Synthesis of β-lactam peptide adducts is extremely challenging; a specific 
synthetic strategy is required since direct penicilloylation of peptides occurs 
mainly on N-terminal amino group (unpublished data). Another major obstacle 
specific to piperacillin is its acid liability. Acid treatment of peptides either during 
chain elongation or during cleavage of the peptides from the support is a 
necessary component of peptide synthesis and such treatment causes 
degradation of piperacillin hapten and a partial degradation due to the acid 
susceptibility of thiazolidine ring. Consequently, provisions are required to avoid 
loss of the piperacillin group during peptide synthesis. We therefore developed a 
method utilizing piperacillin attached to the ε-amino group of lysine to produce a 
peptide containing Lys541 of HSA and the neighbouring amino acids (i.e., 
ATK(piperacillin)EQLK). The procedure utilized specific protecting groups for 
blocking reactive side chain groups in the peptide synthesis, which are readily 
removable under mild conditions without disrupting the piperacillin hapten. The 
synthetic peptide was chemically and physically indistinguishable from its 
endogenous counterpart in terms of retention time, ionization efficiency and 
fragmentation mechanism. Therefore, it was ideal to be used as a standard in 
targeted mass spectrometric quantification of piperacillin HSA binding. 
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4.5.1 CF patients plasma samples (piperacillin tolerant) 
3.9% of Lys 541 in HSA isolated from plasma of patients exposed to piperacillin 
for 14 days was modified with piperacillin hapten. If one assumes that the albumin 
concentration in patient plasma is 40g/L and a typical plasma volume of 
approximately 2.4 litres, one can estimate that approximately 29.3 mg of 
piperacillin binds covalently to this single Lys residue in the average patient. Since 
up to 4 Lys are modified by piperacillin hapten, the overall body burden likely 
exceeds 80mg. The level of Lys541 binding ranged from 2.7-4.7%, indicating that 
there is a 2-fold difference in exposure to piperacillin-HSA adducts in patients 
exposed to the same treatment regimen. The analyses were conducted on three 
separate occasions to confirm that the difference does not originate from sample 
processing/analysis. Somewhat surprisingly, the hydrolyzed form of piperacillin 
hapten was the only moiety bound to HSA in patient plasma, which indicates that 
this form of the hapten almost certainly interacts with T-cell receptors expressed 
on antigen-specific T-cells.   
4.5.2 Piperacillin hypersensitive patients derived T-cells clones 
It is possible that TCCs cultured with free piperacillin are activated by the drug 
hapten bound covalently to protein carriers other than HSA. For this reason, 
synthetic β-lactam HSA adducts were generated to (1) confirm that piperacillin 
HSA adducts act as T-cell antigens (2) assess the relationship between the level 
of hapten binding and the T-cell response and (3) study T-cell reactivity with other 
β-lactam protein adducts. 
Piperacillin HSA adducts were generated with 3.6-23.5% Lys541 modification by 
culturing piperacillin with HSA at ratios of 10:1-250:1. By analysing the adducts 
formed we have found that the percentage of peptide modifications in HSA are 
time and concentration dependent. This may explain the higher prevalence of 
piperacillin hypersensitivity reaction in CF patients since piperacillin is 
administered in high doses and for long durations to combat the more frequent, 
relentless bacterial infections. Such prolonged high doses would trigger the 
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generation of piperacillin-HSA adducts in sufficient levels for developing 
piperacillin hypersensitivity reactions.  
The decision to use the (2mg/mL) of piperacillin-HSA adduct generated using a 
250:1 drug:protein molar ratio for the generation of T-cell lines and for the testing 
of clones was based upon the following: 
1. A previous study showed that this dose was the optimal for activating T-
cells (El-Ghaiesh, 2011). 
2. The dose response curve shows clearly that the conjugate generated at 
250:1 piperacillin:HSA molar ratio has the highest percentage of lysine 
residues modified. Consequently, we assumed that this molar ratio would 
impose the strongest antigenic stimulus and therefore have the greatest 
chance of activating T-cells.  
A panel of CD4+ clones displaying activity against piperacillin HSA adducts 
(responses against unmodified HSA were not observed) were expanded for the 
functional studies discussed below.  
The response of all piperacillin HSA adduct-responsive clones was blocked by 
glutaraldehyde fixation indicating that the clones were activated via a hapten 
mechanism involving the generation of antigenic HSA-derived peptides. 
Furthermore, the response was restricted to the piperacillin hapten structure, as 
other β-lactam HSA adducts did not activate the T-cells. An increase in the level 
of piperacillin modification at Lys541 correlated with the strength of T-cell 
proliferative response (Figure 4.14). 
After we generated free and conjugate specific clones, a range of experiments 
were conducted to explore the concentration and the time required for the 
activation to occur.  In each experiment, we looked at the level of piperacillin-HSA 
binding as a marker for the level of binding that we see in the patients.  
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Free piperacillin clones, in general, are not responsive to HSA conjugates (Figure 
4.8 B).  However, the response of the clones was processing dependent. Thus, 
we assumed that they would respond to some form of protein adduct.  
Thus, in experiments with free piperacillin responsive clones, modified HSA was 
used as a marker for the level of binding in culture after the activation of T-cells. 
The data quantifying piperacillin protein adducts in plasma led us to measure the 
threshold level of HSA modification required to activate T-cells from 
hypersensitive patients. CD4+ TCCs were cultured with antigen presenting cells 
and titrated concentrations of piperacillin to ascertain the lowest drug 
concentration associated with a significant proliferative response. Supernatant 
was removed after 48h to quantify the level of piperacillin hapten HSA binding. 
Piperacillin-modified K541 was detectable at 0.1mM, the lowest concentration 
associated with the activation of T-cells. A dose-dependent increase in the level 
of modification was observed with piperacillin concentrations associated with a 
20-fold increase in the proliferation of T-cells (i.e., 0.5-4mM). Moreover, Lys 541 
binding was detected after only 4h with piperacillin concentrations of (2mM) and 
above. Importantly, equivalent levels of Lys541 modification were detected in 
patient plasma and in vitro with piperacillin concentrations that stimulated a T-cell 
proliferative response.  
To estimate the absolute levels of HSA binding required for triggering T-cells, 
antigen-presenting cells were pulsed with piperacillin (2mM) for 1-48h prior to 
washing and exposure of clones to the pulsed cells. Supernatant was removed to 
quantify piperacillin hapten HSA binding at each time-point. Antigen-presenting 
cells pulsed with piperacillin for 1 and 4h did not stimulate T-cells and this 
coincided with low levels of Lys541 modification. In contrast, antigen presenting 
cells pulsed with piperacillin for 24h stimulated all clones to proliferate and the 
strength of the response was stronger to that seen with the free drug. At this time-
point 2.8% of Lys541 was modified with piperacillin hapten.  
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On the other hand, piperacillin-HSA primed clones were firstly activated with an 
adduct generated at a drug:protein ratio of 10:1 (Figure 4.8 A) ; quantitative mass 
spectrometry revealed that 3.6% of Lys541 was modified with piperacillin hapten. 
Furthermore, from the dose response experiment based calculations (Figure 
4.11) we found that piperacillin-HSA primed clones were activated by as lower as 
(2.87%) of piperacillin modified lysine residues.    
In summary, both the free piperacillin and the piperacillin-HSA primed clones 
would respond to conjugates levels that are equivalent to that seen in patients 
plasma.  
All together, these data imply that piperacillin protein conjugates play a pivotal 
role in piperacillin mediated hypersensitivity reactions.               
Finding a proliferative response to piperacillin-HSA adducts without cross-
reactivity to other β-lactams indicates that: 
1. Penicilloyl core structure is not necessary alone to mediate specific 
antigenic signals to activate T-cells. 
2. The piperacillin-HSA adduct antigenic determinants are highly specific.  
Previous research has compared cross-reactivity of free piperacillin-specific 
TCCs with other β-lactam antibiotics. No cross reactivity was observed between 
free piperacillin and penicillin G and amoxicillin   (El-Ghaiesh et al., 2012) which 
is similar to our current data with β-lactam protein adducts and confirms that the 
penicilloyl core structure is not the only determinant for drug-specific T-cell 
activation. To elaborate more, the previous study investigated the fine specificity 
of free piperacillin-specific responses using cefoperazone (3rd generation 
cephalosporin), which contains side chain closely related to piperacillin (Figure 
4.23). The thiazolidine ring (of piperacillin) is replaced with 6 membered 
(dihydrothiazine) ring (for cefoperazone). Once more, there was no proliferative 
response to cefoperazone as compared with that of free piperacillin.  
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In summary, neither the penicilloyl core structure nor the side chains alone play 
an important role in mediating piperacillin specific responses. The missing ring in 
this conundrum is the specific piperacillin modified peptides which confer free 
piperacillin specific responses as shown in our experiment of cross-reactivity.   
By comparing free piperacillin-specific clones to clones responsive (primed) 
against other β-lactam antibiotics such as flucloxacillin, we see a different cross-
reactivity profile. Free flucloxacillin-specific clones are highly cross reactive.           
T-cell proliferative responses are also detected with piperacillin, amoxicillin, and 
penicillin G (Monshi et al 2013). Since the core β-lactams ring structure is the 
same in all the antibiotics, the study suggests that both the core penicilloyl 
structure and the MHC binding peptides provide the required energy to drive T-
cell responses (Figure 4.23).   
Another example of a drug hapten is SMX. SMX is an inactive drug (unable to 
form haptens) which undergoes metabolism to form SMX-NO, which forms 
conjugates with multiple cellular proteins and HSA. However, instead of modifying 
lysine residues it modifies cysteine and cysteine modified proteins have been 
shown tom activate T-cells.         
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Analysis of the clones using FACS technique showed a predominance of CD4+, 
which is consistent with that of free piperacillin responsive clones in the previous 
chapter.  
FACS analysis also revealed that the clones show a restricted pattern of TCR-Vβ 
expression that is dominated by TCR-Vβ 9. This picture differs from that of the 
free piperacillin clones (previous chapter) which have shown that TCR-Vβ 
expression was diverse. This discrepancy may reflect different antigenic 
determinants, which are presented by APCs to meditate piperacillin specific 
activation of T-cells. However, comparing these results with that of DC-T-cell 
priming (bulks) of naïve healthy volunteers with free piperacillin (previous chapter) 
we can notice a striking similarity in terms of high expression of TCR-Vβ 9, which 
may propose a similar mechanism of T-cell activation and similar antigenic 
determinant. Chemokines expression profile is nearly identical to that expressed 
by the clones of free piperacillin (see previous chapter), however; differences in 
terms of SIs were noted. This profile can provide information on T cell subset i.e. 
these cells are a mixture of Th1 and Th2 cells.  
 
Figure 4.23: Chemical structures of selected β-lactams (Piperacillin, flucloxacillin, 
amoxicillin, penicillin-G) and cefoperazone. 
Conjugated Piperacillin Chapter 4  
 
 
 
229 
 
The results of DC-T-cell priming to piperacillin-HSA conjugates show that the 
priming was unsuccessful. Further work is required to determine the reason for 
these negative results.  
Collectively, our data reveal that the level of drug hapten protein binding in 
patients exposed to a therapeutic treatment regimen is sufficient to activate T-
cells. Thus, it is interesting to speculate why most patients do not develop a drug 
antigen-specific T-cell response and clinical manifestations of hypersensitivity. It 
is possible that the covalent modification of protein per se is not sufficient to 
activate naïve T-cells. The consequence of adduct formation might be determined 
by multiple factors including co-stimulatory/inhibitory signalling and genetic 
factors such as HLA. The interplay between the previous factors altogether 
determines the net result of the piperacillin mediated immune response. 
To further investigate the relationship between adduct formation and the allergic 
phenotype we have recently initiated a prospective investigation of piperacillin 
hypersensitivity. Bloods samples are being collected during repeated drug 
courses and when patients develop an adverse event to define the quantitative 
relationship between antigen formation and the clinical consequence of drug 
exposure.  
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5 Characterization of the specificity and functionality of 
telaprevir specific T-cells isolated from naïve healthy 
volunteers 
Telaprevir is the first antiviral protease inhibitor drug for the treatment of hepatitis 
C. However, its use was associated with high incidence of drug hypersensitivity 
reactions which were of obscure mechanism. Thus, we believed it was important 
to investigate why this drug is associated with such high incidence of frequently 
severe drug hypersensitivity reactions? Furthermore, telaprevir mediated drug 
hypersensitivity can be implemented as a model for other compounds in the same 
chemical class, i.e. protease inhibitors (e.g. boceprevir and semiprevir). We have 
chosen to investigate the metabolite VRT-127394 since it is a major metabolite 
and present in the blood of patients.  
The best approach to explore such reactions is by investigating these reactions 
in telaprevir hypersensitive patients derived cells. However, we couldn’t find such 
patient to recruit. Thus, we decided to work on naïve healthy volunteers derived 
T-cells. 
We have addressed the following questions: 
1. Is it possible to generate telaprevir & VRT-127394 metabolite-responsive 
TCCs from PBMCs of healthy naive volunteers? 
2. What is the phenotype of these clones (proliferation, cytokines secretion, 
TCR-Vβ and chemokine expression)? 
3. Is there is a cross reactivity between telaprevir and VRT-127394 
metabolite?  
4. What is the possible mechanism of activation of these clones? 
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5.1 Aim of Study 
To identify telaprevir and/or telaprevir metabolite (VRT-127394) responsive T-
cells in blood of healthy naive donors and characterize their phenotype and 
function.   
5.2 Materials & methods 
Using PBMCs from naïve healthy volunteers, we tried to generate T-cells 
responsive against telaprevir and the metabolite VRT-127394 by implementing: 
Magnetic bead separation followed by DC-T-cell priming ( 
Figure 5.1). PBMCs priming by incubation with the drugs for 14 days followed 
by T-cell cloning using serial dilution (Figure 5.2). 
After implementing these two methods, a battery of assays to characterize the 
drug-responsive TCCs were used as mentioned in Figure 5.1 and Figure 5.2. 
 
 
Figure 5.1: Methods implemented for the preparation and testing of telaprevir and VRT-
127394 metabolite-specific T-cells from PBMCs of naïve healthy volunteers using the 
DC-T-cell priming technique. 
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Note: Whenever the term telaprevir-m is mentioned in the results or discussion 
of this chapter, it denotes telaprevir metabolite VRT-127394 unless mentioned 
otherwise. 
 
 
 
 
 
 
 
Figure 5.2: Methods implemented for the preparation and testing of telaprevir and VRT-
127394 metabolite specific TCCs from PBMCs of naïve healthy volunteers by incubating 
PBMCs with the drugs. 
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5.3 Results 
5.3.1 Choosing the volunteers 
Three healthy drug-naïve volunteers were recruited in this study and their basic 
demographics are shown in Table 5.1.       
5.3.2 Identifying the drugs optimal dose for priming and T-cell 
assays (Toxicity assay) 
PBMCs from one volunteer (V2) were incubated with serially diluted doses of 
telaprevir and telaprevir-m in the presence or absence of PHA (5µg/mL) for 24 hrs 
and 3H-thymidine was added in the last 16 hrs followed by harvesting and reading 
using beta counter. Fifty micromolar telaprevir and the telaprevir-m completely 
inhibited PHA-driven PBMCs proliferation (Figure 5.3). Thus, it was decided to 
use two concentrations, i.e. (20 µM) & (5 µM) for the generation of telaprevir and 
telaprevir-m specific T-cells. 
Table 5.1: The healthy naïve donors demographics. Three healthy naïve volunteers were 
enrolled in this study to generate telaprevir and telaprevir-m specific T-cells using DCs-T-cell 
priming technique. 
Donor ID Age Sex 
History of 
allergies 
Medical 
history 
V1 42 male Nil Not relevant 
V2 37 male Nil Not relevant 
V3 35 male Nil Not relevant 
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5.3.3 Generation of telaprevir & telaprevir-m specific T-cells from 
healthy naïve volunteers using the DC-T-cell priming 
technique 
Using the DC-T-cell priming technique naive T-cells were exposed to autologous 
dendritic cells and either telaprevir or telaprevir-m (20 µM & 5 µM). In the same 
experiments, SMX-NO was used as an irrelevant drug antigen. After 8 days, T-
cells were tested for their drug-specificity using 3H-thymidine uptake proliferation 
and IFN-γ ELISPOT assays. 
  Quantitative and qualitative measurement of the 
telaprevir and telaprevir-m T-cell response using 3H-
thymidine uptake assay 
Telaprevir-specific T-cell proliferative responses were not observed when the 
telaprevir-primed T-cells were restimulated with dendritic cells and the relevant 
drug antigen. The SI was consistently lower than 1.5. (Figure 5.4).  SMX-NO was 
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Figure 5.3: Toxicity assay for (A) telaprevir and (B) telaprevir-m. 100000 PBMCs/well were 
incubated in triplicate in 96 well plates with serially diluted doses of telaprevir and telaprevir-m 
in the presence of PHA (5µg/mL) for 24 hrs. In the last 16 hrs (0.5µ Ci)/well 3H-thymidine was 
added that was followed by harvesting and reading the plate by beta counter. Error bars 
represent standard deviation. (cpm) represents count per minute (radiation unit). 
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included as an irrelevant drug antigen and again the telaprevir primed T-cells were 
not stimulated to proliferate.   
A similar pattern was observed with the telaprevir-m primed T-cells. Restimulation 
of the primed T-cells with telaprevir-m generally yielded SIs less than 1.5. 
However, a small increase in proliferation was observed with donor 3 at one drug 
concentration (Figure 5.5). For both sets of experiments there was no statistical 
significant response (as analyzed by Kruskal-Wallis test at p<0.05 significance 
level).  
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Figure 5.4: 3H-thymidine uptake proliferation assay for telaprevir bulks at (A) (20 µM) & 
(B) (5 µM) doses. T-cells were incubated with autologous DCs and serially diluted doses of 
telaprevir and (50 µM) or SMX-NO for 72 hr. 3H-thymidine was added in last 16 hrs that was 
followed by harvesting and reading using beta counter.  Error bars represent standard 
deviation. (SI) represents stimulation index. 
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In contrast to telaprevir and telaprevir-m, SMX-NO successfully primed the naïve 
T-cells. Restimulation of the primed T-cells with SMX-NO resulted in a dose-
dependent proliferative response in all three donors (Figure 5.6). Moreover, there 
was no cross reactivity with telaprevir or telaprevir-m.  
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Figure 5.5: 3H-thymidine uptake proliferation assay for telaprevir-m bulks with telaprevir-
m at (A) (20 µM) & (B) (5 µM) doses. T-cells were incubated with autologous DCs and serially 
diluted doses of telaprevir-m and (50 µM) SMX-NO for 72 hr. 3H-thymidine was added in last 
16 hrs that is followed by harvesting and reading using beta counter. Error bars represent 
standard deviation. (SI) represents stimulation index.  
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Figure 5.6: 3H-thymidine uptake proliferation assay for SMX-NO bulks. T-cells were 
incubated with autologous DCs and serially diluted doses of SMX-NO and (20 µM) telaprevir-
m for V1 and (20 µM) telaprevir for V2 and V3 and for 72 hr. 3H-thymidine was added in last 16 
hrs. This was followed by harvesting and reading using beta counter.  Error bars represent 
standard deviation. (SI) represents stimulation index. 
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  Quantitative and qualitative measurement of IFN-γ 
secretion of the bulks by ELISPOT 
IFN-γ secretion from telaprevir, telaprevir-m and SMX-NO primed cells was 
measured using ELISPOT technique. In each experiment, the primed T-cells were 
restimulated with the relevant or irrelevant drug antigen prior to assessment of 
IFN- release. IFN- release from the telaprevir-primed T-cells was not detected 
(Figure 5.7). Similar results were obtained with T-cells primed against telaprevir-
m (i.e. telaprevir-m-specific IFN- release was generally not detected (Figure 5.8). 
A small increase in IFN- release was seen with donor 2 at both telaprevir-m 
priming concentrations; however, at lower priming concentration the level of 
cytokine released was the same as that seen with the irrelevant antigen SMX-NO.          
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Figure 5.7: IFN-γ secretion from bulks primed with telaprevir at (A) (20 µM) & (B) (5 µM). 
T-cells were incubated with autologous DCs and serially diluted doses of telaprevir and SMX-
NO for 48 hrs on a ELISPOT plate coated with IFN-γ antibody, followed by harvesting and 
reading using ELISPOT counter. Error bars represent standard deviation. (SFU) represents 
spot forming unit i.e cytokine secreting cell. 
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In contrast, restimulation of SMX-NO-primed T-cells with SMX-NO resulted in the 
dose-dependent release of IFN-. No cross reactivity was observed with telaprevir 
or telaprevir-m (Figure 5.9).  
0
M
 T
el
-m

5 
M
 T
el
-m

10
 
M
 T
el
-m

20
 M
 S
M
X
-N
O

50
 
0
M
 T
el
-m

5 
M
 T
el
-m

10
 
M
 T
el
-m

20
 M
 S
M
X
-N
O

50
 
0
M
 T
el
-m

5 
M
 T
el
-m

10
 
M
 T
el
-m

20
 M
 S
M
X
-N
O

50
 
0
100
200
300
400
500
600
V1
V2
V3
C
y
to
k
in
e
 s
e
c
re
ti
o
n
 (
S
F
U
)
 
0
M
 T
el
-m

5 
M
 T
el
-m

10
 
M
 T
el
-m

20
 M
 S
M
X
-N
O

50
 
0
M
 T
el
-m

5 
M
 T
el
-m

10
 
M
 T
el
-m

20
 M
 S
M
X
-N
O

50
 
0
M
 T
el
-m

5 
M
 T
el
-m

10
 
M
 T
el
-m

20
 M
 S
M
X
-N
O

50
 
0
100
200
300
400
500
600
V1
V2
V3
C
y
to
k
in
e
 s
e
c
re
ti
o
n
 (
S
F
U
)
 
Figure 5.8: IFN-γ secretion of bulks with telaprevir-m at (A) (20 µM) & (B) (5 µM) doses 
for three naïve healthy volunteers. T-cells were incubated with autologous DCs and serially 
diluted doses of telaprevir-m and (50 µM) SMX-NO for 48 hrs on ELISPOT plate coated with 
antibody for IFN-γ, followed by harvesting and reading using ELISPOT counter. Error bars 
represent standard deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
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  Generation of telaprevir-m specific clones from PBMCs 
bulks 
TCCs were generated from bulks of volunteer V1 using the serial dilution 
technique. 192 well growing clones were expanded. However, none of these 
clones were stimulated to proliferate in the presence of telaprevir or telaprevir-m.   
5.3.4 Generation Telaprevir & telaprevir-m specific T-cells from 
healthy naïve volunteers using PBMCs priming technique 
Three drug-naïve healthy volunteers were recruited, formally consented. Their 
basic demographics are summarized in Table 3.4 
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Figure 5.9:  IFN-γ secretion of (50 µM) SMX-NO bulks from three naïve healthy 
volunteers. T-cells were incubated with autologous DCs and serially diluted doses of SMX-
NO, (20 µM) telaprevir and (20 µM) telaprevir-m for 48 hrs on ELISPOT plate coated with IFN-
γ antibody followed by harvesting and reading using ELISPOT counter. Error bars represent 
standard deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
Table 5.2: The volunteers’ demographics. Three naive healthy volunteers were enrolled in 
this study to generate telaprevir and telaprevir-m specific T-cells using PBMCs priming 
technique. 
Donor ID Age Sex History of allergies Medical history 
V4 35 female Nil Not relevant 
V5 24 female +ve for penicillin Not relevant 
V6 36 Male Nil Not relevant 
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 Quantitative and qualitative measurement of the 
telaprevir, telaprevir-m bulks reactivity using 3H-
thymidine uptake assay 
PBMCs from three volunteers were incubated with telaprevir (20 µM), telaprevir-
m (20 µM) and SMX-NO (50 µM) for different time intervals. After 2-3 weeks, T-
cells assays (3H-thymidine uptake proliferation assay and IFN-γ ELISPOT) were 
carried out to test for antigen specificity. T-cell lines were then restimulated every 
2-4 weeks with irradiated autologous PBMCs and the relevant drug antigen. The 
timing of testing is shown in Table 5.3.  
The proliferative response of T-cells stimulated with the drugs for each volunteer 
bulks are shown in Figure 5.10, Figure 5.11 and Figure 5.11.  In general, 
telaprevir and telaprevir-m did not stimulate cells to proliferate. SIs were lower 
Table 5.3: Timing of 3H-thymidine uptake proliferation assay and IFN-γ ELISPOT 
performed on bulks of the three volunteers. PBMCs were counted to make up (4-6x106 
cells/mL) in medium. Then, aliquoted into 24-well plate as (1mL/well) to make three wells. 
Telaprevir, telaprevir-m and SMX-NO were added (1mL/well) to make the final concentration 
of the drugs as follows (20 µM telaprevir), (20 µM telaprevir-m) and (50 µM SMX-NO). The 
plate was cultured at 37°C and 5% CO2 for 5 days. From day 5, the wells were fed by 
withdrawing (600µL) and adding (660µL) of medium containing (2µL/mL) IL-2 every 2-3 days. 
T-cells assays responses were carried out at the dates of highlighted boxes in the table below 
which include 3H-thymidine proliferation assay & IFN-γ ELISPOT secretion. Highlighted 
squares refer to dates of both (proliferation & ELISPOT) as follows: (orange): telaprevir, (red): 
telaprevir-m and (black): SMX-NO. 
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than 1.5 with no clear dose-dependency observed. In contrast, SMX-NO 
stimulated a stronger dose-dependent proliferative response when compared with 
telaprevir and telaprevir-m primed T-cells; however, the SIs were lower than 1.5.   
There was no statistical significance as measured by Kruskal-Wallis test at p<0.05 
significance level in all tests.  
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Figure 5.10: 3H-thymidine uptake proliferation assay for the V4 volunteer’s bulks primed 
with (A) telaprevir, (B) telaprevir-m and (C) SMX-NO. Naïve T-cells from the volunteer were 
primed by incubation with drugs mentioned above. The primed T-cells were then tested by 3H-
thymidine uptake proliferation assay by incubating PBMCs with autologous irradiated EBV-
transformed B-cells and serially diluted doses the drugs for 48 hrs. Radioactive thymidine was 
added for the last 16 hrs followed by harvesting and reading using a beta counter.  Error bars 
represent standard deviation. (SI) represents stimulation index. 
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Figure 5.11: 3H-thymidine uptake proliferation assay for the V5 volunteer’s bulks primed 
with (A) telaprevir, (B) telaprevir-m and (C) SMX-NO. Volunteer derived PBMCs were primed 
by incubation with drugs mentioned above. Then, tested by 3H-thymidine uptake proliferation 
assay by incubating PBMCs with autologous irradiated EBV-transformed B-cells with serially 
diluted doses of drugs for 48 hrs. Radioactive thymidine was added at last 16 hrs followed by 
harvesting and reading by beta counter.  Error bars represent standard deviation. (SI) represents 
stimulation index. 
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Figure 5.12: 3H-thymidine uptake proliferation assay for the V6 volunteer’s bulks primed 
with (A) telaprevir, (B) telaprevir-m and (C) SMX-NO. Volunteer derived PBMCs were primed 
by incubation with drugs mentioned above. Then, tested by 3H-thymidine uptake proliferation 
assay by incubating PBMCs with autologous irradiated EBV-transformed B-cells with serially 
diluted doses of drugs for 48 hrs. Radioactive thymidine was added at last 16 hrs followed by 
harvesting and reading by beta counter. Error bars represent standard deviation. (SI) represents 
stimulation index. 
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  Quantitative and qualitative measurement of IFN-γ 
secretion from telaprevir and telaprevir-m-primed naïve 
T-cells 
Naive T-cells primed against telaprevir, telaprevir-m and SMX-NO were tested for 
IFN-γ secretion using ELISPOT following restimulation with dendritic cells and 
relevant or irrelevant drug antigen. 
IFN-γ ELISPOT results for the three volunteers are shown in Figure 5.13, Figure 
5.14 and Figure 5.15. Similar to the proliferation results, telaprevir and telaprevir-
m are negative with SIs lower than 1.5 with no clear dose dependent response. 
For SMX-NO the picture shows stronger sensitivity in terms of SIs and dose 
response. In which there are higher SIs (≥1.5) for all volunteers. 
In general, all the results were not significant as analyzed by Kruskal-Wallis test 
at p:<0.05 significance level. 
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Figure 5.13: IFN-γ ELISPOT for the V4 volunteer’s primed bulks with (A) telaprevir, (B) 
telaprevir-m and (C) SMX-NO. Volunteer’s derived PBMCs were primed by incubation with 
drugs mentioned above for two weeks. Then, tested for IFN-γ secretion by ELISPOT technique 
by incubating PBMCs with autologous irradiated EBV-transformed B-cells with serially diluted 
doses the drugs for 48 hrs on a coated ELISPOT plate with IFN-γ antibody followed by 
harvesting and development and reading by ELISPOT counter. Error bars represent standard 
deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
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Figure 5.14: IFN-γ ELISPOT for the V5 volunteer’s bulks with (A) telaprevir, (B) telaprevir-
m and (C) SMX-NO. Volunteer’s derived PBMCs were primed by incubation with drugs 
mentioned above for two weeks. Then, tested for IFN-γ secretion by ELISPOT technique by 
incubating PBMCs with autologous irradiated EBV-transformed B-cells with serially diluted 
doses of the drugs for 48 hrs on a coated ELISPOT plate with IFN-γ antibody followed by 
harvesting, development, and reading by ELISPOT counter.  Error bars represent standard 
deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
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Figure 5.15: IFN-γ ELISPOT for the V6 volunteer’s primed bulks with (A) telaprevir, (B) 
telaprevir-m and (C) SMX-NO. Volunteer’s derived PBMCs were primed by incubation with 
drugs mentioned above for two weeks. Then, tested for IFN-γ secretion by ELISPOT 
technique by incubating PBMCs with autologous irradiated EBV-transformed B-cells with 
serially diluted doses of the drugs for 48 hrs on a coated ELISPOT plate with IFN-γ antibody 
followed by harvesting, development, and reading by ELISPOT counter.  Error bars represent 
standard deviation. (SFU) represents spot forming unit i.e cytokine secreting cell. 
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  Generation of telaprevir and telaprevir-m specific clones 
from telaprevir and telaprevir-m treated PBMCs  
Clones were generated from telaprevir and telaprevir-m treated PBMCs from all 
3 volunteers using serial dilution. Clones were then tested for telaprevir or 
telaprevir-m specificity using a 3H-thymidine uptake proliferation assay.  
Clones responsive to telaprevir and telaprevir-m were not generated with the 
exception of one patient. Twenty telaprevir-m reactive clones (out of 232 clones 
tested) were generated from volunteer V5 (Figure 5.16). SI≥ 2 were regarded as 
positive. 
 
0
10
20
30
40
Clone no (1-232)
2
 P
ro
lif
er
at
io
n 
(S
I)
 
Figure 5.16: Proliferation assay for TCCs generated from telaprevir-m treated PBMCs 
from V5 volunteer. PBMCs were cultured with telaprevir-m (20 µM) for two weeks prior to 
serial dilution. Clones were tested for telaprevir-m specificity by 3H-thymidine uptake 
proliferation assay by incubating T-cells with autologous irradiated EBV-transformed B-cells 
with in two conditions 0 and telaprevir-m (20 µM) for 48 hrs. Radioactive thymidine was added 
for the last 16 hrs followed by harvesting and reading using a beta counter. SIs≥ 2 were 
regarded as positive (as shown by the dotted line). 
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  Measurement of the crossreactivity of telaprevir-m 
responsive clones using 3H-thymidine uptake 
proliferation assay 
The 20 telaprevir-m responsive clones were tested using 3H-thymidine uptake 
proliferation assay with serially diluted doses of telaprevir, telaprevir-m and SMX-
NO (50 µM) as an irrelevant antigen. Fifteen clones proliferated in a dose-
dependent manner in the presence of telaprevir-m. 100% cross reactivity was 
observed between telaprevir and telaprevir-m. The strength of the response 
initiated with both compounds was identical. Crossreactivity between these drugs 
and SMX-NO was not observed (Figure 5.17). Statistical significance was 
observed when all concentrations of telaprevir and telaprevir-m were compared 
with the vehicle control (analyzed Kruskal-Wallis test at p≤0.05 significance level).  
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Figure 5.17: (A) 3H-thymidine uptake proliferation on serially diluted doses of telaprevir 
and telaprevir-m showing 20 clones individually from V5 volunteer. (B) The mean 
proliferative response of 15 selected reactive clones. T-cells were incubated with autologous 
irradiated EBV-transformed B-cells with serially diluted doses of telaprevir and telaprevir-m for 
48 hrs. Radioactive thymidine was added at last 16 hrs followed by harvesting and reading by 
beta counter. Proliferation was determined by radioactive thymidine incorporation. Statistical 
analysis using Kruskal-Wallis test reveal high statistical significance ** and *** signifying p<0.01 
and p<0.001 respectively. Error bars represent standard deviation. (cpm) represents the count 
per minute (i.e. radiation unit). 
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  APCs pulsing assay 
Two clones were tested for their sensitivity to telaprevir-m in the presence of 
telaprevir-m pulsed autologous irradiated EBV-transformed B-cells (Figure 5.18).          
Clones (42 and 124) were not stimulated to proliferate when exposed APCs 
pulsed with telaprevir-m for 1 or 16 hrs. Soluble telaprevir-m was used as a 
positive control. Both clones proliferated vigorously with soluble drugs (SI=10.02, 
SI=14.57 respectively).   
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Figure 5.18: APCs pulsing assay. APCs (irradiated autologous EBV-transformed B-cells) 
were incubated with telaprevir-m (20 µM) in a 24 well plate for 1 or 16 hrs. APCs were then 
harvested, washed twice, irradiated and incubated with T-cells in the 96- well test plate. Wells 
with unpulsed irradiated APCs, T-cells, with and without telaprevir-m (20 µM) were included in 
the test plate as negative and positive controls, respectively.  After 48 hrs radioactive thymidine 
was added (for 16 hrs). Subsequently cells were harvested and incorporated radioactivity 
counted using a beta counter. 
 
 
Telaprevir & Metabolite  Chapter 5 
 
 
 
253 
 
  Qualitative and quantitative measurement of telaprevir-
m clones in terms of sensitivity and specificity (cross 
reactivity) using IFN-γ ELISPOT technique 
The 15 clones that proved to be sensitive in the proliferation assay were tested 
for IFN-γ secretion using the ELISPOT technique.  
Many clones secreted IFN-γ in response to telaprevir and telaprevir-m in a dose-
dependent manner (Figure 5.19). A high degree of cross reactivity was observed 
between telaprevir and telaprevir-m. However, due to the variation between 
clones, no statistical significance was observed when the combined data was 
analyzed using Kruskal-Wallis test. 
Detailed analysis of 7 clones showed that 2 clones (132, 124) secreted IFN- in 
response to telaprevir-m alone, while the other 5 clones responded in the 
presence of both telaprevir and telaprevir-m to various extents (Figure 5.20). 
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Figure 5.19: IFN-γ ELISPOT for 15 telaprevir-m responsive clones when challenged with 
serially diluted doses of telaprevir and telaprevir-m. T-cells were incubated with irradiated 
autologous EBV-transformed B-cells with serially diluted doses of the drugs on an ELISPOT 
coated with an IFN-γ antibody for 48 hrs followed by development and reading by ELISPOT 
counter. Error bars represent standard deviation. SFU represents spot forming unit (cytokine 
secreting cell). 
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  Measurement of T-cell receptor expression using the 
Fluorescence-activated cell sorting (FACS) 
 CD4/CD8 phenotype, CD45RO expression (memory phenotype) 
Thirteen telaprevir sensitive clones were analyzed using flow cytometry for their 
CD4/CD8 phenotype and CD45RO expression (memory phenotype). 
10 clones were shown to be CD4+ (76.9%) while 3 clones were CD8+ (23%) 
(Figure 5.21). All clones were CD45RO+, i.e., memory T-cells.  
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Figure 5.20: IFN-γ secretion ELISPOT of 7 representative clones. T-cells were incubated 
with autologous irradiated EBV-transformed B-cells with serially diluted doses of the drugs for 
48 hrs on an ELISPOT plate coated with IFN-γ antibody followed by development and reading 
by spot counter. The dashed line shows the SI threshold =2 to identify the sensitive clones. 
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 TCR-Vβ expression 
Thirteen telaprevir sensitive clones were analyzed for TCR-Vβ expression using 
flow cytometry. The analysis showed a restricted pattern of TCR-Vβ in which there 
was a high expression of TCR-Vβ 22 (n=6, 46%), TCR-Vβ 2 (n=5, 38%) and TCR-
Vβ 5.1 (n=1, 8%). One clones did not express any TCR-Vβ in the antibody panel 
(Figure 5.22).     
           
 
 
Figure 5.21: CD4/CD8 analysis by FACS for 13 telaprevir sensitive clones. (50 µL) T-cells 
suspension was stained with (3 µL) of CD3, CD4, CD8 and kept on ice (at 4C˚) for (20 min) in 
FACS tubes. Then, FACS buffer was added followed by centrifugation. Cells were resuspended 
in FACS buffer (200 µL). Then, analyzed using flow cytometry. 
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Figure 5.22:  TCR-Vβ expression of 13 TCCs using FACS method. (50 µL) T-cells 
suspension were stained with (5 µL) fluorochrome antibodies for TCR-Vβ and kept at room 
temperature for (20 min) in FACS tubes. Then, (500 µL/tube) FACS buffer was added followed 
by centrifugation. Then, cells were resuspended in (200 µL) FACS buffer.  Finally, the cells 
were analyzed using FACS machine. 
 
  Characterization of chemokine receptors and CD69 
expression on telaprevir-m responsive T-cells clones: 
Fifteen telaprevir-m responsive clones were tested for their expression of 
chemokine receptors and CD69 using flow cytometry.  
High expression of the following chemokine receptors was observed (all data 
presented in terms of MFI): CCR4 3.40±1.04, CXCR3 3.16±1.52, CXCR6 
2.25±0.41 and CCR9 2.06±0.31. CD69 expression was 1.7±0.8 (Figure 5.23). 
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Figure 5.23: Chemokine receptor expression and CD69 analysis using flow cytometry 
for 15 telaprevir clones. (A) Graph showing the chemokine receptor expression in 
ascending order and CD69. (B) Values for chemokine receptor analysis and CD69 
expression.   T-cells suspension (50 µL) were stained with fluorochrome antibodies (3 µL) for 
the above-mentioned chemokines and CD69 and kept at 4º for 20 min in FACS tubes. Then, 
FACS buffer (500 µL/tube) was added. Cells were then resuspended in FACS buffer (200 µL) 
and analyzed by flow cytometry. Error bars represent standard deviation. 
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5.4 Discussion 
Telaprevir hypersensitivity was identified relatively soon after widespread 
administration of the drug. Reactions have a delayed onset and are observed at 
a therapeutic dose of the drug, which both indicate that the adaptive immune 
system may be involved in the disease pathogenesis. A high incidence of mild 
skin reactions is observed in patients exposed to traditional treatments for 
hepatitis C (i.e. pegylated interferon-α and ribavirin); however, the frequency of 
reactions is increased when telaprevir is administered. Furthermore, a small 
number of patients develop severe reactions such as Stevens Johnson syndrome 
and toxic epidermal necrolysis. Since pharmacogenetic studies failed to identify 
an association between expression of a specific HLA alleles and development of 
mild or severe reactions, the objective of this chapter was to investigate if it was 
possible to identify telaprevir-responsive T-cells in healthy drug-naïve donors. 
Since telaprevir readily converts to its isomer in patients, T-cell responses against 
telaprevir and this primary metabolite were studied.    
The first problem that we faced was to identify the optimal dose for priming and 
testing T-cells with telaprevir and telaprevir-m. Thus, we carried out a toxicity 
assay which revealed that both drugs inhibited mitogen-driven T-cell proliferation 
at the same concentration (i.e. 50 µM). Thus, we chose two doses (20 µM, 5 µM) 
for priming T-cells against both telaprevir and telaprevir-m and to monitor the 
response using proliferation and cytokine release as markers of T-cell activation. 
For the purpose of comparison with the clinical data, a study on Japanese HCV 
patients have shown that the mean Cmax for telaprevir was (5.4 µM) at a steady 
state (Yamada et al., 2012). For the unbound fraction, the Cmax was approximately 
(2 µM) (Kwong et al., 2011). Telaprevir-m maximal plasma concentrations at the 
steady state were found to be almost equivalent to those of telaprevir (Nakada et 
al., 2014). Thus, the lower concentration used in T-cell assays was similar to that 
circulating in patient plasma. 
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Two approaches have been described in the literature to detect drug-specific T-
cells in healthy naïve donors and these are summarized below.  
 Drug-stimulation of pre-activated memory T-cells (Engler et al., 2004): 
Peripheral blood lymphocytes undergo several rounds of antigen-driven 
stimulation using peripheral blood mononuclear cells as antigen presenting 
cells. The aim of this protocol is to expand the number of antigen-responsive 
T-cells prior to analysis of antigen-specificity.      
 Drug stimulation of naive T-cells (Faulkner et al., 2012): This assay relies 
on the isolation and culture of highly pure T-cell and antigen presenting cell 
populations. Immature monocyte-derived dendritic cells and naive T-cells are 
used as antigen presenting cells and responder cells, respectively. After 8-day 
culture period, T-cells are re-exposed to the drug antigen and dendritic cells 
and antigen specificity is measured shortly after. 
 
Both assays were used to detect telaprevir and telaprevir-m responsive T-cells.  
The proliferation assay is widely used since it is highly applicable with many 
different drugs in different immune reactions that are mediated by drug specific T-
cells. In addition, with high sensitivity (approximately 76%) and specificity (95%) 
it can be used to measure the priming of T-cells in both quantitative and qualitative 
ways (Pichler, 2014). On the other hand, IFN-γ ELISPOT is highly sensitive assay 
that can detect 10-1000 SFU per million PBMCs. Moreover, IFN-γ ELISPOT is 
especially important in measuring Tc1 (cytotoxic) and Th1 (helper) responses 
(Smith et al., 2001). Thus, two assays were used following T-cell priming to detect 
T-cell responses after the primed cells were restimulated with autologous antigen 
presenting cells (PBMCs) and the relevant drug antigen. 
PBMCs from hypersensitive patients are expected to contain drug-specific T-cells 
as sensitization occurs at the time of drug exposure and just prior to the 
hypersensitivity reaction. In contrast, PBMCs from drug-naïve healthy volunteers 
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should not be activated with the drug and this is indeed the case. PBMCs from 
healthy volunteers are not activated to at least 10 drugs antigens commonly used 
in Liverpool. Moreover, factors like a specific HLA allele or TCR-Vβ profile might 
make the T-cells from hypersensitive patients more sensitive to the culprit drug.  
We have noticed from the previous two chapters that patients derived PBMCs 
were more productive in terms of the number of clones generated as compared 
with naïve healthy volunteers.    
Thus, blood samples were collected from three telaprevir-naïve healthy 
volunteers. PBMCs were separated and then naïve T-cells primed using the 
established DC-T-cell priming assay. Despite multiple attempts, telaprevir- and 
telaprevir-m-responsive T-cells were not detected in proliferation or ELISPOT 
assays. Furthermore, TCCs were generated from telaprevir-treated T-cells; 
however, none of the clones were stimulated to proliferate with telaprevir or 
telaprevir-m.    
SMX-NO a well-established drug antigen was used as an irrelevant drug antigen 
with cells from each volunteer. In agreement with data presented in chapter 3, 
naive T-cells were activated with SMX-NO. Restimulation of the primed T-cells 
resulted in a dose-dependent proliferative response and the release of IFN-. 
Moreover, it is obvious that there was no cross reactivity between SMX-NO and 
telaprevir or telaprevir-m. 
The reason behind non-productivity of DC-T-cell priming could be attributed to the 
volunteer selection. Volunteers vary in their criteria regarding HLA, TCR-Vβ, age, 
sex and many other parameters that were discussed in the previous chapters. 
Thus, T-cell responses might have been detected if an increased number of 
volunteers were studied. However, it is also possible that telaprevir does not 
activate naïve T-cells. As what has been shown with abacavir recently, the drug 
might interact with HLA molecules expressed on antigen presenting cells to 
stimulate pre-existing memory T-cells. For this reason, we also utilized the second 
culture method outlined above, which uses PBMCs and not purified naïve T-cells.  
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PBMCs were cultured with telaprevir, telaprevir-M and SMX-NO for several 
weeks. At various time-points the T-cell lines were tested for their drug-specificity 
using proliferation and IFN-γ secretion as readouts over several variable dates for 
the purpose of optimising the assay with the final target to get the highest yield in 
terms of sensitivity and specificity of the bulks for telaprevir or telaprevir-m.      
For the volunteers 4 and 5 there was no SMX-NO cultures at the start of the 
priming because there were not enough cells to prepare all the priming sets for 
these volunteers. However, following a second blood donation, SMX-NO-specific 
T-cell lines were established. Similar to the data discussed above, we were 
generally unsuccessful at generating telaprevir and telaprevir-m-responsive T-cell 
lines.  
However, lines generated from V5 and V6 showed very weak T-cell responses to 
telaprevir. Thus, we attempted to generate telaprevir and telaprevir-m sensitive 
clones from for the T-cell lines of all volunteers V4, V5 and V6 using the serial 
dilution technique.  
Twenty CD4+ and CD8+ clones out of 232 clones generated were stimulated to 
proliferate with telaprevir-m.  Clones displayed 100% cross-reactivity with 
telaprevir and drug stimulation was also associated with the secretion of IFN-. 
Telaprevir-m-pulsed antigen presenting cells did not activate the clones; thus, the 
drug likely binds directly to MHC molecules expressed on the surface of antigen 
presenting cells to activate the cells via a p-i mechanism. Clones expressed 
different T-cell receptor Vβ, which indicates that they do not originate from a 
common precursor. Finally, the clones were not activated with the structurally 
irrelevant antigen SMX-NO.    
A marked expression of the following chemokine receptors was found on the 
clones: CCR4, CXCR3, CXCR6 and CCR9. CCR4 and CXCR3 are skin homing 
receptors (Restifo et al., 2013). This would provide an explanation for the patho-
mechanism underlying skin reactions in telaprevir hypersensitivity. Telaprevir 
specific T-cells expressing CCR4 and CXCR3 would migrate to skin to exert their 
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actions. CXCR3  is expressed by Th1 T-cells while CCR4 is expressed by Th2 T-
cells (Kim et al., 2001). These finding suggest a mixed population of Th1 and Th2 
T-cells populations. 
CCR9 is well known marker as a gut homing receptor for T-cells (Agace, 2008). 
It has a role in the development of small and large intestinal inflammation. 
Moreover,CCR9 antagonists have been found to be effective in ulcerative colitis 
treatment (Bekker et al., 2015).  Intestinal involvement in case of telaprevir 
hypersensitivity is very common [diarrhoea (25%), ano-rectal discomfort (11%) 
and Haemorrhoids (12%)]. The underlying mechanism of intestinal disruption is 
not known. However, topical steroids are indicated in the management of 
intestinal involvement (Pockros, 2012), which may give a clue that an immune 
pathogenesis linked with high levels of CCR9 expression and T-cells activation.    
Notably, CXCR6 is also elevated on the drug specific T-cells. CXCR6 has a role 
in T-cell migration to the liver (Heesch et al., 2014). Another study has described 
a role for CXCR6 in chronic inflammatory conditions (Wilbanks et al., 2001).   
 
The most notable observation in this study was that telaprevir has been shown for 
the first time to activate T-cells. Clones were generated from 1 out of 3 volunteers 
studied. It could be that this donor would be susceptible to telaprevir 
hypersensitivity if exposed to the drug. However, many more volunteers would 
need to be studied to directly relate the frequency of T-cell responses detected in 
vitro to the incidence of reactions observed in exposed patients. Our data also 
highlights the limitation of existing T-cell priming assays using cells from healthy 
volunteers. Both assays lacked the sensitivity to detect telaprevir-responsive T-
cells. Finally, in on-going experiments researchers in Liverpool are utilizing other 
metabolites of telaprevir to attempt to define the major antigenic determinants that 
activate T-cells. 
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6 Final Discussion 
The objective of this work was to investigate mechanisms of drug specific T-cell 
activation. The project focuses for the most part on the β-lactam antibiotic 
piperacillin for three reasons. First, clinical samples from a well-defined patient 
cohort were available; second, T-cells have been isolated from patients previously 
and shown to be drug-specific; finally, mass spectrometric methods are 
established to characterize drug-protein binding in in vitro cell culture. Thus, it is 
possible to relate the chemistry of drug antigen formation to the activation of T-
cells from hypersensitive patients. Piperacillin-specific T-cells cloned from the 
hypersensitive patients were used to explore whether the parent drug and/or drug 
protein adducts stimulate proliferative responses and cytokine release via ligation 
of specific T-cell receptors. T-cell clones are useful to work with as all cells derive 
from the same precursor and hence express the same T-cell receptor. Clones can 
be expanded using mitogens from a single cell up to approximately 10x106 cells, 
which allows for detailed mechanistic and phenotypic characterization. Hence, it 
was also possible to characterize the clones in terms of T-cell receptor and 
chemokine receptor expression.   
One of the major problems that we faced in the study was the diminished 
sensitivity of clones over time which is a well-recognized phenomenon that has 
been noted previously (Pauken and Wherry, 2015). In general, TCCs retain their 
specificity and are able to respond in proliferation and cytokine release assays for 
about 2 months. However, their activity shows downward trend and the duration 
of time when experiments can be conducted varies from clone to clone. T-cell 
clones are incubated in culture medium, which although supplemented with 
nutrients and kept in optimal temperature and CO2 levels, is still an unnatural 
environment. Consequently, they become exhausted, which manifests in the form 
of poor proliferation and/or poor cytokine secretion.  Therefore, restimulation of 
the clones was performed on periodic schedule. Nevertheless, T-cells expansion 
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does not mean necessarily that the newly generated cells have a higher or even 
similar reactivity to their ancestors in terms of sensitivity (although they do retain 
the same specificity). Previous research has shown that repeated stimulation 
leads to T-cells exhaustion and ultimately a non-responsive state (Pauken and 
Wherry, 2015).  
Thus, all of the studies described in this thesis were conducted in a narrow time 
window when the clones were optimally responsive. When different numbers of 
clones were used in individual experiments this was almost always due to T-cell 
exhaustion.         
6.1 Free piperacillin and conjugated piperacillin  
Since Landsteiner first wrote about drug haptens in 1935, there have been great 
leaps forward in our understanding of drug hypersensitivity, resulting in two main 
theories to explain pathways of drug-specific T-cell activation: the hapten 
hypothesis and p-i mechanism.   
We have tried to broaden the knowledge of drug hypersensitivity reactions 
especially regarding the role of drug-protein conjugates in the activation of T-cells. 
In this thesis, we have focused on β-lactam hypersensitivity since all β-lactam 
antibiotics form protein adducts through the irreversible modification of specific 
amino acid residues on proteins such as human serum albumin (HSA). The β-
lactam ring of drugs such as piperacillin is attacked by lysine residues of proteins 
leading to ring opening and binding of penicilloyl groups. Previous studies have 
shown the pivotal role of drug-protein adducts in T-cells activation (Thierse et al., 
2005;Ortmann et al., 1992;Weltzien et al., 1996).  
The results described in chapters 3 and 4, show that piperacillin hypersensitive 
patients with CF display two distinct T-cell responses: one involves free 
piperacillin and the other piperacillin-HSA conjugates. Both sets of T-cell clones 
show comparable features in terms of cytokine secretion, chemokine expression 
and CD4/CD8 phenotype. However, there was a difference in TCR-Vβ 
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expression, which was diverse for free piperacillin-responsive clones, but more 
restricted for clones activated with piperacillin-HSA adducts.  
Both sets of clones are activated by a pathway dependent on APCs protein 
processing (as shown by APCs fixation assays). Thus, the activation of both sets 
of clones seems to involve a hapten mechanism. Pulsing assays using free 
piperacillin have shown that clones are activated upon incubation with APCs that 
have been incubated with free piperacillin for long durations (24-48 hrs). This is 
the time required to generate high levels of protein adduct in cell culture (Whitaker 
et al., 2011). Similar lengths of incubation were required for T-cell clones to 
respond to piperacillin-HSA adducts. This likely relates to the time required for 
protein processing and the liberation of MHC binding peptides. The lowest level 
of piperacillin-HSA modification required to trigger T-cells was found to be 2.8% 
which correlates well with piperacillin-HSA adducts levels detected in serum of 
patients exposed to a 14-day course of treatment (2.7-4.7% [mean 3.86%]). 
Collectively, these data show that T-cell stimulatory levels of drug protein adduct 
are formed in plasma of almost all patients exposed to piperacillin. Since the 
majority of patients exposed to the drug do not develop hypersensitivity, additional 
factors must be required to translate the antigenic signal into an immune response 
and tissue injury. The nature of these signals is not known, but may relate to 
disease status at the time of the hypersensitivity reaction. For example, infection 
is known to result in activation of important signalling pathways the innate immune 
system. Furthermore, innate immune signalling is critical for the activation of naïve 
T-cells to drug and protein antigens.  
Clones responsive to free piperacillin did not cross react with piperacillin-HSA 
conjugates while clones responsive to piperacillin-HSA conjugates clones showed 
some reactivity to free piperacillin. Incubation of free piperacillin leads to 
modification of lysine residues of HSA but at a low percentage for pip-K541 
peptide and for a shorter duration of time, which is evidently not sufficient to 
produce a T-cell proliferative response or cytokine secretion.  On the other hand, 
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the percentage of modified lysine residues in (250:1) piperacillin-HSA conjugates 
is approximately (25%) and very strong proliferative responses of clones were 
observed.  
Piperacillin-HSA conjugate sensitive clones are not cross reactive with HSA 
conjugates of other β-lactam antibiotics although they share the same β-lactam 
core ring. Thus, the β-lactam core ring per se does not contribute to the fine 
specificity of the clones. It is likely that the major antigenic determinant is the 
piperacillin-modified peptide formed after APC processing of piperacillin-HSA 
conjugate.    
Given that TCCs responsive to free piperacillin are activated via a processing 
dependent pathway, it was unexpected when cross-reactivity with piperacillin-
HSA conjugates was not observed. There are two hypotheses to explain this: 
 1st hypothesis: Each set of clones has a unique piperacillin antigenic 
determinant  
This is supported by the discrepancy in TCR-Vβ expression between the two sets 
of TCCs. Piperacillin is known to modify extracellular proteins in in vitro cultures, 
but ignores intracellular proteins (Monshi, 2013;El-Ghaiesh et al., 2012;Meng et 
al., 2011). This selectivity is restricted to β-lactam antibiotics. Other drugs, like 
SMX, are known to modify multiple intra and extracellular proteins (Naisbitt et al., 
2002;Sanderson et al., 2007;Megherbi et al., 2009;Callan et al., 2009).   
By implementing novel spectrometric methods, we were able to identify albumin 
as the main protein modified by piperacillin binding and identify the profile of 
piperacillin binding at specific lysine residues in terms of dose and incubation time. 
Since the majority of serum bound penicilloyl groups are bound to human serum 
albumin, we have considered it as a model protein for investigating piperacillin-
HSA conjugates formation. Our results confirm that these conjugates are formed 
in piperacillin treated patients and are capable of inducing the host T-cell immune 
response. Although piperacillin-HSA conjugates are found in 100% of piperacillin 
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treated patients, they do not result in a pathogenic immune response unless other 
factors (patient related) are present.   
The in vitro culture medium is supplemented with human AB serum. Thus, it 
contains an array of other serum proteins, albeit and significantly lower levels 
when compared with albumin. It is possible that clones circulating in the periphery 
of hypersensitive patients are activated by different drug-modified peptides and 
the peptides likely originate from different proteins.  
 2nd hypothesis: Both sets of TCCs share the same piperacillin antigenic 
determinant  
It is possible that the antigenic determinant for clones (whether free piperacillin or 
piperacillin-HSA conjugate responsive) is the same (i.e., a piperacillin-modified 
peptide). This hypothesis is supported by the finding of high cross reactivity of the 
piperacillin-HSA clones with free piperacillin. Thus, in ongoing experiments, 
peptide elution studies are being conducted to explore the nature of the culprit 
antigenic determinants that bind to MHC molecules in different hypersensitive 
patients. 
Role of piperacillin metabolism 
Piperacillin is metabolized by the liver to form desethyl piperacillin (approximately 
20% of total piperacillin) which is known to form adducts with serum proteins, 
which may play a role in mediating piperacillin hypersensitivity reactions (Whitaker 
et al., 2011). Thus, there is a need to study the role of desethyl piperacillin and its 
protein adducts.  
As we have shown in chapter 4, piperacillin forms two kinds of adduct with HSA; 
cyclized and hydrolysed variants. Desethyl piperacillin HSA adducts have also 
been detected in plasma of patients exposed to the drug; however, the 
significance of these metabolite-modified proteins in piperacillin hypersensitivity 
needs to be investigated.  
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Role of other nucleophiles 
Although studies on β-lactam antibiotics have characterized a binding interaction 
with lysine residues that results in the formation of penicilloyl adducts, we cannot 
exclude the possibility that other nucleophiles such as histidine, serine and 
cysteine are also modified. Previous studies have found no evidence of other 
modified amino acid residues (Meng et al., 2011). However, as mass 
spectrometric methods develop, minor adducts that might have a massive 
influence on the immune response might be detected. Furthermore, it is possible 
that these adducts are too labile and therefore undetectable using existing 
analytical methods (TSUJI et al., 1975). 
Piperacillin conjugation with other proteins  
As mentioned above, it is likely that piperacillin binds to other serum proteins and 
the subsequent liberation of piperacillin-modified peptides may activate certain T-
cells from hypersensitive patients.  Piperacillin may bind to immunologically active 
molecules such as cytokines as in the case of benzyl penicillin which makes 
adducts with IFN-γ, IL-1B, IL-2, IL-5, IL-13, TNF-α (as shown by western blotting 
assays). Interestingly, many of these cytokines are secreted by piperacillin-
specific T-cells (Whitaker et al., 2011). Hence, it is possible that piperacillin-HSA 
adducts activate the primary T-cell response in patients that leads to the secretion 
of pro-inflammatory cytokines. Piperacillin cytokine binding might generate novel 
antigenic determinants, which would spread the repertoire of drug-responsive T-
cells in hypersensitive patients and potentially extend to duration or severity of the 
iatrogenic disease.        
Site of T-cell priming 
 Blood or skin? 
In all the experiments described in this thesis, I worked on blood-derived T-cells. 
However, there is now extensive evidence that the T cells implicated in drug 
hypersensitivity reactions are actually derived from tissues e.g. skin as in SJS 
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(Schrijvers et al., 2015). Thus, we can address a question: Would our findings 
showing activation of clones from blood of hypersensitive patients with free 
piperacillin and piperacillin-conjugated HSA be different if we have used T-cells 
derived from skin? 
In research conducted by Gaide et al, it has been shown that skin derived T-cells 
are similar to blood derived T-cells in terms of peptide antigen specificity in a 
particular individual. Moreover, skin, lymph nodes and blood derived T-cells were 
shown to descend from a common naïve ancestor and they express similar TCR-
Vβ expression (Gaide et al., 2015). Although these data are somewhat preliminary 
and require replication in different model systems, it seems to suggest that blood- 
and skin-derived clones will display similar antigen specificities.  
Characterisation of skin-derived free piperacillin-responsive T-cells by   Sullivan 
et al (unpublished data at the University of Liverpool) have shown a comparable 
T-cell cytokine secretion profile. However, they have found that skin T-cells 
showed a greater cytolytic activity; specifically, high levels of perforin, granzyme-
B and Fas ligand secretion were detected with the skin-derived clones.  Moreover, 
blood- and skin-derived clones were found to secrete high levels of the tissue-
specific cytokine IL-22 when stimulated with the drug.  
 Role of B-cells 
For a broader, more detailed understanding of the immune mechanisms 
implicated in piperacillin hypersensitivity, there is a need to address the pivotal 
role of B-cells.  
B-cells synthesise specific antibodies to culprit antigens. These antibodies could 
be IgE and thus induce Type I hypersensitivity reactions or IgG and therefore 
could activate complement system or induce cells lysis through the ADCC 
mechanism (Pollara et al., 2011). 
In research conducted in Liverpool in parallel to my investigations, B-cells from 
piperacillin hypersensitive patients showed signs of activation with high 
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expression of CD19 and CD27 (Amali, 2015). Moreover, there was a high level of 
piperacillin-specific IgG in vivo as well as in vitro. In contrast, IgG secretion from 
B-cells derived from tolerant volunteers and healthy controls was at undetectable 
levels after piperacillin stimulation.  These IgG molecules are highly specific to 
piperacillin i.e. they did not bind to benzyl penicillin, penicillin V, amoxicillin and 
aztreonam protein adducts which provides further evidence of the difference in 
antigenic determinants between piperacillin and other antibiotics.  Importantly, the 
role of B-cells in in the skin injury associated with piperacillin-mediated drug 
hypersensitivity reactions is not known. B-cells might impact on the severity or 
nature of the skin reaction; however, it is theoretically possible that the drug-
specific antibodies might down-regulate the cytotoxic T-cell response through 
restricting APC access to drug protein adducts.  
Collectively, the findings of my study provide a step forward in the understanding 
of piperacillin hypersensitivity reactions and also drug hypersensitivity reactions 
in general. The hypotheses, methods and analytic interpretation can be used as 
a model for future studies on other drugs. Moreover, this data may impact on the 
design of safer and more effective drugs. In addition, an understanding of the 
characteristics of drug antigens will contribute positively to the development of 
new diagnostic and predictive screening methods.  
6.2 Telaprevir and its metabolite 
Since the FDA approved use of telaprevir for the treatment of genotype 1 chronic 
hepatitis C in 2011, many reports were made about the side effects of telaprevir. 
These side effects plus the discovery of newer, safer and cheaper agents for 
treating hepatitis C have altogether contributed to the decision of the parent 
company Vertex Pharmaceuticals to discontinue telaprevir production.   
However, it is important to investigate why the drug was associated with such a 
high incidence of frequently severe hypersensitivity reactions. Furthermore, 
telaprevir might represent a model for other compounds in the same chemical 
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class i.e. protease inhibitors for hepatitis C (e.g., boceprevir and semiprevir). This 
research may also improve our understanding of hypersensitive reactions in 
general. 
Since telaprevir-m (VRT-127394) is a major metabolite, we chose to include it in 
our study alongside the parent drug to explore T-cell responses to both 
compounds.  
Telaprevir has previously been shown to promote the secretion of cytokines when 
antigen presenting cells were exposed to the drug at relatively high concentrations 
for a prolonged period of time. However, the ability of telaprevir to activate T-cells 
has not been investigated. Difficulties in recruiting patients with hypersensitivity to 
telaprevir led us to design in vitro environments with cells from healthy donors. 
Two methods were used to identify telaprevir-responsive T-cell clones.  
DC-T-cell priming vs PBMCs priming 
The mechanism of T-cell priming differs greatly between the two methods that 
were employed. This variation is due the different type of the APC used in each 
assay. 
In the DC-T-cell priming assay, antigen presentation is dependent on DCs (DCs 
to naïve T-cells ratio=1:31), whereas antigen presentation in PBMC priming is 
mediated by multiple cells that make up PBMCs. This includes DCs (0.04x106 
cells/mL), B-cells (0.3x106 cells/mL) and macrophages and monocytes (0.55x106 
cells/mL) (Stemcell, 2015). Thus, the ratio of DCs: naïve T-cells in PBMCs in vitro 
culture would be 1:13.5 which is greatly different from the DC-T-cell priming ratio. 
There is a difference in the MHC II density on the different APCs, there are 
approximately (45500 molecules) on each DC while approximately (25000 
molecules) are expressed on B-cell (Shibuya et al., 2015) and macrophages 
express even fewer molecules (Kumar, 2016). However, there are no significant 
differences in the number of MHC class I molecules between the three main APCs 
(DCs, B-cells and the macrophages) (Kumar, 2016).  As MHC molecules play a 
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pivotal role in antigen presentation, it is clear why DCs are so important for 
activating T-cells. Furthermore, dendritic cells are the only cells known to have 
the ability to efficiently prime naïve T-cells (Mellman and Steinman, 2001). 
In DCs priming the naïve T-cells are the only source of drug-specific T-cells (since 
we have implemented bead separation to remove other cell types). While in 
PBMC priming, there are two possible sources of drug-specific T-cells. They are 
either: 
 Naïve T-cells (like DCs priming). 
 Memory T-cells which were primed by previous drug exposure (which does 
not apply here since the study was performed on naïve healthy volunteers 
PBMCs samples). However, there is a still a possibility that drug-specific 
T-cells cross reactive with a peptide antigen. 
The incubation duration is limited to one week in DC-T-cells priming while it is two 
weeks in PBMCs priming. Furthermore, in PBMCs priming, the cells can be 
exposed to the drug several times in the presence of irradiated autologous 
PBMCs (as APCs).   
In case of naïve T-cells, drug-mediated T-cell responses develop in the first 4-7 
days (memory T-cells require 1-3 days) (Mak et al., 2013).  of the remainder of 
the incubation period to allow the primed T-cells to expand. Thus, PBMCs priming 
technique has the privilege of allowing more time for T-cell expansion in addition 
to the boosting effect from the multiple rounds of restimulation. 
In general, the priming assays (whether DC-T-cell or PBMCs priming) presented 
in chapter 5 were unsuccessful. No tangible difference between the two methods 
were detected; telaprevir-specific proliferative responses and IFN-γ secretion 
were not observed. Attempts to generate clones showed that using PBMCs 
priming was more efficient. A relatively large number of telaprevir-m specific 
clones were isolated from volunteer 5 using this method.   
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The detection of drug antigen specific T-cells in healthy volunteers was intriguing.  
As discussed above, it is difficult to determine whether drug-responsive T-cells 
derive from the memory or naïve compartment using the PBMC priming assay; 
however, the negative data with DC-T-cell priming suggests that telaprevir might 
activate pre-existing memory T-cells in healthy volunteers. In ongoing 
experiments, the protocol is being repeated using PBMCs depleted of naive or 
memory T-cells to address this question. Similar conclusions were made about 
the abacavir in HLA-B*57:01+ naïve donors. Abacavir seemed to preferentially 
activate memory T-cells (Lucas et al., 2015).  
Therefore, there is a need to conduct further research to explore the mechanism 
of telaprevir-specific T-cell activation and to define the number of individuals who 
have circulating T-cells that might be activated by the drug.   
******************************************************************************************* 
The data presented in this thesis have made a significant contribution to our 
understanding of immunological adverse drug reactions. Specifically, I have 
helped to delineate the pathomechanism of piperacillin hypersensitivity reactions 
in patients with CF. Moreover; my studies establish the framework for future 
studies characterizing antigenic determinants of culprit drugs. Regarding 
telaprevir, I believe that this study has shown for the first time that the drug 
activates T-cell proliferative responses and cytokine release. There is a need for 
further work on patients derived T-cells to complete the missing pieces in our 
understanding of telaprevir-mediated hypersensitivity reactions. 
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Table 7.1:Biological Reagents and Chemicals  
  Biological Reagent Manufacturer 
1 Amoxicillin Sigma Aldrich 
2 Anti HLA –ABC (purified NA /LE mouse)  BD pharmingen 
3 Anti HLA –DR, DP, DQ (purified NA /LE mouse) BD pharmingen 
4 Antihuman CCR10 conjugated mouse IgG R & D systems 
5 Antihuman CCR2 conjugated mouse IgG R & D systems 
6 Antihuman CCR3 conjugated mouse IgG R & D systems 
7 Antihuman CCR4 conjugated mouse IgG R & D systems 
8 Antihuman CCR5 conjugated mouse IgG R & D systems 
9 Antihuman CCR6 conjugated mouse IgG R & D systems 
10 Antihuman CCR8 conjugated mouse IgG R & D systems 
11 Antihuman CCR9 conjugated mouse IgG R & D systems 
12 Antihuman CD69 conjugated mouse IgG BD Biosciences 
13 Antihuman CXCR10 conjugated mouse IgG BD Biosciences 
14 Antihuman CXCR3 conjugated mouse IgG BD Biosciences 
15 Antihuman CXCR6 conjugated mouse IgG BD Biosciences 
16 Antihuman E-cad conjugated mouse IgG BD Biosciences 
17 APC Mouse Anti-Human CD3 BD Biosciences 
18 BCIP/NBT-plus Mabtech AB 
19 BD CompBeads BD 
20 Bovine serum albumin BSA Sigma-Aldrich 
21 Bradford reagent BIO-RAD 
22 Carboxyfluorescein succinimidyl ester (CFSE) eBioscience Ltd.  
23 
CD14 Microbeads Human conjugated to monoclonal CD14 
antibodies (isotype: mouse IgG2a) 
Miltenyi Biotec 
24 
CD25 MicroBeads II human: MicroBeads conjugated to 
monoclonal anti-human CD25 antibodies (isotype: mouse 
IgG1). 
Miltenyi Biotec 
25 CD4 microbeads Beckman Coulter   
26 CD4 multisort kit  Beckman Coulter   
27 
CD45RO MicroBeads, human: MicroBeads conjugated to 
monoclonal mouse anti-human CD45RO antibodies (isotype: 
mouse IgG2a). 
Miltenyi Biotec 
28 CD8 microbeads  Beckman Coulter   
29 CD8 multisort kit  Beckman Coulter   
30 Cy5.5 mouse antihuman CD45ro BD pharmingen 
31 Cyclosporin-A (98.5%) Fluka Analytical 
32 dichloromethane Sigma Aldrich 
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33 dimethylformamide Sigma Aldrich 
34 DMSO Sigma-Aldrich 
35 
Ethylene diamine tetra acetic acid disodium salt solution 
[EDTA] 0.5M 
Sigma-Aldrich 
36 Fetal bovine serum Gibco, Invitrogen 
37 FITC Mouse Anti-Human CD4 BD Biosciences 
38 FITC mouse antihuman CD45ra BD pharmingen 
39 Flucloxacillin CP pharmaceuticals ltd 
40 Fmoc-L-amino acids Sigma Aldrich 
41 Glutaraldehyde solution Sigma Aldrich 
42 Glycine Sigma Aldrich 
43 Hank's buffered salt solution [HBSS] Sigma-Aldrich 
44 Heat inactivated pooled human AB serum Innovative research 
45 HEPES 1M Sigma-Aldrich 
46 Human GM-CSF Peprotech 
47 Human AB serum  Innovative Research  
48 Human Fasl ELISPOT kit Abcam 
49 Human Granzyme B ELISPOT kit Mabtech AB 
50 Human IFN-y ELISPOT kit Mabtech AB 
51 Human IL-13 ELISPOT kit Mabtech AB 
52 Human IL-5 ELISPOT kit Mabtech AB 
53 Human Perforin ELISPOT kit Mabtech AB 
54 Human serum albumin crystallized and Iyophillized Sigma-Aldrich 
55 Interleukin (IL)-2 PeproTech EC Ltd 
56 Interleukin (IL)-4  PeproTech EC Ltd 
57 Isotype MHC I control (purified NA /LE mouse IgG) BD pharmingen 
58 Isotype MHC II control (purified NA /LE mouse IgG) BD pharmingen 
59 L-Glutamine Sigma-Aldrich 
60 Lyrnphoprep Axis Shield 
61 
Monkey marmoset peripheral blood lymphocyte (B95-8 cell 
line) 
Abd Serotec 
62 Mouse antihuman CCR4 PE BD pharmingen 
63 Mouse antihuman CCR8 FITC  BD pharmingen 
64 Mouse antihuman CCR8 PE BD pharmingen 
65 N, N'-Dicyclohexylcarbodiimide Sigma Aldrich 
66 N-methylmorpholine Sigma Aldrich 
67 PE Mouse Anti-Human CD8 BD Biosciences 
68 PeniciIIin/streptomycin Sigma-Aldrich 
69 Penicillin-G sodium salt Sigma Aldrich 
70 Phosphate buffered saline (powder) Sigma Aldrich 
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71 
Phytohemagglutinin PHA-P, cell culture tested, lyophilized 
powder 
Sigma-Aldrich 
72 Piperacillin sodium salt Sigma- Aldrich 
73 Piperidine Sigma Aldrich 
74 RPMI 1640 Sigma-Aldrich 
75 Secondary goat anti-mouse HRP conjugated antibody   Dako, 
76 Skimmed Milk Powder Sigma-Aldrich 
77 SMX-NO  Dalton Pharma Services 
78 Sodium azide Sigma Aldrich 
79 Streptavidine-ALP Mabtech AB 
80 Tetanus toxoid 
Statens seruminstitut 
(Copenhagen, Denmark). 
81 Transferrin Sigma-Aldrich 
82 Trifluoroacetic acid Sigma Aldrich 
83 Tritiated [3H]-methyl thymidine Moravek 
84 Trypan blue (0.2 % w/v)   
85 Trypsin   Promega 
86 Tube A: TCR Vβ Kit (Vβ 5.3 PE, Vβ 7   PE+FITC, Vβ 3 FITC) Beckman Coulter   
87 Tube B: Vβ 9 PE, Vβ 17 PE+FITC, Vβ 16 FITC Beckman Coulter   
88 Tube C: Vβ 18 PE, Vβ 5.1 PE+FITC, Vβ 20 FITC Beckman Coulter   
89 Tube D: Vβ 13.1 PE, Vβ 13.6, PE+FITC, Vβ 8   FITC Beckman Coulter   
90 Tube E: Vβ 5.2 PE, Vβ 2 PE+FITC, Vβ 12 FITC Beckman Coulter   
91 Tube F: Vβ 23 PE, Vβ 1 PE+FITC, Vβ 21.3 FITC Beckman Coulter   
92 Tube G: Vβ 11 PE, Vβ 22 PE+FITC, Vβ 14 FITC Beckman Coulter   
93 Tube H: Vβ 13.2 PE, Vβ 4 PE+FITC, Vβ 7.2   FITC Beckman Coulter   
94 Tween®20 Sigma Aldrich 
95 Western Lightning Chemiluminescence reagent  Perkin Elmer 
 
 
Table 7.2: Labware utilized. 
 Lab ware Manufacturer 
1 AID ELISPOT reader  AID Diagnostika GmbH  
2 C18 PepMap column Dionex 
3 Centrifugal concentrator  SpeedVac, Eppendorf 
4 centrifugal filter  Amicon Ultra-15, Millipore 
5 Culture tubes with caps (FACS Tubes) /polystyrene Simport 
6 Drying Oven   Sciquip 
7 ECL sensitive film  Kodak 
8 ELISPOT plates Millipore 
9 ELISPOT Reader AID Gmbh 
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10 FACS Canto II flow cytometer BD Biosciences 
11 Filters Sartorius 
12 Jupiter C18 column (10μm C18, 250 mm × 10mm) Phenomenex 
13 Leica DME microscope  Leica Microsystems  
14 Lithium Heparinized Vacuette Tubes Greiner Bio-One Ltd 
15 LS Columns Miltenyi Biotec 
16 LS Columns    Miltenyi Biotec 
17 Microbeta Trilux (beta Counter) PerkinElmer 
18 Microsealer WALLAC 1495-021 TWALLAC 
19 MS Columns Miltenyi Biotec 
20 Neubauer haemacytometer  Sigma-Aldrich  
21 Nitrocellulose membrane GE Healthcare Life Sciences 
22 Nitrocellulose membrane  Amersham Biosciences 
23 PicoTip  New Objective 
24 POROS anti-HSA affinity cartridge  Applied Biosystems, Foster City, USA 
25 Printed Filtermat A  PerkinElmer 
26 Quadrupole-linear ion trap mass spectrometer   Sciex 
27 Sample Bag for Microbeta TM PerkinElmer 
28 T-175 flasks Thermo Scientific  
29 Tomtec Harvestor 96 Receptor Technologies 
30 Transwell plates Corning Incorporated 
31 Vision Workstation Applied Biosystems 
32 Vivaspin Ultrafiltration tubes  Vivaproducts 
33 Wax scintillent meltilex A PerkinElmer 
34 ZipTips  Millipore 
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